6	SIMPONI.xml:S1:4:1	O
ADVERSE	SIMPONI.xml:S1:6:7	O
REACTIONS	SIMPONI.xml:S1:14:9	O

The	SIMPONI.xml:S1:27:3	O
most	SIMPONI.xml:S1:31:4	O
serious	SIMPONI.xml:S1:36:7	O
adverse	SIMPONI.xml:S1:44:7	O
reactions	SIMPONI.xml:S1:52:9	O
were	SIMPONI.xml:S1:62:4	O
:	SIMPONI.xml:S1:66:1	O

Serious	SIMPONI.xml:S1:75:7	B-Severity
Infections	SIMPONI.xml:S1:83:10	B-AdverseReaction
[	SIMPONI.xml:S1:94:1	O
see	SIMPONI.xml:S1:95:3	O
Warnings	SIMPONI.xml:S1:100:8	O
and	SIMPONI.xml:S1:109:3	O
Precautions	SIMPONI.xml:S1:113:11	O
(	SIMPONI.xml:S1:125:1	O
5.1	SIMPONI.xml:S1:126:3	O
)	SIMPONI.xml:S1:129:1	O
]	SIMPONI.xml:S1:132:1	O

Malignancies	SIMPONI.xml:S1:140:12	B-AdverseReaction
[	SIMPONI.xml:S1:153:1	O
see	SIMPONI.xml:S1:154:3	O
Warnings	SIMPONI.xml:S1:159:8	O
and	SIMPONI.xml:S1:168:3	O
Precautions	SIMPONI.xml:S1:172:11	O
(	SIMPONI.xml:S1:184:1	O
5.2	SIMPONI.xml:S1:185:3	O
)	SIMPONI.xml:S1:188:1	O
]	SIMPONI.xml:S1:191:1	O

EXCERPT	SIMPONI.xml:S1:201:7	O
:	SIMPONI.xml:S1:208:1	O
Most	SIMPONI.xml:S1:212:4	O
common	SIMPONI.xml:S1:217:6	O
adverse	SIMPONI.xml:S1:224:7	O
reactions	SIMPONI.xml:S1:232:9	O
(	SIMPONI.xml:S1:242:1	O
incidence	SIMPONI.xml:S1:243:9	O
3%	SIMPONI.xml:S1:255:2	O
)	SIMPONI.xml:S1:257:1	O
are	SIMPONI.xml:S1:259:3	O
:	SIMPONI.xml:S1:262:1	O
upper	SIMPONI.xml:S1:264:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:270:11	I-AdverseReaction
tract	SIMPONI.xml:S1:282:5	I-AdverseReaction
infection	SIMPONI.xml:S1:288:9	I-AdverseReaction
,	SIMPONI.xml:S1:297:1	O
viral	SIMPONI.xml:S1:299:5	B-AdverseReaction
infection	SIMPONI.xml:S1:305:9	I-AdverseReaction
,	SIMPONI.xml:S1:314:1	O
bronchitis	SIMPONI.xml:S1:316:10	B-AdverseReaction
,	SIMPONI.xml:S1:326:1	O
hypertension	SIMPONI.xml:S1:328:12	B-AdverseReaction
,	SIMPONI.xml:S1:340:1	O
and	SIMPONI.xml:S1:342:3	O
rash	SIMPONI.xml:S1:346:4	B-AdverseReaction
(	SIMPONI.xml:S1:351:1	O
6.1	SIMPONI.xml:S1:354:3	O
)	SIMPONI.xml:S1:359:1	O
.	SIMPONI.xml:S1:360:1	O

To	SIMPONI.xml:S1:368:2	O

report	SIMPONI.xml:S1:371:6	O
SUSPECTED	SIMPONI.xml:S1:378:9	O
ADVERSE	SIMPONI.xml:S1:388:7	O
REACTIONS	SIMPONI.xml:S1:396:9	O
,	SIMPONI.xml:S1:405:1	O
contactJanssen	SIMPONI.xml:S1:407:14	O
Biotech	SIMPONI.xml:S1:422:7	O
,	SIMPONI.xml:S1:429:1	O
Inc	SIMPONI.xml:S1:431:3	O
.	SIMPONI.xml:S1:434:1	O

at	SIMPONI.xml:S1:436:2	O
1	SIMPONI.xml:S1:439:1	O
-	SIMPONI.xml:S1:440:1	O
800	SIMPONI.xml:S1:441:3	O
-	SIMPONI.xml:S1:444:1	O
JANSSEN	SIMPONI.xml:S1:445:7	O
(	SIMPONI.xml:S1:453:1	O
1	SIMPONI.xml:S1:454:1	O
-	SIMPONI.xml:S1:455:1	O
800	SIMPONI.xml:S1:456:3	O
-	SIMPONI.xml:S1:459:1	O
526	SIMPONI.xml:S1:460:3	O
-	SIMPONI.xml:S1:463:1	O
7736	SIMPONI.xml:S1:464:4	O
)	SIMPONI.xml:S1:468:1	O
or	SIMPONI.xml:S1:470:2	O
FDA	SIMPONI.xml:S1:473:3	O
at	SIMPONI.xml:S1:477:2	O
1	SIMPONI.xml:S1:480:1	O
-	SIMPONI.xml:S1:481:1	O
800	SIMPONI.xml:S1:482:3	O
-	SIMPONI.xml:S1:485:1	O
FDA	SIMPONI.xml:S1:486:3	O
-	SIMPONI.xml:S1:489:1	O
1088	SIMPONI.xml:S1:490:4	O
or	SIMPONI.xml:S1:495:2	O
www	SIMPONI.xml:S1:499:3	O
.	SIMPONI.xml:S1:502:1	O
fda	SIMPONI.xml:S1:503:3	O
.	SIMPONI.xml:S1:506:1	O
gov	SIMPONI.xml:S1:507:3	O
medwatch	SIMPONI.xml:S1:511:8	O
.	SIMPONI.xml:S1:519:1	O

6.1	SIMPONI.xml:S1:533:3	O

Clinical	SIMPONI.xml:S1:537:8	O
Trials	SIMPONI.xml:S1:546:6	O
Experience	SIMPONI.xml:S1:553:10	O

Because	SIMPONI.xml:S1:567:7	O
clinical	SIMPONI.xml:S1:575:8	O
trials	SIMPONI.xml:S1:584:6	O
are	SIMPONI.xml:S1:591:3	O
conducted	SIMPONI.xml:S1:595:9	O
under	SIMPONI.xml:S1:605:5	O
widely	SIMPONI.xml:S1:611:6	O
varying	SIMPONI.xml:S1:618:7	O
conditions	SIMPONI.xml:S1:626:10	O
,	SIMPONI.xml:S1:636:1	O
adverse	SIMPONI.xml:S1:638:7	O
reaction	SIMPONI.xml:S1:646:8	O
rates	SIMPONI.xml:S1:655:5	O
observed	SIMPONI.xml:S1:661:8	O
in	SIMPONI.xml:S1:670:2	O
the	SIMPONI.xml:S1:673:3	O
clinical	SIMPONI.xml:S1:677:8	O
trials	SIMPONI.xml:S1:686:6	O
of	SIMPONI.xml:S1:693:2	O
a	SIMPONI.xml:S1:696:1	O
drug	SIMPONI.xml:S1:698:4	O
cannot	SIMPONI.xml:S1:703:6	O
be	SIMPONI.xml:S1:710:2	O
directly	SIMPONI.xml:S1:713:8	O
compared	SIMPONI.xml:S1:722:8	O
to	SIMPONI.xml:S1:731:2	O
rates	SIMPONI.xml:S1:734:5	O
in	SIMPONI.xml:S1:740:2	O
the	SIMPONI.xml:S1:743:3	O
clinical	SIMPONI.xml:S1:747:8	O
trials	SIMPONI.xml:S1:756:6	O
of	SIMPONI.xml:S1:763:2	O
another	SIMPONI.xml:S1:766:7	O
drug	SIMPONI.xml:S1:774:4	O
and	SIMPONI.xml:S1:779:3	O
may	SIMPONI.xml:S1:783:3	O
not	SIMPONI.xml:S1:787:3	O
reflect	SIMPONI.xml:S1:791:7	O
the	SIMPONI.xml:S1:799:3	O
rates	SIMPONI.xml:S1:803:5	O
observed	SIMPONI.xml:S1:809:8	O
in	SIMPONI.xml:S1:818:2	O
clinical	SIMPONI.xml:S1:821:8	O
practice	SIMPONI.xml:S1:830:8	O
.	SIMPONI.xml:S1:838:1	O

The	SIMPONI.xml:S1:844:3	O
safety	SIMPONI.xml:S1:848:6	O
data	SIMPONI.xml:S1:855:4	O
described	SIMPONI.xml:S1:860:9	O
below	SIMPONI.xml:S1:870:5	O
are	SIMPONI.xml:S1:876:3	O
based	SIMPONI.xml:S1:880:5	O
on	SIMPONI.xml:S1:886:2	O
one	SIMPONI.xml:S1:889:3	O
,	SIMPONI.xml:S1:892:1	O
randomized	SIMPONI.xml:S1:894:10	O
,	SIMPONI.xml:S1:904:1	O
double	SIMPONI.xml:S1:906:6	O
-	SIMPONI.xml:S1:912:1	O
blind	SIMPONI.xml:S1:913:5	O
,	SIMPONI.xml:S1:918:1	O
controlled	SIMPONI.xml:S1:920:10	O
Phase	SIMPONI.xml:S1:931:5	O
3	SIMPONI.xml:S1:937:1	O
trial	SIMPONI.xml:S1:939:5	O
in	SIMPONI.xml:S1:945:2	O
patients	SIMPONI.xml:S1:948:8	O
with	SIMPONI.xml:S1:957:4	O
RA	SIMPONI.xml:S1:962:2	O
receiving	SIMPONI.xml:S1:965:9	O
SIMPONI	SIMPONI.xml:S1:975:7	O
ARIA	SIMPONI.xml:S1:983:4	O
by	SIMPONI.xml:S1:988:2	O
intravenous	SIMPONI.xml:S1:991:11	O
infusion	SIMPONI.xml:S1:1003:8	O
(	SIMPONI.xml:S1:1012:1	O
Trial	SIMPONI.xml:S1:1013:5	O
1	SIMPONI.xml:S1:1019:1	O
)	SIMPONI.xml:S1:1020:1	O
.	SIMPONI.xml:S1:1021:1	O

The	SIMPONI.xml:S1:1023:3	O
protocol	SIMPONI.xml:S1:1027:8	O
included	SIMPONI.xml:S1:1036:8	O
provisions	SIMPONI.xml:S1:1045:10	O
for	SIMPONI.xml:S1:1056:3	O
patients	SIMPONI.xml:S1:1060:8	O
taking	SIMPONI.xml:S1:1069:6	O
placebo	SIMPONI.xml:S1:1076:7	O
to	SIMPONI.xml:S1:1084:2	O
receive	SIMPONI.xml:S1:1087:7	O
treatment	SIMPONI.xml:S1:1095:9	O
with	SIMPONI.xml:S1:1105:4	O
SIMPONI	SIMPONI.xml:S1:1110:7	O
ARIA	SIMPONI.xml:S1:1118:4	O
at	SIMPONI.xml:S1:1123:2	O
Week	SIMPONI.xml:S1:1126:4	O
16	SIMPONI.xml:S1:1131:2	O
or	SIMPONI.xml:S1:1134:2	O
Week	SIMPONI.xml:S1:1137:4	O
24	SIMPONI.xml:S1:1142:2	O
either	SIMPONI.xml:S1:1145:6	O
by	SIMPONI.xml:S1:1152:2	O
patient	SIMPONI.xml:S1:1155:7	O
response	SIMPONI.xml:S1:1163:8	O
(	SIMPONI.xml:S1:1172:1	O
based	SIMPONI.xml:S1:1173:5	O
on	SIMPONI.xml:S1:1179:2	O
uncontrolled	SIMPONI.xml:S1:1182:12	O
disease	SIMPONI.xml:S1:1195:7	O
activity	SIMPONI.xml:S1:1203:8	O
)	SIMPONI.xml:S1:1211:1	O
or	SIMPONI.xml:S1:1213:2	O
by	SIMPONI.xml:S1:1216:2	O
design	SIMPONI.xml:S1:1219:6	O
,	SIMPONI.xml:S1:1225:1	O
so	SIMPONI.xml:S1:1227:2	O
that	SIMPONI.xml:S1:1230:4	O
adverse	SIMPONI.xml:S1:1235:7	O
events	SIMPONI.xml:S1:1243:6	O
cannot	SIMPONI.xml:S1:1250:6	O
always	SIMPONI.xml:S1:1257:6	O
be	SIMPONI.xml:S1:1264:2	O
unambiguously	SIMPONI.xml:S1:1267:13	O
attributed	SIMPONI.xml:S1:1281:10	O
to	SIMPONI.xml:S1:1292:2	O
a	SIMPONI.xml:S1:1295:1	O
given	SIMPONI.xml:S1:1297:5	O
treatment	SIMPONI.xml:S1:1303:9	O
.	SIMPONI.xml:S1:1312:1	O

Comparisons	SIMPONI.xml:S1:1314:11	O
between	SIMPONI.xml:S1:1326:7	O
placebo	SIMPONI.xml:S1:1334:7	O
and	SIMPONI.xml:S1:1342:3	O
SIMPONI	SIMPONI.xml:S1:1346:7	O
ARIA	SIMPONI.xml:S1:1354:4	O
were	SIMPONI.xml:S1:1359:4	O
based	SIMPONI.xml:S1:1364:5	O
on	SIMPONI.xml:S1:1370:2	O
the	SIMPONI.xml:S1:1373:3	O
first	SIMPONI.xml:S1:1377:5	O
24	SIMPONI.xml:S1:1383:2	O
weeks	SIMPONI.xml:S1:1386:5	O
of	SIMPONI.xml:S1:1392:2	O
exposure	SIMPONI.xml:S1:1395:8	O
.	SIMPONI.xml:S1:1403:1	O

Trial	SIMPONI.xml:S1:1409:5	O
1	SIMPONI.xml:S1:1415:1	O
included	SIMPONI.xml:S1:1417:8	O
197	SIMPONI.xml:S1:1426:3	O
control	SIMPONI.xml:S1:1430:7	O
-	SIMPONI.xml:S1:1437:1	O
treated	SIMPONI.xml:S1:1438:7	O
patients	SIMPONI.xml:S1:1446:8	O
and	SIMPONI.xml:S1:1455:3	O
463	SIMPONI.xml:S1:1459:3	O
SIMPONI	SIMPONI.xml:S1:1463:7	O
ARIA	SIMPONI.xml:S1:1471:4	O
-	SIMPONI.xml:S1:1475:1	O
treated	SIMPONI.xml:S1:1476:7	O
patients	SIMPONI.xml:S1:1484:8	O
(	SIMPONI.xml:S1:1493:1	O
which	SIMPONI.xml:S1:1494:5	O
includes	SIMPONI.xml:S1:1500:8	O
control	SIMPONI.xml:S1:1509:7	O
-	SIMPONI.xml:S1:1516:1	O
treated	SIMPONI.xml:S1:1517:7	O
patients	SIMPONI.xml:S1:1525:8	O
who	SIMPONI.xml:S1:1534:3	O
switched	SIMPONI.xml:S1:1538:8	O
to	SIMPONI.xml:S1:1547:2	O
SIMPONI	SIMPONI.xml:S1:1550:7	O
ARIA	SIMPONI.xml:S1:1558:4	O
at	SIMPONI.xml:S1:1563:2	O
Week	SIMPONI.xml:S1:1566:4	O
16	SIMPONI.xml:S1:1571:2	O
)	SIMPONI.xml:S1:1573:1	O
.	SIMPONI.xml:S1:1574:1	O

The	SIMPONI.xml:S1:1576:3	O
proportion	SIMPONI.xml:S1:1580:10	O
of	SIMPONI.xml:S1:1591:2	O
patients	SIMPONI.xml:S1:1594:8	O
who	SIMPONI.xml:S1:1603:3	O
discontinued	SIMPONI.xml:S1:1607:12	O
treatment	SIMPONI.xml:S1:1620:9	O
due	SIMPONI.xml:S1:1630:3	O
to	SIMPONI.xml:S1:1634:2	O
adverse	SIMPONI.xml:S1:1637:7	O
reactions	SIMPONI.xml:S1:1645:9	O
in	SIMPONI.xml:S1:1655:2	O
the	SIMPONI.xml:S1:1658:3	O
controlled	SIMPONI.xml:S1:1662:10	O
phase	SIMPONI.xml:S1:1673:5	O
of	SIMPONI.xml:S1:1679:2	O
Trial	SIMPONI.xml:S1:1682:5	O
1	SIMPONI.xml:S1:1688:1	O
through	SIMPONI.xml:S1:1690:7	O
Week	SIMPONI.xml:S1:1698:4	O
24	SIMPONI.xml:S1:1703:2	O
was	SIMPONI.xml:S1:1706:3	O
3.5%	SIMPONI.xml:S1:1710:4	O
for	SIMPONI.xml:S1:1715:3	O
SIMPONI	SIMPONI.xml:S1:1719:7	O
ARIA	SIMPONI.xml:S1:1727:4	O
-	SIMPONI.xml:S1:1731:1	O
treated	SIMPONI.xml:S1:1732:7	O
patients	SIMPONI.xml:S1:1740:8	O
and	SIMPONI.xml:S1:1749:3	O
0.5%	SIMPONI.xml:S1:1753:4	O
for	SIMPONI.xml:S1:1758:3	O
placebo	SIMPONI.xml:S1:1762:7	O
-	SIMPONI.xml:S1:1769:1	O
treated	SIMPONI.xml:S1:1770:7	O
patients	SIMPONI.xml:S1:1778:8	O
.	SIMPONI.xml:S1:1786:1	O

Upper	SIMPONI.xml:S1:1788:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:1794:11	I-AdverseReaction
tract	SIMPONI.xml:S1:1806:5	I-AdverseReaction
infection	SIMPONI.xml:S1:1812:9	I-AdverseReaction
was	SIMPONI.xml:S1:1822:3	O
the	SIMPONI.xml:S1:1826:3	O
most	SIMPONI.xml:S1:1830:4	O
common	SIMPONI.xml:S1:1835:6	O
adverse	SIMPONI.xml:S1:1842:7	O
reaction	SIMPONI.xml:S1:1850:8	O
reported	SIMPONI.xml:S1:1859:8	O
in	SIMPONI.xml:S1:1868:2	O
the	SIMPONI.xml:S1:1871:3	O
trial	SIMPONI.xml:S1:1875:5	O
through	SIMPONI.xml:S1:1881:7	O
Week	SIMPONI.xml:S1:1889:4	O
24	SIMPONI.xml:S1:1894:2	O
occurring	SIMPONI.xml:S1:1897:9	O
in	SIMPONI.xml:S1:1907:2	O
6.5%	SIMPONI.xml:S1:1910:4	O
of	SIMPONI.xml:S1:1915:2	O
SIMPONI	SIMPONI.xml:S1:1918:7	O
ARIA	SIMPONI.xml:S1:1926:4	O
-	SIMPONI.xml:S1:1930:1	O
treated	SIMPONI.xml:S1:1931:7	O
patients	SIMPONI.xml:S1:1939:8	O
as	SIMPONI.xml:S1:1948:2	O
compared	SIMPONI.xml:S1:1951:8	O
with	SIMPONI.xml:S1:1960:4	O
7.6%	SIMPONI.xml:S1:1965:4	O
of	SIMPONI.xml:S1:1970:2	O
control	SIMPONI.xml:S1:1973:7	O
-	SIMPONI.xml:S1:1980:1	O
treated	SIMPONI.xml:S1:1981:7	O
patients	SIMPONI.xml:S1:1989:8	O
,	SIMPONI.xml:S1:1997:1	O
respectively	SIMPONI.xml:S1:1999:12	O
.	SIMPONI.xml:S1:2011:1	O

Infections	SIMPONI.xml:S1:2021:10	O

Serious	SIMPONI.xml:S1:2038:7	B-Severity
infections	SIMPONI.xml:S1:2046:10	B-AdverseReaction
observed	SIMPONI.xml:S1:2057:8	O
in	SIMPONI.xml:S1:2066:2	O
SIMPONI	SIMPONI.xml:S1:2069:7	O
ARIA	SIMPONI.xml:S1:2077:4	O
-	SIMPONI.xml:S1:2081:1	O
treated	SIMPONI.xml:S1:2082:7	O
patients	SIMPONI.xml:S1:2090:8	O
included	SIMPONI.xml:S1:2099:8	O
sepsis	SIMPONI.xml:S1:2108:6	B-AdverseReaction
,	SIMPONI.xml:S1:2114:1	O
pneumonia	SIMPONI.xml:S1:2116:9	B-AdverseReaction
,	SIMPONI.xml:S1:2125:1	O
cellulitis	SIMPONI.xml:S1:2127:10	B-AdverseReaction
,	SIMPONI.xml:S1:2137:1	O
abscess	SIMPONI.xml:S1:2139:7	B-AdverseReaction
,	SIMPONI.xml:S1:2146:1	O
opportunistic	SIMPONI.xml:S1:2148:13	B-AdverseReaction
infections	SIMPONI.xml:S1:2162:10	I-AdverseReaction
,	SIMPONI.xml:S1:2172:1	O
tuberculosis	SIMPONI.xml:S1:2174:12	B-AdverseReaction
(	SIMPONI.xml:S1:2187:1	O
TB	SIMPONI.xml:S1:2188:2	B-AdverseReaction
)	SIMPONI.xml:S1:2190:1	O
,	SIMPONI.xml:S1:2191:1	O
and	SIMPONI.xml:S1:2193:3	O
invasive	SIMPONI.xml:S1:2197:8	B-AdverseReaction
fungal	SIMPONI.xml:S1:2206:6	I-AdverseReaction
infections	SIMPONI.xml:S1:2213:10	I-AdverseReaction
.	SIMPONI.xml:S1:2223:1	O

Cases	SIMPONI.xml:S1:2225:5	O
of	SIMPONI.xml:S1:2231:2	O
TB	SIMPONI.xml:S1:2234:2	B-AdverseReaction
included	SIMPONI.xml:S1:2237:8	O
pulmonary	SIMPONI.xml:S1:2246:9	B-AdverseReaction
and	SIMPONI.xml:S1:2256:3	O
extrapulmonary	SIMPONI.xml:S1:2260:14	B-AdverseReaction
TB	SIMPONI.xml:S1:2275:2	I-AdverseReaction
.	SIMPONI.xml:S1:2277:1	O

The	SIMPONI.xml:S1:2279:3	O
majority	SIMPONI.xml:S1:2283:8	O
of	SIMPONI.xml:S1:2292:2	O
the	SIMPONI.xml:S1:2295:3	O
TB	SIMPONI.xml:S1:2299:2	B-AdverseReaction
cases	SIMPONI.xml:S1:2302:5	O
occurred	SIMPONI.xml:S1:2308:8	O
in	SIMPONI.xml:S1:2317:2	O
countries	SIMPONI.xml:S1:2320:9	O
with	SIMPONI.xml:S1:2330:4	O
a	SIMPONI.xml:S1:2335:1	O
high	SIMPONI.xml:S1:2337:4	O
incidence	SIMPONI.xml:S1:2342:9	O
rate	SIMPONI.xml:S1:2352:4	O
of	SIMPONI.xml:S1:2357:2	O
TB	SIMPONI.xml:S1:2360:2	O
[	SIMPONI.xml:S1:2364:1	O
see	SIMPONI.xml:S1:2365:3	O
Warnings	SIMPONI.xml:S1:2370:8	O
and	SIMPONI.xml:S1:2379:3	O
Precautions	SIMPONI.xml:S1:2383:11	O
(	SIMPONI.xml:S1:2395:1	O
5.1	SIMPONI.xml:S1:2396:3	O
)	SIMPONI.xml:S1:2399:1	O
]	SIMPONI.xml:S1:2402:1	O
.	SIMPONI.xml:S1:2405:1	O

In	SIMPONI.xml:S1:2411:2	O
the	SIMPONI.xml:S1:2414:3	O
controlled	SIMPONI.xml:S1:2418:10	O
phase	SIMPONI.xml:S1:2429:5	O
of	SIMPONI.xml:S1:2435:2	O
Trial	SIMPONI.xml:S1:2438:5	O
1	SIMPONI.xml:S1:2444:1	O
through	SIMPONI.xml:S1:2446:7	O
Week	SIMPONI.xml:S1:2454:4	O
24	SIMPONI.xml:S1:2459:2	O
,	SIMPONI.xml:S1:2461:1	O
infections	SIMPONI.xml:S1:2463:10	B-AdverseReaction
were	SIMPONI.xml:S1:2474:4	O
observed	SIMPONI.xml:S1:2479:8	O
in	SIMPONI.xml:S1:2488:2	O
27%	SIMPONI.xml:S1:2491:3	O
of	SIMPONI.xml:S1:2495:2	O
SIMPONI	SIMPONI.xml:S1:2498:7	O
ARIA	SIMPONI.xml:S1:2506:4	O
-	SIMPONI.xml:S1:2510:1	O
treated	SIMPONI.xml:S1:2511:7	O
patients	SIMPONI.xml:S1:2519:8	O
compared	SIMPONI.xml:S1:2528:8	O
with	SIMPONI.xml:S1:2537:4	O
24%	SIMPONI.xml:S1:2542:3	O
of	SIMPONI.xml:S1:2546:2	O
control	SIMPONI.xml:S1:2549:7	O
-	SIMPONI.xml:S1:2556:1	O
treated	SIMPONI.xml:S1:2557:7	O
patients	SIMPONI.xml:S1:2565:8	O
,	SIMPONI.xml:S1:2573:1	O
and	SIMPONI.xml:S1:2575:3	O
serious	SIMPONI.xml:S1:2579:7	B-Severity
infections	SIMPONI.xml:S1:2587:10	B-AdverseReaction
were	SIMPONI.xml:S1:2598:4	O
observed	SIMPONI.xml:S1:2603:8	O
in	SIMPONI.xml:S1:2612:2	O
0.9%	SIMPONI.xml:S1:2615:4	O
of	SIMPONI.xml:S1:2620:2	O
SIMPONI	SIMPONI.xml:S1:2623:7	O
ARIA	SIMPONI.xml:S1:2631:4	O
-	SIMPONI.xml:S1:2635:1	O
treated	SIMPONI.xml:S1:2636:7	O
patients	SIMPONI.xml:S1:2644:8	O
and	SIMPONI.xml:S1:2653:3	O
0.0%	SIMPONI.xml:S1:2657:4	O
of	SIMPONI.xml:S1:2662:2	O
control	SIMPONI.xml:S1:2665:7	O
-	SIMPONI.xml:S1:2672:1	O
treated	SIMPONI.xml:S1:2673:7	O
patients	SIMPONI.xml:S1:2681:8	O
.	SIMPONI.xml:S1:2689:1	O

Through	SIMPONI.xml:S1:2691:7	O
Week	SIMPONI.xml:S1:2699:4	O
24	SIMPONI.xml:S1:2704:2	O
,	SIMPONI.xml:S1:2706:1	O
the	SIMPONI.xml:S1:2708:3	O
incidence	SIMPONI.xml:S1:2712:9	O
of	SIMPONI.xml:S1:2722:2	O
serious	SIMPONI.xml:S1:2725:7	B-Severity
infections	SIMPONI.xml:S1:2733:10	B-AdverseReaction
per	SIMPONI.xml:S1:2744:3	O
100	SIMPONI.xml:S1:2748:3	O
patient	SIMPONI.xml:S1:2752:7	O
-	SIMPONI.xml:S1:2759:1	O
years	SIMPONI.xml:S1:2760:5	O
of	SIMPONI.xml:S1:2766:2	O
follow	SIMPONI.xml:S1:2769:6	O
-	SIMPONI.xml:S1:2775:1	O
up	SIMPONI.xml:S1:2776:2	O
was	SIMPONI.xml:S1:2779:3	O
2.2	SIMPONI.xml:S1:2783:3	O
(	SIMPONI.xml:S1:2787:1	O
95%	SIMPONI.xml:S1:2788:3	O
CI	SIMPONI.xml:S1:2792:2	O
0.61	SIMPONI.xml:S1:2795:4	O
,	SIMPONI.xml:S1:2799:1	O
5.71	SIMPONI.xml:S1:2801:4	O
)	SIMPONI.xml:S1:2805:1	O
for	SIMPONI.xml:S1:2807:3	O
the	SIMPONI.xml:S1:2811:3	O
SIMPONI	SIMPONI.xml:S1:2815:7	O
ARIA	SIMPONI.xml:S1:2823:4	O
group	SIMPONI.xml:S1:2828:5	O
,	SIMPONI.xml:S1:2833:1	O
and	SIMPONI.xml:S1:2835:3	O
0	SIMPONI.xml:S1:2839:1	O
(	SIMPONI.xml:S1:2841:1	O
0.00	SIMPONI.xml:S1:2842:4	O
,	SIMPONI.xml:S1:2846:1	O
3.79	SIMPONI.xml:S1:2848:4	O
)	SIMPONI.xml:S1:2852:1	O
for	SIMPONI.xml:S1:2854:3	O
the	SIMPONI.xml:S1:2858:3	O
placebo	SIMPONI.xml:S1:2862:7	O
group	SIMPONI.xml:S1:2870:5	O
.	SIMPONI.xml:S1:2875:1	O

In	SIMPONI.xml:S1:2877:2	O
the	SIMPONI.xml:S1:2880:3	O
controlled	SIMPONI.xml:S1:2884:10	O
and	SIMPONI.xml:S1:2895:3	O
uncontrolled	SIMPONI.xml:S1:2899:12	O
portions	SIMPONI.xml:S1:2912:8	O
of	SIMPONI.xml:S1:2921:2	O
Trial	SIMPONI.xml:S1:2924:5	O
1	SIMPONI.xml:S1:2930:1	O
,	SIMPONI.xml:S1:2931:1	O
958	SIMPONI.xml:S1:2933:3	O
total	SIMPONI.xml:S1:2937:5	O
patient	SIMPONI.xml:S1:2943:7	O
-	SIMPONI.xml:S1:2950:1	O
years	SIMPONI.xml:S1:2951:5	O
of	SIMPONI.xml:S1:2957:2	O
follow	SIMPONI.xml:S1:2960:6	O
-	SIMPONI.xml:S1:2966:1	O
up	SIMPONI.xml:S1:2967:2	O
with	SIMPONI.xml:S1:2970:4	O
a	SIMPONI.xml:S1:2975:1	O
median	SIMPONI.xml:S1:2977:6	O
follow	SIMPONI.xml:S1:2984:6	O
-	SIMPONI.xml:S1:2990:1	O
up	SIMPONI.xml:S1:2991:2	O
of	SIMPONI.xml:S1:2994:2	O
approximately	SIMPONI.xml:S1:2997:13	O
92	SIMPONI.xml:S1:3011:2	O
weeks	SIMPONI.xml:S1:3014:5	O
,	SIMPONI.xml:S1:3019:1	O
the	SIMPONI.xml:S1:3021:3	O
incidence	SIMPONI.xml:S1:3025:9	O
per	SIMPONI.xml:S1:3035:3	O
100	SIMPONI.xml:S1:3039:3	O
patient	SIMPONI.xml:S1:3043:7	O
-	SIMPONI.xml:S1:3050:1	O
years	SIMPONI.xml:S1:3051:5	O
of	SIMPONI.xml:S1:3057:2	O
all	SIMPONI.xml:S1:3060:3	O
serious	SIMPONI.xml:S1:3064:7	B-Severity
infections	SIMPONI.xml:S1:3072:10	B-AdverseReaction
was	SIMPONI.xml:S1:3083:3	O
4.07	SIMPONI.xml:S1:3087:4	O
(	SIMPONI.xml:S1:3092:1	O
CI	SIMPONI.xml:S1:3093:2	O
:	SIMPONI.xml:S1:3095:1	O
2.90	SIMPONI.xml:S1:3097:4	O
,	SIMPONI.xml:S1:3101:1	O
5.57	SIMPONI.xml:S1:3103:4	O
)	SIMPONI.xml:S1:3107:1	O
in	SIMPONI.xml:S1:3109:2	O
patients	SIMPONI.xml:S1:3112:8	O
receiving	SIMPONI.xml:S1:3121:9	O
SIMPONI	SIMPONI.xml:S1:3131:7	O
ARIA	SIMPONI.xml:S1:3139:4	O
[	SIMPONI.xml:S1:3145:1	O
see	SIMPONI.xml:S1:3146:3	O
Warnings	SIMPONI.xml:S1:3151:8	O
and	SIMPONI.xml:S1:3160:3	O
Precautions	SIMPONI.xml:S1:3164:11	O
(	SIMPONI.xml:S1:3176:1	O
5.1	SIMPONI.xml:S1:3177:3	O
)	SIMPONI.xml:S1:3180:1	O
]	SIMPONI.xml:S1:3183:1	O
.	SIMPONI.xml:S1:3186:1	O

In	SIMPONI.xml:S1:3188:2	O
the	SIMPONI.xml:S1:3191:3	O
controlled	SIMPONI.xml:S1:3195:10	O
and	SIMPONI.xml:S1:3206:3	O
uncontrolled	SIMPONI.xml:S1:3210:12	O
portions	SIMPONI.xml:S1:3223:8	O
of	SIMPONI.xml:S1:3232:2	O
Trial	SIMPONI.xml:S1:3235:5	O
1	SIMPONI.xml:S1:3241:1	O
,	SIMPONI.xml:S1:3242:1	O
in	SIMPONI.xml:S1:3244:2	O
SIMPONI	SIMPONI.xml:S1:3247:7	O
ARIA	SIMPONI.xml:S1:3255:4	O
treated	SIMPONI.xml:S1:3260:7	O
patients	SIMPONI.xml:S1:3268:8	O
,	SIMPONI.xml:S1:3276:1	O
the	SIMPONI.xml:S1:3278:3	O
incidence	SIMPONI.xml:S1:3282:9	O
of	SIMPONI.xml:S1:3292:2	O
active	SIMPONI.xml:S1:3295:6	B-AdverseReaction
TB	SIMPONI.xml:S1:3302:2	I-AdverseReaction
per	SIMPONI.xml:S1:3305:3	O
100	SIMPONI.xml:S1:3309:3	O
patient	SIMPONI.xml:S1:3313:7	O
-	SIMPONI.xml:S1:3320:1	O
years	SIMPONI.xml:S1:3321:5	O
was	SIMPONI.xml:S1:3327:3	O
0.31	SIMPONI.xml:S1:3331:4	O
(	SIMPONI.xml:S1:3336:1	O
95%	SIMPONI.xml:S1:3337:3	O
CI	SIMPONI.xml:S1:3341:2	O
:	SIMPONI.xml:S1:3343:1	O
0.06	SIMPONI.xml:S1:3345:4	O
;	SIMPONI.xml:S1:3349:1	O
0.92	SIMPONI.xml:S1:3351:4	O
)	SIMPONI.xml:S1:3355:1	O
and	SIMPONI.xml:S1:3357:3	O
the	SIMPONI.xml:S1:3361:3	O
incidence	SIMPONI.xml:S1:3365:9	O
of	SIMPONI.xml:S1:3375:2	O
other	SIMPONI.xml:S1:3378:5	O
opportunistic	SIMPONI.xml:S1:3384:13	B-AdverseReaction
infections	SIMPONI.xml:S1:3398:10	I-AdverseReaction
per	SIMPONI.xml:S1:3409:3	O
100	SIMPONI.xml:S1:3413:3	O
patient	SIMPONI.xml:S1:3417:7	O
-	SIMPONI.xml:S1:3424:1	O
years	SIMPONI.xml:S1:3425:5	O
was	SIMPONI.xml:S1:3431:3	O
0.42	SIMPONI.xml:S1:3435:4	O
(	SIMPONI.xml:S1:3440:1	O
95%	SIMPONI.xml:S1:3441:3	O
CI	SIMPONI.xml:S1:3445:2	O
:	SIMPONI.xml:S1:3447:1	O
0.11	SIMPONI.xml:S1:3449:4	O
,	SIMPONI.xml:S1:3453:1	O
1.07	SIMPONI.xml:S1:3455:4	O
)	SIMPONI.xml:S1:3459:1	O
.	SIMPONI.xml:S1:3460:1	O

Malignancies	SIMPONI.xml:S1:3470:12	O

One	SIMPONI.xml:S1:3489:3	O
case	SIMPONI.xml:S1:3493:4	O
of	SIMPONI.xml:S1:3498:2	O
malignancy	SIMPONI.xml:S1:3501:10	B-AdverseReaction
other	SIMPONI.xml:S1:3512:5	O
than	SIMPONI.xml:S1:3518:4	O
lymphoma	SIMPONI.xml:S1:3523:8	B-AdverseReaction
and	SIMPONI.xml:S1:3532:3	O
NMSC	SIMPONI.xml:S1:3536:4	B-AdverseReaction
with	SIMPONI.xml:S1:3541:4	O
SIMPONI	SIMPONI.xml:S1:3546:7	O
ARIA	SIMPONI.xml:S1:3554:4	O
was	SIMPONI.xml:S1:3559:3	O
reported	SIMPONI.xml:S1:3563:8	O
through	SIMPONI.xml:S1:3572:7	O
Week	SIMPONI.xml:S1:3580:4	O
24	SIMPONI.xml:S1:3585:2	O
during	SIMPONI.xml:S1:3588:6	O
the	SIMPONI.xml:S1:3595:3	O
controlled	SIMPONI.xml:S1:3599:10	O
phase	SIMPONI.xml:S1:3610:5	O
of	SIMPONI.xml:S1:3616:2	O
Trial	SIMPONI.xml:S1:3619:5	O
1	SIMPONI.xml:S1:3625:1	O
.	SIMPONI.xml:S1:3626:1	O

In	SIMPONI.xml:S1:3628:2	O
the	SIMPONI.xml:S1:3631:3	O
controlled	SIMPONI.xml:S1:3635:10	O
and	SIMPONI.xml:S1:3646:3	O
uncontrolled	SIMPONI.xml:S1:3650:12	O
portions	SIMPONI.xml:S1:3663:8	O
through	SIMPONI.xml:S1:3672:7	O
approximately	SIMPONI.xml:S1:3680:13	O
92	SIMPONI.xml:S1:3694:2	O
weeks	SIMPONI.xml:S1:3697:5	O
,	SIMPONI.xml:S1:3702:1	O
the	SIMPONI.xml:S1:3704:3	O
incidence	SIMPONI.xml:S1:3708:9	O
of	SIMPONI.xml:S1:3718:2	O
malignancies	SIMPONI.xml:S1:3721:12	B-AdverseReaction
per	SIMPONI.xml:S1:3734:3	O
100	SIMPONI.xml:S1:3738:3	O
patient	SIMPONI.xml:S1:3742:7	O
-	SIMPONI.xml:S1:3749:1	O
years	SIMPONI.xml:S1:3750:5	O
,	SIMPONI.xml:S1:3755:1	O
other	SIMPONI.xml:S1:3757:5	O
than	SIMPONI.xml:S1:3763:4	O
lymphoma	SIMPONI.xml:S1:3768:8	B-AdverseReaction
and	SIMPONI.xml:S1:3777:3	O
NMSC	SIMPONI.xml:S1:3781:4	B-AdverseReaction
,	SIMPONI.xml:S1:3785:1	O
in	SIMPONI.xml:S1:3787:2	O
SIMPONI	SIMPONI.xml:S1:3790:7	O
ARIA	SIMPONI.xml:S1:3798:4	O
-	SIMPONI.xml:S1:3802:1	O
treated	SIMPONI.xml:S1:3803:7	O
patients	SIMPONI.xml:S1:3811:8	O
was	SIMPONI.xml:S1:3820:3	O
0.31	SIMPONI.xml:S1:3824:4	O
(	SIMPONI.xml:S1:3829:1	O
CI	SIMPONI.xml:S1:3830:2	O
:	SIMPONI.xml:S1:3832:1	O
0.06	SIMPONI.xml:S1:3834:4	O
,	SIMPONI.xml:S1:3838:1	O
0.92	SIMPONI.xml:S1:3840:4	O
)	SIMPONI.xml:S1:3844:1	O
and	SIMPONI.xml:S1:3846:3	O
the	SIMPONI.xml:S1:3850:3	O
incidence	SIMPONI.xml:S1:3854:9	O
of	SIMPONI.xml:S1:3864:2	O
NMSC	SIMPONI.xml:S1:3867:4	B-AdverseReaction
was	SIMPONI.xml:S1:3872:3	O
0.1	SIMPONI.xml:S1:3876:3	O
(	SIMPONI.xml:S1:3880:1	O
95%	SIMPONI.xml:S1:3881:3	O
CI	SIMPONI.xml:S1:3885:2	O
:	SIMPONI.xml:S1:3887:1	O
0.00	SIMPONI.xml:S1:3889:4	O
,	SIMPONI.xml:S1:3893:1	O
0.58	SIMPONI.xml:S1:3895:4	O
)	SIMPONI.xml:S1:3899:1	O
.	SIMPONI.xml:S1:3900:1	O

Liver	SIMPONI.xml:S1:3910:5	O
Enzyme	SIMPONI.xml:S1:3916:6	O
Elevations	SIMPONI.xml:S1:3923:10	O

There	SIMPONI.xml:S1:3940:5	O
have	SIMPONI.xml:S1:3946:4	O
been	SIMPONI.xml:S1:3951:4	O
reports	SIMPONI.xml:S1:3956:7	O
of	SIMPONI.xml:S1:3964:2	O
severe	SIMPONI.xml:S1:3967:6	B-Severity
hepatic	SIMPONI.xml:S1:3974:7	B-AdverseReaction
reactions	SIMPONI.xml:S1:3982:9	I-AdverseReaction
including	SIMPONI.xml:S1:3992:9	O
acute	SIMPONI.xml:S1:4002:5	B-AdverseReaction
liver	SIMPONI.xml:S1:4008:5	I-AdverseReaction
failure	SIMPONI.xml:S1:4014:7	I-AdverseReaction
in	SIMPONI.xml:S1:4022:2	O
patients	SIMPONI.xml:S1:4025:8	O
receiving	SIMPONI.xml:S1:4034:9	O
TNF	SIMPONI.xml:S1:4044:3	B-DrugClass
-	SIMPONI.xml:S1:4047:1	I-DrugClass
blockers	SIMPONI.xml:S1:4048:8	I-DrugClass
.	SIMPONI.xml:S1:4056:1	O

In	SIMPONI.xml:S1:4062:2	O
the	SIMPONI.xml:S1:4065:3	O
controlled	SIMPONI.xml:S1:4069:10	O
phase	SIMPONI.xml:S1:4080:5	O
of	SIMPONI.xml:S1:4086:2	O
Trial	SIMPONI.xml:S1:4089:5	O
1	SIMPONI.xml:S1:4095:1	O
,	SIMPONI.xml:S1:4096:1	O
through	SIMPONI.xml:S1:4098:7	O
Week	SIMPONI.xml:S1:4106:4	O
24	SIMPONI.xml:S1:4111:2	O
,	SIMPONI.xml:S1:4113:1	O
ALT	SIMPONI.xml:S1:4115:3	B-AdverseReaction
elevations	SIMPONI.xml:S1:4119:10	I-AdverseReaction
5	SIMPONI.xml:S1:4133:1	B-Severity
ULN	SIMPONI.xml:S1:4137:3	I-Severity
occurred	SIMPONI.xml:S1:4141:8	O
in	SIMPONI.xml:S1:4150:2	O
0.8%	SIMPONI.xml:S1:4153:4	O
of	SIMPONI.xml:S1:4158:2	O
SIMPONI	SIMPONI.xml:S1:4161:7	O
ARIA	SIMPONI.xml:S1:4169:4	O
-	SIMPONI.xml:S1:4173:1	O
treated	SIMPONI.xml:S1:4174:7	O
patients	SIMPONI.xml:S1:4182:8	O
and	SIMPONI.xml:S1:4191:3	O
0%	SIMPONI.xml:S1:4195:2	O
of	SIMPONI.xml:S1:4198:2	O
control	SIMPONI.xml:S1:4201:7	O
-	SIMPONI.xml:S1:4208:1	O
treated	SIMPONI.xml:S1:4209:7	O
patients	SIMPONI.xml:S1:4217:8	O
and	SIMPONI.xml:S1:4226:3	O
ALT	SIMPONI.xml:S1:4230:3	B-AdverseReaction
elevations	SIMPONI.xml:S1:4234:10	I-AdverseReaction
3	SIMPONI.xml:S1:4248:1	B-Severity
ULN	SIMPONI.xml:S1:4252:3	I-Severity
occurred	SIMPONI.xml:S1:4256:8	O
in	SIMPONI.xml:S1:4265:2	O
2.3%	SIMPONI.xml:S1:4268:4	O
of	SIMPONI.xml:S1:4273:2	O
SIMPONI	SIMPONI.xml:S1:4276:7	O
ARIA	SIMPONI.xml:S1:4284:4	O
-	SIMPONI.xml:S1:4288:1	O
treated	SIMPONI.xml:S1:4289:7	O
patients	SIMPONI.xml:S1:4297:8	O
and	SIMPONI.xml:S1:4306:3	O
2.5%	SIMPONI.xml:S1:4310:4	O
of	SIMPONI.xml:S1:4315:2	O
control	SIMPONI.xml:S1:4318:7	O
-	SIMPONI.xml:S1:4325:1	O
treated	SIMPONI.xml:S1:4326:7	O
patients	SIMPONI.xml:S1:4334:8	O
.	SIMPONI.xml:S1:4342:1	O

Since	SIMPONI.xml:S1:4348:5	O
many	SIMPONI.xml:S1:4354:4	O
of	SIMPONI.xml:S1:4359:2	O
the	SIMPONI.xml:S1:4362:3	O
patients	SIMPONI.xml:S1:4366:8	O
in	SIMPONI.xml:S1:4375:2	O
the	SIMPONI.xml:S1:4378:3	O
Phase	SIMPONI.xml:S1:4382:5	O
3	SIMPONI.xml:S1:4388:1	O
trial	SIMPONI.xml:S1:4390:5	O
were	SIMPONI.xml:S1:4396:4	O
also	SIMPONI.xml:S1:4401:4	O
taking	SIMPONI.xml:S1:4406:6	O
medications	SIMPONI.xml:S1:4413:11	O
that	SIMPONI.xml:S1:4425:4	O
cause	SIMPONI.xml:S1:4430:5	O
liver	SIMPONI.xml:S1:4436:5	O
enzyme	SIMPONI.xml:S1:4442:6	O
elevations	SIMPONI.xml:S1:4449:10	O
(	SIMPONI.xml:S1:4460:1	O
e	SIMPONI.xml:S1:4461:1	O
.	SIMPONI.xml:S1:4462:1	O
g	SIMPONI.xml:S1:4463:1	O
.	SIMPONI.xml:S1:4464:1	O
,	SIMPONI.xml:S1:4465:1	O
nonsteroidal	SIMPONI.xml:S1:4467:12	O
anti	SIMPONI.xml:S1:4480:4	O
-	SIMPONI.xml:S1:4484:1	O
inflammatory	SIMPONI.xml:S1:4485:12	O
drugs	SIMPONI.xml:S1:4498:5	O
[	SIMPONI.xml:S1:4504:1	O
NSAIDs	SIMPONI.xml:S1:4505:6	O
]	SIMPONI.xml:S1:4511:1	O
,	SIMPONI.xml:S1:4512:1	O
methotrexate	SIMPONI.xml:S1:4514:12	O
[	SIMPONI.xml:S1:4527:1	O
MTX	SIMPONI.xml:S1:4528:3	O
]	SIMPONI.xml:S1:4531:1	O
,	SIMPONI.xml:S1:4532:1	O
or	SIMPONI.xml:S1:4534:2	O
isoniazid	SIMPONI.xml:S1:4537:9	O
prophylaxis	SIMPONI.xml:S1:4547:11	O
)	SIMPONI.xml:S1:4558:1	O
,	SIMPONI.xml:S1:4559:1	O
the	SIMPONI.xml:S1:4561:3	O
relationship	SIMPONI.xml:S1:4565:12	O
between	SIMPONI.xml:S1:4578:7	O
SIMPONI	SIMPONI.xml:S1:4586:7	O
ARIA	SIMPONI.xml:S1:4594:4	O
and	SIMPONI.xml:S1:4599:3	O
liver	SIMPONI.xml:S1:4603:5	O
enzyme	SIMPONI.xml:S1:4609:6	O
elevation	SIMPONI.xml:S1:4616:9	O
is	SIMPONI.xml:S1:4626:2	O
not	SIMPONI.xml:S1:4629:3	O
clear	SIMPONI.xml:S1:4633:5	O
.	SIMPONI.xml:S1:4638:1	O

Autoimmune	SIMPONI.xml:S1:4648:10	O
Disorders	SIMPONI.xml:S1:4659:9	O
and	SIMPONI.xml:S1:4669:3	O
Autoantibodies	SIMPONI.xml:S1:4673:14	O

The	SIMPONI.xml:S1:4694:3	O
use	SIMPONI.xml:S1:4698:3	O
of	SIMPONI.xml:S1:4702:2	O
TNF	SIMPONI.xml:S1:4705:3	B-DrugClass
-	SIMPONI.xml:S1:4708:1	I-DrugClass
blockers	SIMPONI.xml:S1:4709:8	I-DrugClass
,	SIMPONI.xml:S1:4717:1	O
of	SIMPONI.xml:S1:4719:2	O
which	SIMPONI.xml:S1:4722:5	O
SIMPONI	SIMPONI.xml:S1:4728:7	O
ARIA	SIMPONI.xml:S1:4736:4	O
is	SIMPONI.xml:S1:4741:2	O
a	SIMPONI.xml:S1:4744:1	O
member	SIMPONI.xml:S1:4746:6	O
,	SIMPONI.xml:S1:4752:1	O
has	SIMPONI.xml:S1:4754:3	O
been	SIMPONI.xml:S1:4758:4	O
associated	SIMPONI.xml:S1:4763:10	O
with	SIMPONI.xml:S1:4774:4	O
the	SIMPONI.xml:S1:4779:3	O
formation	SIMPONI.xml:S1:4783:9	B-AdverseReaction
of	SIMPONI.xml:S1:4793:2	I-AdverseReaction
autoantibodies	SIMPONI.xml:S1:4796:14	I-AdverseReaction
and	SIMPONI.xml:S1:4811:3	O
,	SIMPONI.xml:S1:4814:1	O
rarely	SIMPONI.xml:S1:4816:6	O
,	SIMPONI.xml:S1:4822:1	O
with	SIMPONI.xml:S1:4824:4	O
the	SIMPONI.xml:S1:4829:3	O
development	SIMPONI.xml:S1:4833:11	O
of	SIMPONI.xml:S1:4845:2	O
a	SIMPONI.xml:S1:4848:1	O
lupus	SIMPONI.xml:S1:4850:5	B-AdverseReaction
-	SIMPONI.xml:S1:4855:1	I-AdverseReaction
like	SIMPONI.xml:S1:4856:4	I-AdverseReaction
syndrome	SIMPONI.xml:S1:4861:8	I-AdverseReaction
.	SIMPONI.xml:S1:4869:1	O

At	SIMPONI.xml:S1:4875:2	O
Week	SIMPONI.xml:S1:4878:4	O
20	SIMPONI.xml:S1:4883:2	O
in	SIMPONI.xml:S1:4886:2	O
Trial	SIMPONI.xml:S1:4889:5	O
1	SIMPONI.xml:S1:4895:1	O
,	SIMPONI.xml:S1:4896:1	O
17%	SIMPONI.xml:S1:4898:3	O
of	SIMPONI.xml:S1:4902:2	O
SIMPONI	SIMPONI.xml:S1:4905:7	O
ARIA	SIMPONI.xml:S1:4913:4	O
-	SIMPONI.xml:S1:4917:1	O
treated	SIMPONI.xml:S1:4918:7	O
patients	SIMPONI.xml:S1:4926:8	O
and	SIMPONI.xml:S1:4935:3	O
13%	SIMPONI.xml:S1:4939:3	O
of	SIMPONI.xml:S1:4943:2	O
control	SIMPONI.xml:S1:4946:7	O
patients	SIMPONI.xml:S1:4954:8	O
were	SIMPONI.xml:S1:4963:4	O
newly	SIMPONI.xml:S1:4968:5	B-AdverseReaction
ANA	SIMPONI.xml:S1:4974:3	I-AdverseReaction
-	SIMPONI.xml:S1:4977:1	I-AdverseReaction
positive	SIMPONI.xml:S1:4978:8	I-AdverseReaction
(	SIMPONI.xml:S1:4987:1	O
at	SIMPONI.xml:S1:4988:2	B-Severity
titers	SIMPONI.xml:S1:4991:6	I-Severity
of	SIMPONI.xml:S1:4998:2	I-Severity
1	SIMPONI.xml:S1:5001:1	I-Severity
:	SIMPONI.xml:S1:5002:1	I-Severity
160	SIMPONI.xml:S1:5003:3	I-Severity
or	SIMPONI.xml:S1:5007:2	O
greater	SIMPONI.xml:S1:5010:7	O
)	SIMPONI.xml:S1:5017:1	O
.	SIMPONI.xml:S1:5018:1	O

Of	SIMPONI.xml:S1:5020:2	O
these	SIMPONI.xml:S1:5023:5	O
patients	SIMPONI.xml:S1:5029:8	O
,	SIMPONI.xml:S1:5037:1	O
one	SIMPONI.xml:S1:5039:3	O
SIMPONI	SIMPONI.xml:S1:5043:7	O
ARIA	SIMPONI.xml:S1:5051:4	O
-	SIMPONI.xml:S1:5055:1	O
treated	SIMPONI.xml:S1:5056:7	O
patient	SIMPONI.xml:S1:5064:7	O
and	SIMPONI.xml:S1:5072:3	O
no	SIMPONI.xml:S1:5076:2	B-Negation
control	SIMPONI.xml:S1:5079:7	O
-	SIMPONI.xml:S1:5086:1	O
treated	SIMPONI.xml:S1:5087:7	O
patients	SIMPONI.xml:S1:5095:8	O
had	SIMPONI.xml:S1:5104:3	O
newly	SIMPONI.xml:S1:5108:5	B-AdverseReaction
positive	SIMPONI.xml:S1:5114:8	I-AdverseReaction
anti	SIMPONI.xml:S1:5123:4	I-AdverseReaction
-	SIMPONI.xml:S1:5127:1	I-AdverseReaction
dsDNA	SIMPONI.xml:S1:5128:5	I-AdverseReaction
antibodies	SIMPONI.xml:S1:5134:10	I-AdverseReaction
.	SIMPONI.xml:S1:5144:1	O

Administration	SIMPONI.xml:S1:5154:14	O
Reactions	SIMPONI.xml:S1:5169:9	O

In	SIMPONI.xml:S1:5185:2	O
the	SIMPONI.xml:S1:5188:3	O
controlled	SIMPONI.xml:S1:5192:10	O
phase	SIMPONI.xml:S1:5203:5	O
of	SIMPONI.xml:S1:5209:2	O
Trial	SIMPONI.xml:S1:5212:5	O
1	SIMPONI.xml:S1:5218:1	O
through	SIMPONI.xml:S1:5220:7	O
Week	SIMPONI.xml:S1:5228:4	O
24	SIMPONI.xml:S1:5233:2	O
,	SIMPONI.xml:S1:5235:1	O
1.1%	SIMPONI.xml:S1:5237:4	O
of	SIMPONI.xml:S1:5242:2	O
SIMPONI	SIMPONI.xml:S1:5245:7	O
ARIA	SIMPONI.xml:S1:5253:4	O
infusions	SIMPONI.xml:S1:5258:9	O
were	SIMPONI.xml:S1:5268:4	O
associated	SIMPONI.xml:S1:5273:10	O
with	SIMPONI.xml:S1:5284:4	O
an	SIMPONI.xml:S1:5289:2	O
infusion	SIMPONI.xml:S1:5292:8	B-AdverseReaction
reaction	SIMPONI.xml:S1:5301:8	I-AdverseReaction
compared	SIMPONI.xml:S1:5310:8	O
with	SIMPONI.xml:S1:5319:4	O
0.2%	SIMPONI.xml:S1:5324:4	O
of	SIMPONI.xml:S1:5329:2	O
infusions	SIMPONI.xml:S1:5332:9	O
in	SIMPONI.xml:S1:5342:2	O
the	SIMPONI.xml:S1:5345:3	O
control	SIMPONI.xml:S1:5349:7	O
group	SIMPONI.xml:S1:5357:5	O
.	SIMPONI.xml:S1:5362:1	O

The	SIMPONI.xml:S1:5364:3	O
most	SIMPONI.xml:S1:5368:4	O
common	SIMPONI.xml:S1:5373:6	O
infusion	SIMPONI.xml:S1:5380:8	O
reaction	SIMPONI.xml:S1:5389:8	O
in	SIMPONI.xml:S1:5398:2	O
SIMPONI	SIMPONI.xml:S1:5401:7	O
ARIA	SIMPONI.xml:S1:5409:4	O
treated	SIMPONI.xml:S1:5414:7	O
patients	SIMPONI.xml:S1:5422:8	O
was	SIMPONI.xml:S1:5431:3	O
rash	SIMPONI.xml:S1:5435:4	B-AdverseReaction
.	SIMPONI.xml:S1:5439:1	O

No	SIMPONI.xml:S1:5441:2	B-Negation
serious	SIMPONI.xml:S1:5444:7	B-Severity
infusion	SIMPONI.xml:S1:5452:8	B-AdverseReaction
reactions	SIMPONI.xml:S1:5461:9	I-AdverseReaction
were	SIMPONI.xml:S1:5471:4	O
reported	SIMPONI.xml:S1:5476:8	O
.	SIMPONI.xml:S1:5484:1	O

Immunogenicity	SIMPONI.xml:S1:5494:14	O

Antibodies	SIMPONI.xml:S1:5515:10	O
to	SIMPONI.xml:S1:5526:2	O
SIMPONI	SIMPONI.xml:S1:5529:7	O
ARIA	SIMPONI.xml:S1:5537:4	O
were	SIMPONI.xml:S1:5542:4	O
detected	SIMPONI.xml:S1:5547:8	O
in	SIMPONI.xml:S1:5556:2	O
13	SIMPONI.xml:S1:5559:2	O
(	SIMPONI.xml:S1:5562:1	O
3%	SIMPONI.xml:S1:5563:2	O
)	SIMPONI.xml:S1:5565:1	O
golimumab	SIMPONI.xml:S1:5567:9	O
-	SIMPONI.xml:S1:5576:1	O
treated	SIMPONI.xml:S1:5577:7	O
patients	SIMPONI.xml:S1:5585:8	O
following	SIMPONI.xml:S1:5594:9	O
IV	SIMPONI.xml:S1:5604:2	O
administration	SIMPONI.xml:S1:5607:14	O
of	SIMPONI.xml:S1:5622:2	O
SIMPONI	SIMPONI.xml:S1:5625:7	O
ARIA	SIMPONI.xml:S1:5633:4	O
in	SIMPONI.xml:S1:5638:2	O
combination	SIMPONI.xml:S1:5641:11	O
with	SIMPONI.xml:S1:5653:4	O
MTX	SIMPONI.xml:S1:5658:3	O
through	SIMPONI.xml:S1:5662:7	O
Week	SIMPONI.xml:S1:5670:4	O
24	SIMPONI.xml:S1:5675:2	O
of	SIMPONI.xml:S1:5678:2	O
Trial	SIMPONI.xml:S1:5681:5	O
1	SIMPONI.xml:S1:5687:1	O
.	SIMPONI.xml:S1:5688:1	O

All	SIMPONI.xml:S1:5694:3	O
patients	SIMPONI.xml:S1:5698:8	O
who	SIMPONI.xml:S1:5707:3	O
were	SIMPONI.xml:S1:5711:4	O
positive	SIMPONI.xml:S1:5716:8	O
for	SIMPONI.xml:S1:5725:3	O
antibodies	SIMPONI.xml:S1:5729:10	O
to	SIMPONI.xml:S1:5740:2	O
golimumab	SIMPONI.xml:S1:5743:9	O
had	SIMPONI.xml:S1:5753:3	O
neutralizing	SIMPONI.xml:S1:5757:12	O
antibodies	SIMPONI.xml:S1:5770:10	O
based	SIMPONI.xml:S1:5781:5	O
on	SIMPONI.xml:S1:5787:2	O
an	SIMPONI.xml:S1:5790:2	O
in	SIMPONI.xml:S1:5793:2	O
vitro	SIMPONI.xml:S1:5796:5	O
cell	SIMPONI.xml:S1:5802:4	O
-	SIMPONI.xml:S1:5806:1	O
based	SIMPONI.xml:S1:5807:5	O
assay	SIMPONI.xml:S1:5813:5	O
.	SIMPONI.xml:S1:5818:1	O

The	SIMPONI.xml:S1:5820:3	O
small	SIMPONI.xml:S1:5824:5	O
number	SIMPONI.xml:S1:5830:6	O
of	SIMPONI.xml:S1:5837:2	O
patients	SIMPONI.xml:S1:5840:8	O
positive	SIMPONI.xml:S1:5849:8	O
for	SIMPONI.xml:S1:5858:3	O
antibodies	SIMPONI.xml:S1:5862:10	O
to	SIMPONI.xml:S1:5873:2	O
SIMPONI	SIMPONI.xml:S1:5876:7	O
ARIA	SIMPONI.xml:S1:5884:4	O
limits	SIMPONI.xml:S1:5889:6	O
the	SIMPONI.xml:S1:5896:3	O
ability	SIMPONI.xml:S1:5900:7	O
to	SIMPONI.xml:S1:5908:2	O
draw	SIMPONI.xml:S1:5911:4	O
definitive	SIMPONI.xml:S1:5916:10	O
conclusions	SIMPONI.xml:S1:5927:11	O
regarding	SIMPONI.xml:S1:5939:9	O
the	SIMPONI.xml:S1:5949:3	O
relationship	SIMPONI.xml:S1:5953:12	O
between	SIMPONI.xml:S1:5966:7	O
antibodies	SIMPONI.xml:S1:5974:10	O
to	SIMPONI.xml:S1:5985:2	O
golimumab	SIMPONI.xml:S1:5988:9	O
and	SIMPONI.xml:S1:5998:3	O
clinical	SIMPONI.xml:S1:6002:8	O
efficacy	SIMPONI.xml:S1:6011:8	O
or	SIMPONI.xml:S1:6020:2	O
safety	SIMPONI.xml:S1:6023:6	O
measures	SIMPONI.xml:S1:6030:8	O
.	SIMPONI.xml:S1:6038:1	O

The	SIMPONI.xml:S1:6044:3	O
data	SIMPONI.xml:S1:6048:4	O
above	SIMPONI.xml:S1:6053:5	O
reflect	SIMPONI.xml:S1:6059:7	O
the	SIMPONI.xml:S1:6067:3	O
percentage	SIMPONI.xml:S1:6071:10	O
of	SIMPONI.xml:S1:6082:2	O
patients	SIMPONI.xml:S1:6085:8	O
whose	SIMPONI.xml:S1:6094:5	O
test	SIMPONI.xml:S1:6100:4	O
results	SIMPONI.xml:S1:6105:7	O
were	SIMPONI.xml:S1:6113:4	O
considered	SIMPONI.xml:S1:6118:10	O
positive	SIMPONI.xml:S1:6129:8	O
for	SIMPONI.xml:S1:6138:3	O
antibodies	SIMPONI.xml:S1:6142:10	O
to	SIMPONI.xml:S1:6153:2	O
SIMPONI	SIMPONI.xml:S1:6156:7	O
ARIA	SIMPONI.xml:S1:6164:4	O
in	SIMPONI.xml:S1:6169:2	O
an	SIMPONI.xml:S1:6172:2	O
ELISA	SIMPONI.xml:S1:6175:5	O
assay	SIMPONI.xml:S1:6181:5	O
.	SIMPONI.xml:S1:6186:1	O

The	SIMPONI.xml:S1:6188:3	O
ELISA	SIMPONI.xml:S1:6192:5	O
assay	SIMPONI.xml:S1:6198:5	O
is	SIMPONI.xml:S1:6204:2	O
subject	SIMPONI.xml:S1:6207:7	O
to	SIMPONI.xml:S1:6215:2	O
interference	SIMPONI.xml:S1:6218:12	O
by	SIMPONI.xml:S1:6231:2	O
co	SIMPONI.xml:S1:6234:2	O
-	SIMPONI.xml:S1:6236:1	O
present	SIMPONI.xml:S1:6237:7	O
golimumab	SIMPONI.xml:S1:6245:9	O
and	SIMPONI.xml:S1:6255:3	O
thus	SIMPONI.xml:S1:6259:4	O
the	SIMPONI.xml:S1:6264:3	O
results	SIMPONI.xml:S1:6268:7	O
are	SIMPONI.xml:S1:6276:3	O
an	SIMPONI.xml:S1:6280:2	O
underestimate	SIMPONI.xml:S1:6283:13	O
of	SIMPONI.xml:S1:6297:2	O
the	SIMPONI.xml:S1:6300:3	O
rate	SIMPONI.xml:S1:6304:4	O
of	SIMPONI.xml:S1:6309:2	O
product	SIMPONI.xml:S1:6312:7	O
immunogenicity	SIMPONI.xml:S1:6320:14	O
and	SIMPONI.xml:S1:6335:3	O
are	SIMPONI.xml:S1:6339:3	O
in	SIMPONI.xml:S1:6343:2	O
addition	SIMPONI.xml:S1:6346:8	O
highly	SIMPONI.xml:S1:6355:6	O
dependent	SIMPONI.xml:S1:6362:9	O
on	SIMPONI.xml:S1:6372:2	O
the	SIMPONI.xml:S1:6375:3	O
sensitivity	SIMPONI.xml:S1:6379:11	O
and	SIMPONI.xml:S1:6391:3	O
specificity	SIMPONI.xml:S1:6395:11	O
of	SIMPONI.xml:S1:6407:2	O
the	SIMPONI.xml:S1:6410:3	O
assay	SIMPONI.xml:S1:6414:5	O
.	SIMPONI.xml:S1:6419:1	O

Additionally	SIMPONI.xml:S1:6421:12	O
,	SIMPONI.xml:S1:6433:1	O
the	SIMPONI.xml:S1:6435:3	O
observed	SIMPONI.xml:S1:6439:8	O
incidence	SIMPONI.xml:S1:6448:9	O
of	SIMPONI.xml:S1:6458:2	O
antibody	SIMPONI.xml:S1:6461:8	O
positivity	SIMPONI.xml:S1:6470:10	O
in	SIMPONI.xml:S1:6481:2	O
an	SIMPONI.xml:S1:6484:2	O
assay	SIMPONI.xml:S1:6487:5	O
may	SIMPONI.xml:S1:6493:3	O
be	SIMPONI.xml:S1:6497:2	O
influenced	SIMPONI.xml:S1:6500:10	O
by	SIMPONI.xml:S1:6511:2	O
several	SIMPONI.xml:S1:6514:7	O
factors	SIMPONI.xml:S1:6522:7	O
including	SIMPONI.xml:S1:6530:9	O
sample	SIMPONI.xml:S1:6540:6	O
handling	SIMPONI.xml:S1:6547:8	O
,	SIMPONI.xml:S1:6555:1	O
timing	SIMPONI.xml:S1:6557:6	O
of	SIMPONI.xml:S1:6564:2	O
sample	SIMPONI.xml:S1:6567:6	O
collection	SIMPONI.xml:S1:6574:10	O
,	SIMPONI.xml:S1:6584:1	O
concomitant	SIMPONI.xml:S1:6586:11	O
medications	SIMPONI.xml:S1:6598:11	O
,	SIMPONI.xml:S1:6609:1	O
and	SIMPONI.xml:S1:6611:3	O
underlying	SIMPONI.xml:S1:6615:10	O
disease	SIMPONI.xml:S1:6626:7	O
.	SIMPONI.xml:S1:6633:1	O

For	SIMPONI.xml:S1:6635:3	O
these	SIMPONI.xml:S1:6639:5	O
reasons	SIMPONI.xml:S1:6645:7	O
,	SIMPONI.xml:S1:6652:1	O
comparison	SIMPONI.xml:S1:6654:10	O
of	SIMPONI.xml:S1:6665:2	O
the	SIMPONI.xml:S1:6668:3	O
incidence	SIMPONI.xml:S1:6672:9	O
of	SIMPONI.xml:S1:6682:2	O
antibodies	SIMPONI.xml:S1:6685:10	O
to	SIMPONI.xml:S1:6696:2	O
SIMPONI	SIMPONI.xml:S1:6699:7	O
ARIA	SIMPONI.xml:S1:6707:4	O
with	SIMPONI.xml:S1:6712:4	O
the	SIMPONI.xml:S1:6717:3	O
incidence	SIMPONI.xml:S1:6721:9	O
of	SIMPONI.xml:S1:6731:2	O
antibodies	SIMPONI.xml:S1:6734:10	O
to	SIMPONI.xml:S1:6745:2	O
other	SIMPONI.xml:S1:6748:5	O
products	SIMPONI.xml:S1:6754:8	O
may	SIMPONI.xml:S1:6763:3	O
be	SIMPONI.xml:S1:6767:2	O
misleading	SIMPONI.xml:S1:6770:10	O
.	SIMPONI.xml:S1:6780:1	O

Other	SIMPONI.xml:S1:6790:5	O
Adverse	SIMPONI.xml:S1:6796:7	O
Reactions	SIMPONI.xml:S1:6804:9	O

Table	SIMPONI.xml:S1:6820:5	O
1	SIMPONI.xml:S1:6826:1	O
summarizes	SIMPONI.xml:S1:6828:10	O
the	SIMPONI.xml:S1:6839:3	O
adverse	SIMPONI.xml:S1:6843:7	O
drug	SIMPONI.xml:S1:6851:4	O
reactions	SIMPONI.xml:S1:6856:9	O
that	SIMPONI.xml:S1:6866:4	O
occurred	SIMPONI.xml:S1:6871:8	O
at	SIMPONI.xml:S1:6880:2	O
a	SIMPONI.xml:S1:6883:1	O
rate	SIMPONI.xml:S1:6885:4	O
of	SIMPONI.xml:S1:6890:2	O
at	SIMPONI.xml:S1:6893:2	O
least	SIMPONI.xml:S1:6896:5	O
1%	SIMPONI.xml:S1:6902:2	O
in	SIMPONI.xml:S1:6905:2	O
the	SIMPONI.xml:S1:6908:3	O
SIMPONI	SIMPONI.xml:S1:6912:7	O
ARIA	SIMPONI.xml:S1:6920:4	O
MTX	SIMPONI.xml:S1:6927:3	O
group	SIMPONI.xml:S1:6931:5	O
with	SIMPONI.xml:S1:6937:4	O
a	SIMPONI.xml:S1:6942:1	O
higher	SIMPONI.xml:S1:6944:6	O
incidence	SIMPONI.xml:S1:6951:9	O
than	SIMPONI.xml:S1:6961:4	O
in	SIMPONI.xml:S1:6966:2	O
the	SIMPONI.xml:S1:6969:3	O
placebo	SIMPONI.xml:S1:6973:7	O
MTX	SIMPONI.xml:S1:6983:3	O
group	SIMPONI.xml:S1:6987:5	O
during	SIMPONI.xml:S1:6993:6	O
the	SIMPONI.xml:S1:7000:3	O
controlled	SIMPONI.xml:S1:7004:10	O
period	SIMPONI.xml:S1:7015:6	O
of	SIMPONI.xml:S1:7022:2	O
Trial	SIMPONI.xml:S1:7025:5	O
1	SIMPONI.xml:S1:7031:1	O
through	SIMPONI.xml:S1:7033:7	O
Week	SIMPONI.xml:S1:7041:4	O
24	SIMPONI.xml:S1:7046:2	O
.	SIMPONI.xml:S1:7048:1	O

Table	SIMPONI.xml:S1:7054:5	O
1	SIMPONI.xml:S1:7060:1	O
:	SIMPONI.xml:S1:7061:1	O
Adverse	SIMPONI.xml:S1:7063:7	O
Drug	SIMPONI.xml:S1:7071:4	O
Reactions	SIMPONI.xml:S1:7076:9	O
Reported	SIMPONI.xml:S1:7086:8	O
by	SIMPONI.xml:S1:7095:2	O
1%	SIMPONI.xml:S1:7101:2	O
of	SIMPONI.xml:S1:7104:2	O
SIMPONI	SIMPONI.xml:S1:7107:7	O
ARIA	SIMPONI.xml:S1:7115:4	O
-	SIMPONI.xml:S1:7119:1	O
Treated	SIMPONI.xml:S1:7120:7	O
Patients	SIMPONI.xml:S1:7128:8	O
and	SIMPONI.xml:S1:7137:3	O
with	SIMPONI.xml:S1:7141:4	O
a	SIMPONI.xml:S1:7146:1	O
Higher	SIMPONI.xml:S1:7148:6	O
Incidence	SIMPONI.xml:S1:7155:9	O
than	SIMPONI.xml:S1:7165:4	O
Placebo	SIMPONI.xml:S1:7170:7	O
-	SIMPONI.xml:S1:7177:1	O
Treated	SIMPONI.xml:S1:7178:7	O
Patients	SIMPONI.xml:S1:7186:8	O
in	SIMPONI.xml:S1:7195:2	O
Trial	SIMPONI.xml:S1:7198:5	O
1	SIMPONI.xml:S1:7204:1	O
through	SIMPONI.xml:S1:7206:7	O
Week	SIMPONI.xml:S1:7214:4	O
24	SIMPONI.xml:S1:7219:2	O

Placebo	SIMPONI.xml:S1:7282:7	O
MTX	SIMPONI.xml:S1:7292:3	O
SIMPONI	SIMPONI.xml:S1:7306:7	O
ARIA	SIMPONI.xml:S1:7314:4	O
MTX	SIMPONI.xml:S1:7321:3	O

Patients	SIMPONI.xml:S1:7336:8	O

treated	SIMPONI.xml:S1:7345:7	O
197	SIMPONI.xml:S1:7399:3	O
463	SIMPONI.xml:S1:7426:3	O

Adverse	SIMPONI.xml:S1:7445:7	O
Reaction	SIMPONI.xml:S1:7453:8	O

Infections	SIMPONI.xml:S1:7502:10	O
and	SIMPONI.xml:S1:7513:3	O
Infestations	SIMPONI.xml:S1:7517:12	O

Upper	SIMPONI.xml:S1:7612:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:7618:11	I-AdverseReaction
tract	SIMPONI.xml:S1:7630:5	I-AdverseReaction
infection	SIMPONI.xml:S1:7636:9	I-AdverseReaction
(	SIMPONI.xml:S1:7646:1	O
such	SIMPONI.xml:S1:7647:4	O
as	SIMPONI.xml:S1:7652:2	O
upper	SIMPONI.xml:S1:7655:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:7661:11	I-AdverseReaction
tract	SIMPONI.xml:S1:7673:5	I-AdverseReaction
infection	SIMPONI.xml:S1:7679:9	I-AdverseReaction
,	SIMPONI.xml:S1:7688:1	O
nasopharyngitis	SIMPONI.xml:S1:7690:15	B-AdverseReaction
,	SIMPONI.xml:S1:7705:1	O
pharyngitis	SIMPONI.xml:S1:7707:11	B-AdverseReaction
,	SIMPONI.xml:S1:7718:1	O
laryngitis	SIMPONI.xml:S1:7720:10	B-AdverseReaction
,	SIMPONI.xml:S1:7730:1	O
and	SIMPONI.xml:S1:7732:3	O
rhinitis	SIMPONI.xml:S1:7736:8	B-AdverseReaction
)	SIMPONI.xml:S1:7744:1	O
12%	SIMPONI.xml:S1:7758:3	O
13%	SIMPONI.xml:S1:7785:3	O

Viral	SIMPONI.xml:S1:7807:5	B-AdverseReaction
infections	SIMPONI.xml:S1:7813:10	I-AdverseReaction
(	SIMPONI.xml:S1:7824:1	O
such	SIMPONI.xml:S1:7825:4	O
as	SIMPONI.xml:S1:7830:2	O
influenza	SIMPONI.xml:S1:7833:9	B-AdverseReaction
and	SIMPONI.xml:S1:7843:3	O
herpes	SIMPONI.xml:S1:7847:6	B-AdverseReaction
)	SIMPONI.xml:S1:7853:1	O
3%	SIMPONI.xml:S1:7867:2	O
4%	SIMPONI.xml:S1:7894:2	O

Bacterial	SIMPONI.xml:S1:7916:9	B-AdverseReaction
infections	SIMPONI.xml:S1:7926:10	I-AdverseReaction
0%	SIMPONI.xml:S1:7976:2	O
1%	SIMPONI.xml:S1:8003:2	O

Bronchitis	SIMPONI.xml:S1:8025:10	B-AdverseReaction
1%	SIMPONI.xml:S1:8085:2	O
3%	SIMPONI.xml:S1:8112:2	O

Vascular	SIMPONI.xml:S1:8133:8	B-AdverseReaction
disorders	SIMPONI.xml:S1:8142:9	I-AdverseReaction

Hypertension	SIMPONI.xml:S1:8243:12	B-AdverseReaction
2%	SIMPONI.xml:S1:8303:2	O
3%	SIMPONI.xml:S1:8330:2	O

Skin	SIMPONI.xml:S1:8351:4	O
and	SIMPONI.xml:S1:8356:3	O
subcutaneous	SIMPONI.xml:S1:8360:12	O
disorders	SIMPONI.xml:S1:8373:9	O

Rash	SIMPONI.xml:S1:8461:4	B-AdverseReaction
1%	SIMPONI.xml:S1:8521:2	O
3%	SIMPONI.xml:S1:8548:2	O

General	SIMPONI.xml:S1:8569:7	O
disorders	SIMPONI.xml:S1:8577:9	O
and	SIMPONI.xml:S1:8587:3	O
administration	SIMPONI.xml:S1:8591:14	O
site	SIMPONI.xml:S1:8606:4	O
conditions	SIMPONI.xml:S1:8611:10	O

Pyrexia	SIMPONI.xml:S1:8685:7	B-AdverseReaction
1%	SIMPONI.xml:S1:8745:2	O
2%	SIMPONI.xml:S1:8772:2	O

Blood	SIMPONI.xml:S1:8793:5	B-AdverseReaction
and	SIMPONI.xml:S1:8799:3	O
lymphatic	SIMPONI.xml:S1:8803:9	B-AdverseReaction
disorders	SIMPONI.xml:S1:8813:9	I-AdverseReaction

Leukopenia	SIMPONI.xml:S1:8903:10	B-AdverseReaction
0%	SIMPONI.xml:S1:8963:2	O
1%	SIMPONI.xml:S1:8990:2	O

Other	SIMPONI.xml:S1:9021:5	O
and	SIMPONI.xml:S1:9027:3	O
less	SIMPONI.xml:S1:9031:4	O
common	SIMPONI.xml:S1:9036:6	O
clinical	SIMPONI.xml:S1:9043:8	O
trial	SIMPONI.xml:S1:9052:5	O
adverse	SIMPONI.xml:S1:9058:7	O
drug	SIMPONI.xml:S1:9066:4	O
reactions	SIMPONI.xml:S1:9071:9	O

Adverse	SIMPONI.xml:S1:9087:7	O

drug	SIMPONI.xml:S1:9095:4	O
reactions	SIMPONI.xml:S1:9100:9	O
that	SIMPONI.xml:S1:9110:4	O
do	SIMPONI.xml:S1:9115:2	O
not	SIMPONI.xml:S1:9118:3	O
appear	SIMPONI.xml:S1:9122:6	O
in	SIMPONI.xml:S1:9129:2	O
Table	SIMPONI.xml:S1:9132:5	O
1	SIMPONI.xml:S1:9138:1	O
or	SIMPONI.xml:S1:9140:2	O
that	SIMPONI.xml:S1:9143:4	O
occurred	SIMPONI.xml:S1:9148:8	O
1%	SIMPONI.xml:S1:9158:2	O
in	SIMPONI.xml:S1:9161:2	O
SIMPONI	SIMPONI.xml:S1:9164:7	O
ARIA	SIMPONI.xml:S1:9172:4	O
-	SIMPONI.xml:S1:9176:1	O
treated	SIMPONI.xml:S1:9177:7	O
patients	SIMPONI.xml:S1:9185:8	O
during	SIMPONI.xml:S1:9194:6	O
Trial	SIMPONI.xml:S1:9201:5	O
1	SIMPONI.xml:S1:9207:1	O
through	SIMPONI.xml:S1:9209:7	O
Week	SIMPONI.xml:S1:9217:4	O
24	SIMPONI.xml:S1:9222:2	O
that	SIMPONI.xml:S1:9225:4	O
do	SIMPONI.xml:S1:9230:2	O
not	SIMPONI.xml:S1:9233:3	O
appear	SIMPONI.xml:S1:9237:6	O
in	SIMPONI.xml:S1:9244:2	O
the	SIMPONI.xml:S1:9247:3	O
Warnings	SIMPONI.xml:S1:9251:8	O
and	SIMPONI.xml:S1:9260:3	O
Precautions	SIMPONI.xml:S1:9264:11	O
section	SIMPONI.xml:S1:9276:7	O
included	SIMPONI.xml:S1:9284:8	O
the	SIMPONI.xml:S1:9293:3	O
following	SIMPONI.xml:S1:9297:9	O
events	SIMPONI.xml:S1:9307:6	O
listed	SIMPONI.xml:S1:9314:6	O
by	SIMPONI.xml:S1:9321:2	O
system	SIMPONI.xml:S1:9324:6	O
organ	SIMPONI.xml:S1:9331:5	O
class	SIMPONI.xml:S1:9337:5	O
:	SIMPONI.xml:S1:9342:1	O

Infections	SIMPONI.xml:S1:9350:10	O
and	SIMPONI.xml:S1:9361:3	O
Infestations	SIMPONI.xml:S1:9365:12	O
:	SIMPONI.xml:S1:9379:1	O
Superficial	SIMPONI.xml:S1:9381:11	B-AdverseReaction
fungal	SIMPONI.xml:S1:9393:6	I-AdverseReaction
infection	SIMPONI.xml:S1:9400:9	I-AdverseReaction
,	SIMPONI.xml:S1:9409:1	O
sinusitis	SIMPONI.xml:S1:9411:9	B-AdverseReaction
,	SIMPONI.xml:S1:9420:1	O
abscess	SIMPONI.xml:S1:9422:7	B-AdverseReaction
,	SIMPONI.xml:S1:9429:1	O
lower	SIMPONI.xml:S1:9431:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:9437:11	I-AdverseReaction
tract	SIMPONI.xml:S1:9449:5	I-AdverseReaction
infection	SIMPONI.xml:S1:9455:9	I-AdverseReaction
(	SIMPONI.xml:S1:9465:1	O
pneumonia	SIMPONI.xml:S1:9466:9	B-AdverseReaction
)	SIMPONI.xml:S1:9475:1	O
,	SIMPONI.xml:S1:9476:1	O
pyelonephritis	SIMPONI.xml:S1:9478:14	B-AdverseReaction

Investigations	SIMPONI.xml:S1:9499:14	O
:	SIMPONI.xml:S1:9515:1	O
Alanine	SIMPONI.xml:S1:9517:7	B-AdverseReaction
aminotransferase	SIMPONI.xml:S1:9525:16	I-AdverseReaction
increased	SIMPONI.xml:S1:9542:9	I-AdverseReaction
,	SIMPONI.xml:S1:9551:1	O
aspartate	SIMPONI.xml:S1:9553:9	B-AdverseReaction
aminotransferase	SIMPONI.xml:S1:9563:16	I-AdverseReaction
increased	SIMPONI.xml:S1:9580:9	I-AdverseReaction
,	SIMPONI.xml:S1:9589:1	O
neutrophil	SIMPONI.xml:S1:9591:10	B-AdverseReaction
count	SIMPONI.xml:S1:9602:5	I-AdverseReaction
decreased	SIMPONI.xml:S1:9608:9	I-AdverseReaction

Nervous	SIMPONI.xml:S1:9624:7	O
system	SIMPONI.xml:S1:9632:6	O
disorders	SIMPONI.xml:S1:9639:9	O
:	SIMPONI.xml:S1:9650:1	O
Dizziness	SIMPONI.xml:S1:9652:9	B-AdverseReaction
,	SIMPONI.xml:S1:9661:1	O
paresthesia	SIMPONI.xml:S1:9663:11	B-AdverseReaction

Gastrointestinal	SIMPONI.xml:S1:9681:16	O
disorders	SIMPONI.xml:S1:9698:9	O
:	SIMPONI.xml:S1:9709:1	O
Constipation	SIMPONI.xml:S1:9711:12	B-AdverseReaction

6.2	SIMPONI.xml:S1:9730:3	O
Post	SIMPONI.xml:S1:9734:4	O
-	SIMPONI.xml:S1:9738:1	O
marketing	SIMPONI.xml:S1:9739:9	O
Experience	SIMPONI.xml:S1:9749:10	O

There	SIMPONI.xml:S1:9763:5	O
is	SIMPONI.xml:S1:9769:2	O
no	SIMPONI.xml:S1:9772:2	O
post	SIMPONI.xml:S1:9775:4	O
-	SIMPONI.xml:S1:9779:1	O
marketing	SIMPONI.xml:S1:9780:9	O
experience	SIMPONI.xml:S1:9790:10	O
available	SIMPONI.xml:S1:9801:9	O
for	SIMPONI.xml:S1:9811:3	O
SIMPONI	SIMPONI.xml:S1:9815:7	O
ARIA	SIMPONI.xml:S1:9823:4	O
.	SIMPONI.xml:S1:9827:1	O

The	SIMPONI.xml:S1:9829:3	O
following	SIMPONI.xml:S1:9833:9	O
adverse	SIMPONI.xml:S1:9843:7	O
reactions	SIMPONI.xml:S1:9851:9	O
have	SIMPONI.xml:S1:9861:4	O
been	SIMPONI.xml:S1:9866:4	O
identified	SIMPONI.xml:S1:9871:10	O
during	SIMPONI.xml:S1:9882:6	O
post	SIMPONI.xml:S1:9889:4	O
-	SIMPONI.xml:S1:9893:1	O
approval	SIMPONI.xml:S1:9894:8	O
use	SIMPONI.xml:S1:9903:3	O
of	SIMPONI.xml:S1:9907:2	O
the	SIMPONI.xml:S1:9910:3	O
subcutaneous	SIMPONI.xml:S1:9914:12	O
formulation	SIMPONI.xml:S1:9927:11	O
of	SIMPONI.xml:S1:9939:2	O
golimumab	SIMPONI.xml:S1:9942:9	O
.	SIMPONI.xml:S1:9951:1	O

Because	SIMPONI.xml:S1:9953:7	O
these	SIMPONI.xml:S1:9961:5	O
reactions	SIMPONI.xml:S1:9967:9	O
are	SIMPONI.xml:S1:9977:3	O
reported	SIMPONI.xml:S1:9981:8	O
voluntarily	SIMPONI.xml:S1:9990:11	O
from	SIMPONI.xml:S1:10002:4	O
a	SIMPONI.xml:S1:10007:1	O
population	SIMPONI.xml:S1:10009:10	O
of	SIMPONI.xml:S1:10020:2	O
uncertain	SIMPONI.xml:S1:10023:9	O
size	SIMPONI.xml:S1:10033:4	O
,	SIMPONI.xml:S1:10037:1	O
it	SIMPONI.xml:S1:10039:2	O
is	SIMPONI.xml:S1:10042:2	O
not	SIMPONI.xml:S1:10045:3	O
always	SIMPONI.xml:S1:10049:6	O
possible	SIMPONI.xml:S1:10056:8	O
to	SIMPONI.xml:S1:10065:2	O
reliably	SIMPONI.xml:S1:10068:8	O
estimate	SIMPONI.xml:S1:10077:8	O
their	SIMPONI.xml:S1:10086:5	O
frequency	SIMPONI.xml:S1:10092:9	O
or	SIMPONI.xml:S1:10102:2	O
establish	SIMPONI.xml:S1:10105:9	O
a	SIMPONI.xml:S1:10115:1	O
causal	SIMPONI.xml:S1:10117:6	O
relationship	SIMPONI.xml:S1:10124:12	O
to	SIMPONI.xml:S1:10137:2	O
golimumab	SIMPONI.xml:S1:10140:9	O
exposure	SIMPONI.xml:S1:10150:8	O
.	SIMPONI.xml:S1:10158:1	O

Neoplasm	SIMPONI.xml:S1:10166:8	O
Benign	SIMPONI.xml:S1:10175:6	O
and	SIMPONI.xml:S1:10182:3	O
Malignant	SIMPONI.xml:S1:10186:9	O
:	SIMPONI.xml:S1:10197:1	O
Melanoma	SIMPONI.xml:S1:10199:8	B-AdverseReaction
[	SIMPONI.xml:S1:10209:1	O
see	SIMPONI.xml:S1:10210:3	O
Warnings	SIMPONI.xml:S1:10215:8	O
and	SIMPONI.xml:S1:10224:3	O
Precautions	SIMPONI.xml:S1:10228:11	O
(	SIMPONI.xml:S1:10240:1	O
5.2	SIMPONI.xml:S1:10241:3	O
)	SIMPONI.xml:S1:10244:1	O
]	SIMPONI.xml:S1:10247:1	O

Immune	SIMPONI.xml:S1:10257:6	O
System	SIMPONI.xml:S1:10264:6	O
Disorders	SIMPONI.xml:S1:10271:9	O
:	SIMPONI.xml:S1:10282:1	O
Serious	SIMPONI.xml:S1:10284:7	B-Severity
systemic	SIMPONI.xml:S1:10292:8	B-AdverseReaction
hypersensitivity	SIMPONI.xml:S1:10301:16	I-AdverseReaction
reactions	SIMPONI.xml:S1:10318:9	I-AdverseReaction
(	SIMPONI.xml:S1:10328:1	O
including	SIMPONI.xml:S1:10329:9	O
anaphylactic	SIMPONI.xml:S1:10339:12	B-AdverseReaction
reaction	SIMPONI.xml:S1:10352:8	I-AdverseReaction
)	SIMPONI.xml:S1:10360:1	O
[	SIMPONI.xml:S1:10363:1	O
see	SIMPONI.xml:S1:10364:3	O
Warnings	SIMPONI.xml:S1:10369:8	O
and	SIMPONI.xml:S1:10378:3	O
Precautions	SIMPONI.xml:S1:10382:11	O
(	SIMPONI.xml:S1:10394:1	O
5.10	SIMPONI.xml:S1:10395:4	O
)	SIMPONI.xml:S1:10399:1	O
]	SIMPONI.xml:S1:10402:1	O
,	SIMPONI.xml:S1:10405:1	O
sarcoidosis	SIMPONI.xml:S1:10407:11	B-AdverseReaction

Respiratory	SIMPONI.xml:S1:10425:11	O
,	SIMPONI.xml:S1:10436:1	O
thoracic	SIMPONI.xml:S1:10438:8	O
and	SIMPONI.xml:S1:10447:3	O
mediastinal	SIMPONI.xml:S1:10451:11	O
disorders	SIMPONI.xml:S1:10463:9	O
:	SIMPONI.xml:S1:10474:1	O
Interstitial	SIMPONI.xml:S1:10476:12	B-AdverseReaction
lung	SIMPONI.xml:S1:10489:4	I-AdverseReaction
disease	SIMPONI.xml:S1:10494:7	I-AdverseReaction

Skin	SIMPONI.xml:S1:10508:4	O
and	SIMPONI.xml:S1:10513:3	O
subcutaneous	SIMPONI.xml:S1:10517:12	O
tissue	SIMPONI.xml:S1:10530:6	O
disorders	SIMPONI.xml:S1:10537:9	O
:	SIMPONI.xml:S1:10548:1	O
Skin	SIMPONI.xml:S1:10550:4	B-AdverseReaction
exfoliation	SIMPONI.xml:S1:10555:11	I-AdverseReaction
,	SIMPONI.xml:S1:10566:1	O
bullous	SIMPONI.xml:S1:10568:7	B-AdverseReaction
skin	SIMPONI.xml:S1:10576:4	I-AdverseReaction
reactions	SIMPONI.xml:S1:10581:9	I-AdverseReaction
\n\n	SIMPONI.xml:S2:0:2	O
BOXED	SIMPONI.xml:S2:6:5	O
WARNING	SIMPONI.xml:S2:12:7	O
:	SIMPONI.xml:S2:19:1	O
WARNING	SIMPONI.xml:S2:21:7	O
:	SIMPONI.xml:S2:28:1	O
SERIOUS	SIMPONI.xml:S2:30:7	B-Severity
INFECTIONS	SIMPONI.xml:S2:38:10	B-AdverseReaction
AND	SIMPONI.xml:S2:49:3	O
MALIGNANCY	SIMPONI.xml:S2:53:10	B-AdverseReaction
\n\n	SIMPONI.xml:S2:63:2	O
WARNING	SIMPONI.xml:S2:69:7	O
:	SIMPONI.xml:S2:76:1	O
SERIOUS	SIMPONI.xml:S2:78:7	B-Severity
INFECTIONS	SIMPONI.xml:S2:86:10	B-AdverseReaction
AND	SIMPONI.xml:S2:97:3	O
MALIGNANCY	SIMPONI.xml:S2:101:10	B-AdverseReaction
\n\n	SIMPONI.xml:S2:113:2	O
EXCERPT	SIMPONI.xml:S2:117:7	O
:	SIMPONI.xml:S2:124:1	O
WARNING	SIMPONI.xml:S2:128:7	O
:	SIMPONI.xml:S2:135:1	O
SERIOUS	SIMPONI.xml:S2:138:7	B-Severity
INFECTIONS	SIMPONI.xml:S2:146:10	B-AdverseReaction
AND	SIMPONI.xml:S2:157:3	O
MALIGNANCY	SIMPONI.xml:S2:161:10	B-AdverseReaction
\n\n\n\n	SIMPONI.xml:S2:171:4	O
See	SIMPONI.xml:S2:178:3	O
full	SIMPONI.xml:S2:182:4	O
prescribing	SIMPONI.xml:S2:187:11	O
information	SIMPONI.xml:S2:199:11	O
for	SIMPONI.xml:S2:211:3	O
complete	SIMPONI.xml:S2:215:8	O
boxed	SIMPONI.xml:S2:224:5	O
warning	SIMPONI.xml:S2:230:7	O
.	SIMPONI.xml:S2:237:1	O

Serious	SIMPONI.xml:S2:248:7	B-Severity
infections	SIMPONI.xml:S2:256:10	B-AdverseReaction
leading	SIMPONI.xml:S2:267:7	O
to	SIMPONI.xml:S2:275:2	O
hospitalization	SIMPONI.xml:S2:278:15	O
or	SIMPONI.xml:S2:294:2	O
death	SIMPONI.xml:S2:297:5	B-AdverseReaction
including	SIMPONI.xml:S2:303:9	O
tuberculosis	SIMPONI.xml:S2:313:12	B-AdverseReaction
(	SIMPONI.xml:S2:326:1	O
TB	SIMPONI.xml:S2:327:2	B-AdverseReaction
)	SIMPONI.xml:S2:329:1	O
,	SIMPONI.xml:S2:330:1	O
bacterial	SIMPONI.xml:S2:332:9	B-AdverseReaction
sepsis	SIMPONI.xml:S2:342:6	I-AdverseReaction
,	SIMPONI.xml:S2:348:1	O
invasive	SIMPONI.xml:S2:350:8	B-AdverseReaction
fungal	SIMPONI.xml:S2:359:6	I-AdverseReaction
(	SIMPONI.xml:S2:366:1	O
such	SIMPONI.xml:S2:367:4	O
as	SIMPONI.xml:S2:372:2	O
histoplasmosis	SIMPONI.xml:S2:375:14	B-AdverseReaction
)	SIMPONI.xml:S2:389:1	O
,	SIMPONI.xml:S2:390:1	O
and	SIMPONI.xml:S2:392:3	O
other	SIMPONI.xml:S2:396:5	O
opportunistic	SIMPONI.xml:S2:402:13	B-AdverseReaction
infections	SIMPONI.xml:S2:416:10	I-AdverseReaction
have	SIMPONI.xml:S2:427:4	O
occurred	SIMPONI.xml:S2:432:8	O
in	SIMPONI.xml:S2:441:2	O
patients	SIMPONI.xml:S2:444:8	O
receiving	SIMPONI.xml:S2:453:9	O
SIMPONI	SIMPONI.xml:S2:463:7	O
ARIA	SIMPONI.xml:S2:471:4	O
(	SIMPONI.xml:S2:476:1	O
5.1	SIMPONI.xml:S2:477:3	O
)	SIMPONI.xml:S2:480:1	O
.	SIMPONI.xml:S2:481:1	O

Discontinue	SIMPONI.xml:S2:488:11	O
SIMPONI	SIMPONI.xml:S2:500:7	O
ARIA	SIMPONI.xml:S2:508:4	O
if	SIMPONI.xml:S2:513:2	O
a	SIMPONI.xml:S2:516:1	O
patient	SIMPONI.xml:S2:518:7	O
develops	SIMPONI.xml:S2:526:8	O
a	SIMPONI.xml:S2:535:1	O
serious	SIMPONI.xml:S2:537:7	O
infection	SIMPONI.xml:S2:545:9	O
or	SIMPONI.xml:S2:555:2	O
sepsis	SIMPONI.xml:S2:558:6	O
(	SIMPONI.xml:S2:565:1	O
5.1	SIMPONI.xml:S2:566:3	O
)	SIMPONI.xml:S2:569:1	O
.	SIMPONI.xml:S2:570:1	O

Perform	SIMPONI.xml:S2:577:7	O
test	SIMPONI.xml:S2:585:4	O
for	SIMPONI.xml:S2:590:3	O
latent	SIMPONI.xml:S2:594:6	O
TB	SIMPONI.xml:S2:601:2	O
;	SIMPONI.xml:S2:603:1	O
if	SIMPONI.xml:S2:605:2	O
positive	SIMPONI.xml:S2:608:8	O
,	SIMPONI.xml:S2:616:1	O
start	SIMPONI.xml:S2:618:5	O
treatment	SIMPONI.xml:S2:624:9	O
for	SIMPONI.xml:S2:634:3	O
TB	SIMPONI.xml:S2:638:2	O
prior	SIMPONI.xml:S2:641:5	O
to	SIMPONI.xml:S2:647:2	O
starting	SIMPONI.xml:S2:650:8	O
SIMPONI	SIMPONI.xml:S2:659:7	O
ARIA	SIMPONI.xml:S2:667:4	O
(	SIMPONI.xml:S2:672:1	O
5.1	SIMPONI.xml:S2:673:3	O
)	SIMPONI.xml:S2:676:1	O
.	SIMPONI.xml:S2:677:1	O

Monitor	SIMPONI.xml:S2:684:7	O
all	SIMPONI.xml:S2:692:3	O
patients	SIMPONI.xml:S2:696:8	O
for	SIMPONI.xml:S2:705:3	O
active	SIMPONI.xml:S2:709:6	O
TB	SIMPONI.xml:S2:716:2	O
during	SIMPONI.xml:S2:719:6	O
treatment	SIMPONI.xml:S2:726:9	O
,	SIMPONI.xml:S2:735:1	O
even	SIMPONI.xml:S2:737:4	O
if	SIMPONI.xml:S2:742:2	O
initial	SIMPONI.xml:S2:745:7	O
latent	SIMPONI.xml:S2:753:6	O
TB	SIMPONI.xml:S2:760:2	O
test	SIMPONI.xml:S2:763:4	O
is	SIMPONI.xml:S2:768:2	O
negative	SIMPONI.xml:S2:771:8	O
(	SIMPONI.xml:S2:780:1	O
5.1	SIMPONI.xml:S2:781:3	O
)	SIMPONI.xml:S2:784:1	O
.	SIMPONI.xml:S2:785:1	O

Lymphoma	SIMPONI.xml:S2:792:8	B-AdverseReaction
and	SIMPONI.xml:S2:801:3	O
other	SIMPONI.xml:S2:805:5	O
malignancies	SIMPONI.xml:S2:811:12	B-AdverseReaction
,	SIMPONI.xml:S2:823:1	O
some	SIMPONI.xml:S2:825:4	O
fatal	SIMPONI.xml:S2:830:5	B-AdverseReaction
,	SIMPONI.xml:S2:835:1	O
have	SIMPONI.xml:S2:837:4	O
been	SIMPONI.xml:S2:842:4	O
reported	SIMPONI.xml:S2:847:8	O
in	SIMPONI.xml:S2:856:2	O
children	SIMPONI.xml:S2:859:8	O
and	SIMPONI.xml:S2:868:3	O
adolescent	SIMPONI.xml:S2:872:10	O
patients	SIMPONI.xml:S2:883:8	O
treated	SIMPONI.xml:S2:892:7	O
with	SIMPONI.xml:S2:900:4	O
TNF	SIMPONI.xml:S2:905:3	O
blockers	SIMPONI.xml:S2:909:8	O
,	SIMPONI.xml:S2:917:1	O
of	SIMPONI.xml:S2:919:2	O
which	SIMPONI.xml:S2:922:5	O
SIMPONI	SIMPONI.xml:S2:928:7	O
ARIA	SIMPONI.xml:S2:936:4	O
is	SIMPONI.xml:S2:941:2	O
a	SIMPONI.xml:S2:944:1	O
member	SIMPONI.xml:S2:946:6	O
(	SIMPONI.xml:S2:953:1	O
5.2	SIMPONI.xml:S2:954:3	O
)	SIMPONI.xml:S2:957:1	O
.	SIMPONI.xml:S2:958:1	O

SERIOUS	SIMPONI.xml:S2:973:7	O
INFECTIONS	SIMPONI.xml:S2:981:10	O
\n\n\n\n	SIMPONI.xml:S2:993:4	O
Patients	SIMPONI.xml:S2:1000:8	O
treated	SIMPONI.xml:S2:1009:7	O
with	SIMPONI.xml:S2:1017:4	O
SIMPONI	SIMPONI.xml:S2:1022:7	O
ARIA	SIMPONI.xml:S2:1030:4	O
are	SIMPONI.xml:S2:1035:3	O
at	SIMPONI.xml:S2:1039:2	O
increased	SIMPONI.xml:S2:1042:9	O
risk	SIMPONI.xml:S2:1052:4	B-Factor
for	SIMPONI.xml:S2:1057:3	O
developing	SIMPONI.xml:S2:1061:10	O
serious	SIMPONI.xml:S2:1072:7	B-Severity
infections	SIMPONI.xml:S2:1080:10	B-AdverseReaction
that	SIMPONI.xml:S2:1091:4	O
may	SIMPONI.xml:S2:1096:3	B-Factor
lead	SIMPONI.xml:S2:1100:4	O
to	SIMPONI.xml:S2:1105:2	O
hospitalization	SIMPONI.xml:S2:1108:15	O
or	SIMPONI.xml:S2:1124:2	O
death	SIMPONI.xml:S2:1127:5	B-AdverseReaction
[	SIMPONI.xml:S2:1135:1	O
see	SIMPONI.xml:S2:1136:3	O
Warnings	SIMPONI.xml:S2:1142:8	O
and	SIMPONI.xml:S2:1151:3	O
Precautions	SIMPONI.xml:S2:1155:11	O
(	SIMPONI.xml:S2:1167:1	O
5.1	SIMPONI.xml:S2:1168:3	O
)	SIMPONI.xml:S2:1171:1	O
]	SIMPONI.xml:S2:1174:1	O
.	SIMPONI.xml:S2:1177:1	O

Most	SIMPONI.xml:S2:1180:4	O
patients	SIMPONI.xml:S2:1185:8	O
who	SIMPONI.xml:S2:1194:3	O
developed	SIMPONI.xml:S2:1198:9	O
these	SIMPONI.xml:S2:1208:5	O
infections	SIMPONI.xml:S2:1214:10	B-AdverseReaction
were	SIMPONI.xml:S2:1225:4	O
taking	SIMPONI.xml:S2:1230:6	O
concomitant	SIMPONI.xml:S2:1237:11	O
immunosuppressants	SIMPONI.xml:S2:1249:18	O
such	SIMPONI.xml:S2:1268:4	O
as	SIMPONI.xml:S2:1273:2	O
methotrexate	SIMPONI.xml:S2:1276:12	O
or	SIMPONI.xml:S2:1289:2	O
corticosteroids	SIMPONI.xml:S2:1292:15	O
.	SIMPONI.xml:S2:1307:1	O

Discontinue	SIMPONI.xml:S2:1317:11	O
SIMPONI	SIMPONI.xml:S2:1329:7	O
ARIA	SIMPONI.xml:S2:1337:4	O
if	SIMPONI.xml:S2:1342:2	O
a	SIMPONI.xml:S2:1345:1	O
patient	SIMPONI.xml:S2:1347:7	O
develops	SIMPONI.xml:S2:1355:8	O
a	SIMPONI.xml:S2:1364:1	O
serious	SIMPONI.xml:S2:1366:7	O
infection	SIMPONI.xml:S2:1374:9	O
.	SIMPONI.xml:S2:1383:1	O

Reported	SIMPONI.xml:S2:1393:8	O
infections	SIMPONI.xml:S2:1402:10	O
with	SIMPONI.xml:S2:1413:4	O
TNF	SIMPONI.xml:S2:1418:3	O
-	SIMPONI.xml:S2:1421:1	O
blockers	SIMPONI.xml:S2:1422:8	O
,	SIMPONI.xml:S2:1430:1	O
of	SIMPONI.xml:S2:1432:2	O
which	SIMPONI.xml:S2:1435:5	O
SIMPONI	SIMPONI.xml:S2:1441:7	O
ARIA	SIMPONI.xml:S2:1449:4	O
is	SIMPONI.xml:S2:1454:2	O
a	SIMPONI.xml:S2:1457:1	O
member	SIMPONI.xml:S2:1459:6	O
,	SIMPONI.xml:S2:1465:1	O
include	SIMPONI.xml:S2:1467:7	O
:	SIMPONI.xml:S2:1474:1	O
\n\n\n\n	SIMPONI.xml:S2:1477:4	O
Active	SIMPONI.xml:S2:1485:6	B-AdverseReaction
tuberculosis	SIMPONI.xml:S2:1492:12	I-AdverseReaction
,	SIMPONI.xml:S2:1504:1	O
including	SIMPONI.xml:S2:1506:9	O
reactivation	SIMPONI.xml:S2:1516:12	B-AdverseReaction
of	SIMPONI.xml:S2:1529:2	I-AdverseReaction
latent	SIMPONI.xml:S2:1532:6	I-AdverseReaction
tuberculosis	SIMPONI.xml:S2:1539:12	I-AdverseReaction
.	SIMPONI.xml:S2:1551:1	O

Patients	SIMPONI.xml:S2:1553:8	O
with	SIMPONI.xml:S2:1562:4	O
tuberculosis	SIMPONI.xml:S2:1567:12	B-AdverseReaction
have	SIMPONI.xml:S2:1580:4	O
frequently	SIMPONI.xml:S2:1585:10	O
presented	SIMPONI.xml:S2:1596:9	O
with	SIMPONI.xml:S2:1606:4	O
disseminated	SIMPONI.xml:S2:1611:12	I-AdverseReaction
or	SIMPONI.xml:S2:1624:2	O
extrapulmonary	SIMPONI.xml:S2:1627:14	I-AdverseReaction
disease	SIMPONI.xml:S2:1642:7	O
.	SIMPONI.xml:S2:1649:1	O

Test	SIMPONI.xml:S2:1651:4	O
patients	SIMPONI.xml:S2:1656:8	O
for	SIMPONI.xml:S2:1665:3	O
latent	SIMPONI.xml:S2:1669:6	O
tuberculosis	SIMPONI.xml:S2:1676:12	O
before	SIMPONI.xml:S2:1689:6	O
SIMPONI	SIMPONI.xml:S2:1696:7	O
ARIA	SIMPONI.xml:S2:1704:4	O
use	SIMPONI.xml:S2:1709:3	O
and	SIMPONI.xml:S2:1713:3	O
during	SIMPONI.xml:S2:1717:6	O
therapy	SIMPONI.xml:S2:1724:7	O
.	SIMPONI.xml:S2:1731:1	O

Initiate	SIMPONI.xml:S2:1733:8	O
treatment	SIMPONI.xml:S2:1742:9	O
for	SIMPONI.xml:S2:1752:3	O
latent	SIMPONI.xml:S2:1756:6	O
tuberculosis	SIMPONI.xml:S2:1763:12	O
prior	SIMPONI.xml:S2:1776:5	O
to	SIMPONI.xml:S2:1782:2	O
SIMPONI	SIMPONI.xml:S2:1785:7	O
ARIA	SIMPONI.xml:S2:1793:4	O
use	SIMPONI.xml:S2:1798:3	O
.	SIMPONI.xml:S2:1801:1	O

Invasive	SIMPONI.xml:S2:1808:8	B-AdverseReaction
fungal	SIMPONI.xml:S2:1817:6	I-AdverseReaction
infections	SIMPONI.xml:S2:1824:10	I-AdverseReaction
,	SIMPONI.xml:S2:1834:1	O
including	SIMPONI.xml:S2:1836:9	O
histoplasmosis	SIMPONI.xml:S2:1846:14	B-AdverseReaction
,	SIMPONI.xml:S2:1860:1	O
coccidioidomycosis	SIMPONI.xml:S2:1862:18	B-AdverseReaction
,	SIMPONI.xml:S2:1880:1	O
candidiasis	SIMPONI.xml:S2:1882:11	B-AdverseReaction
,	SIMPONI.xml:S2:1893:1	O
aspergillosis	SIMPONI.xml:S2:1895:13	B-AdverseReaction
,	SIMPONI.xml:S2:1908:1	O
blastomycosis	SIMPONI.xml:S2:1910:13	B-AdverseReaction
and	SIMPONI.xml:S2:1924:3	O
pneumocystosis	SIMPONI.xml:S2:1928:14	B-AdverseReaction
.	SIMPONI.xml:S2:1942:1	O

Patients	SIMPONI.xml:S2:1944:8	O
with	SIMPONI.xml:S2:1953:4	O
histoplasmosis	SIMPONI.xml:S2:1958:14	O
or	SIMPONI.xml:S2:1973:2	O
other	SIMPONI.xml:S2:1976:5	O
invasive	SIMPONI.xml:S2:1982:8	O
fungal	SIMPONI.xml:S2:1991:6	O
infections	SIMPONI.xml:S2:1998:10	O
may	SIMPONI.xml:S2:2009:3	O
present	SIMPONI.xml:S2:2013:7	O
with	SIMPONI.xml:S2:2021:4	O
disseminated	SIMPONI.xml:S2:2026:12	O
,	SIMPONI.xml:S2:2038:1	O
rather	SIMPONI.xml:S2:2040:6	O
than	SIMPONI.xml:S2:2047:4	O
localized	SIMPONI.xml:S2:2052:9	O
,	SIMPONI.xml:S2:2061:1	O
disease	SIMPONI.xml:S2:2063:7	O
.	SIMPONI.xml:S2:2070:1	O

Antigen	SIMPONI.xml:S2:2072:7	O
and	SIMPONI.xml:S2:2080:3	O
antibody	SIMPONI.xml:S2:2084:8	O
testing	SIMPONI.xml:S2:2093:7	O
for	SIMPONI.xml:S2:2101:3	O
histoplasmosis	SIMPONI.xml:S2:2105:14	O
may	SIMPONI.xml:S2:2120:3	O
be	SIMPONI.xml:S2:2124:2	O
negative	SIMPONI.xml:S2:2127:8	O
in	SIMPONI.xml:S2:2136:2	O
some	SIMPONI.xml:S2:2139:4	O
patients	SIMPONI.xml:S2:2144:8	O
with	SIMPONI.xml:S2:2153:4	O
active	SIMPONI.xml:S2:2158:6	O
infection	SIMPONI.xml:S2:2165:9	O
.	SIMPONI.xml:S2:2174:1	O

Consider	SIMPONI.xml:S2:2176:8	O
empiric	SIMPONI.xml:S2:2185:7	O
anti	SIMPONI.xml:S2:2193:4	O
-	SIMPONI.xml:S2:2197:1	O
fungal	SIMPONI.xml:S2:2198:6	O
therapy	SIMPONI.xml:S2:2205:7	O
in	SIMPONI.xml:S2:2213:2	O
patients	SIMPONI.xml:S2:2216:8	O
at	SIMPONI.xml:S2:2225:2	O
risk	SIMPONI.xml:S2:2228:4	O
for	SIMPONI.xml:S2:2233:3	O
invasive	SIMPONI.xml:S2:2237:8	O
fungal	SIMPONI.xml:S2:2246:6	O
infections	SIMPONI.xml:S2:2253:10	O
who	SIMPONI.xml:S2:2264:3	O
develop	SIMPONI.xml:S2:2268:7	O
severe	SIMPONI.xml:S2:2276:6	O
systemic	SIMPONI.xml:S2:2283:8	O
illness	SIMPONI.xml:S2:2292:7	O
.	SIMPONI.xml:S2:2299:1	O

Bacterial	SIMPONI.xml:S2:2306:9	B-AdverseReaction
,	SIMPONI.xml:S2:2315:1	O
viral	SIMPONI.xml:S2:2317:5	B-AdverseReaction
,	SIMPONI.xml:S2:2322:1	O
and	SIMPONI.xml:S2:2324:3	O
other	SIMPONI.xml:S2:2328:5	O
infections	SIMPONI.xml:S2:2334:10	I-AdverseReaction
due	SIMPONI.xml:S2:2345:3	I-AdverseReaction
to	SIMPONI.xml:S2:2349:2	I-AdverseReaction
opportunistic	SIMPONI.xml:S2:2352:13	I-AdverseReaction
pathogens	SIMPONI.xml:S2:2366:9	I-AdverseReaction
,	SIMPONI.xml:S2:2375:1	O
including	SIMPONI.xml:S2:2377:9	O
Legionella	SIMPONI.xml:S2:2387:10	I-AdverseReaction
and	SIMPONI.xml:S2:2398:3	O
Listeria	SIMPONI.xml:S2:2402:8	I-AdverseReaction
.	SIMPONI.xml:S2:2410:1	O

Consider	SIMPONI.xml:S2:2419:8	O
the	SIMPONI.xml:S2:2428:3	O
risks	SIMPONI.xml:S2:2432:5	O
and	SIMPONI.xml:S2:2438:3	O
benefits	SIMPONI.xml:S2:2442:8	O
of	SIMPONI.xml:S2:2451:2	O
treatment	SIMPONI.xml:S2:2454:9	O
with	SIMPONI.xml:S2:2464:4	O
SIMPONI	SIMPONI.xml:S2:2469:7	O
ARIA	SIMPONI.xml:S2:2477:4	O
prior	SIMPONI.xml:S2:2482:5	O
to	SIMPONI.xml:S2:2488:2	O
initiating	SIMPONI.xml:S2:2491:10	O
therapy	SIMPONI.xml:S2:2502:7	O
in	SIMPONI.xml:S2:2510:2	O
patients	SIMPONI.xml:S2:2513:8	O
with	SIMPONI.xml:S2:2522:4	O
chronic	SIMPONI.xml:S2:2527:7	O
or	SIMPONI.xml:S2:2535:2	O
recurrent	SIMPONI.xml:S2:2538:9	O
infection	SIMPONI.xml:S2:2548:9	O
.	SIMPONI.xml:S2:2557:1	O

Monitor	SIMPONI.xml:S2:2567:7	O
patients	SIMPONI.xml:S2:2575:8	O
closely	SIMPONI.xml:S2:2584:7	O
for	SIMPONI.xml:S2:2592:3	O
the	SIMPONI.xml:S2:2596:3	O
development	SIMPONI.xml:S2:2600:11	O
of	SIMPONI.xml:S2:2612:2	O
signs	SIMPONI.xml:S2:2615:5	O
and	SIMPONI.xml:S2:2621:3	O
symptoms	SIMPONI.xml:S2:2625:8	O
of	SIMPONI.xml:S2:2634:2	O
infection	SIMPONI.xml:S2:2637:9	O
during	SIMPONI.xml:S2:2647:6	O
and	SIMPONI.xml:S2:2654:3	O
after	SIMPONI.xml:S2:2658:5	O
treatment	SIMPONI.xml:S2:2664:9	O
with	SIMPONI.xml:S2:2674:4	O
SIMPONI	SIMPONI.xml:S2:2679:7	O
ARIA	SIMPONI.xml:S2:2687:4	O
,	SIMPONI.xml:S2:2691:1	O
including	SIMPONI.xml:S2:2693:9	O
the	SIMPONI.xml:S2:2703:3	O
possible	SIMPONI.xml:S2:2707:8	O
development	SIMPONI.xml:S2:2716:11	O
of	SIMPONI.xml:S2:2728:2	O
tuberculosis	SIMPONI.xml:S2:2731:12	O
in	SIMPONI.xml:S2:2744:2	O
patients	SIMPONI.xml:S2:2747:8	O
who	SIMPONI.xml:S2:2756:3	O
tested	SIMPONI.xml:S2:2760:6	O
negative	SIMPONI.xml:S2:2767:8	O
for	SIMPONI.xml:S2:2776:3	O
latent	SIMPONI.xml:S2:2780:6	O
tuberculosis	SIMPONI.xml:S2:2787:12	O
infection	SIMPONI.xml:S2:2800:9	O
prior	SIMPONI.xml:S2:2810:5	O
to	SIMPONI.xml:S2:2816:2	O
initiating	SIMPONI.xml:S2:2819:10	O
therapy	SIMPONI.xml:S2:2830:7	O
[	SIMPONI.xml:S2:2840:1	O
see	SIMPONI.xml:S2:2841:3	O
Warnings	SIMPONI.xml:S2:2847:8	O
and	SIMPONI.xml:S2:2856:3	O
Precautions	SIMPONI.xml:S2:2860:11	O
(	SIMPONI.xml:S2:2872:1	O
5.1	SIMPONI.xml:S2:2873:3	O
)	SIMPONI.xml:S2:2876:1	O
]	SIMPONI.xml:S2:2879:1	O
.	SIMPONI.xml:S2:2882:1	O

MALIGNANCY	SIMPONI.xml:S2:2894:10	O
\n\n\n\n	SIMPONI.xml:S2:2906:4	O
Lymphoma	SIMPONI.xml:S2:2913:8	B-AdverseReaction
and	SIMPONI.xml:S2:2922:3	O
other	SIMPONI.xml:S2:2926:5	O
malignancies	SIMPONI.xml:S2:2932:12	B-AdverseReaction
,	SIMPONI.xml:S2:2944:1	O
some	SIMPONI.xml:S2:2946:4	O
fatal	SIMPONI.xml:S2:2951:5	B-AdverseReaction
,	SIMPONI.xml:S2:2956:1	O
have	SIMPONI.xml:S2:2958:4	O
been	SIMPONI.xml:S2:2963:4	O
reported	SIMPONI.xml:S2:2968:8	O
in	SIMPONI.xml:S2:2977:2	O
children	SIMPONI.xml:S2:2980:8	O
and	SIMPONI.xml:S2:2989:3	O
adolescent	SIMPONI.xml:S2:2993:10	O
patients	SIMPONI.xml:S2:3004:8	O
treated	SIMPONI.xml:S2:3013:7	O
with	SIMPONI.xml:S2:3021:4	O
TNF	SIMPONI.xml:S2:3026:3	O
blockers	SIMPONI.xml:S2:3030:8	O
,	SIMPONI.xml:S2:3038:1	O
of	SIMPONI.xml:S2:3040:2	O
which	SIMPONI.xml:S2:3043:5	O
SIMPONI	SIMPONI.xml:S2:3049:7	O
ARIA	SIMPONI.xml:S2:3057:4	O
is	SIMPONI.xml:S2:3062:2	O
a	SIMPONI.xml:S2:3065:1	O
member	SIMPONI.xml:S2:3067:6	O
[	SIMPONI.xml:S2:3076:1	O
see	SIMPONI.xml:S2:3077:3	O
Warnings	SIMPONI.xml:S2:3083:8	O
and	SIMPONI.xml:S2:3092:3	O
Precautions	SIMPONI.xml:S2:3096:11	O
(	SIMPONI.xml:S2:3108:1	O
5.2	SIMPONI.xml:S2:3109:3	O
)	SIMPONI.xml:S2:3112:1	O
]	SIMPONI.xml:S2:3115:1	O
.	SIMPONI.xml:S2:3118:1	O
\n	SIMPONI.xml:S2:3121:1	O
5	SIMPONI.xml:S3:4:1	O
WARNINGS	SIMPONI.xml:S3:6:8	O
AND	SIMPONI.xml:S3:15:3	O
PRECAUTIONS	SIMPONI.xml:S3:19:11	O

EXCERPT	SIMPONI.xml:S3:37:7	O
:	SIMPONI.xml:S3:44:1	O
Serious	SIMPONI.xml:S3:52:7	B-Severity
infections	SIMPONI.xml:S3:60:10	B-AdverseReaction
-	SIMPONI.xml:S3:71:1	O
Do	SIMPONI.xml:S3:73:2	O
not	SIMPONI.xml:S3:76:3	O
start	SIMPONI.xml:S3:80:5	O
SIMPONI	SIMPONI.xml:S3:86:7	O
ARIA	SIMPONI.xml:S3:94:4	O
during	SIMPONI.xml:S3:99:6	O
an	SIMPONI.xml:S3:106:2	O
active	SIMPONI.xml:S3:109:6	O
infection	SIMPONI.xml:S3:116:9	O
.	SIMPONI.xml:S3:125:1	O

If	SIMPONI.xml:S3:127:2	O
an	SIMPONI.xml:S3:130:2	O
infection	SIMPONI.xml:S3:133:9	O
develops	SIMPONI.xml:S3:143:8	O
,	SIMPONI.xml:S3:151:1	O
monitor	SIMPONI.xml:S3:153:7	O
carefully	SIMPONI.xml:S3:161:9	O
,	SIMPONI.xml:S3:170:1	O
and	SIMPONI.xml:S3:172:3	O
stop	SIMPONI.xml:S3:176:4	O
SIMPONI	SIMPONI.xml:S3:181:7	O
ARIA	SIMPONI.xml:S3:189:4	O
if	SIMPONI.xml:S3:194:2	O
infection	SIMPONI.xml:S3:197:9	O
becomes	SIMPONI.xml:S3:207:7	O
serious	SIMPONI.xml:S3:215:7	O
(	SIMPONI.xml:S3:223:1	O
5.1	SIMPONI.xml:S3:226:3	O
)	SIMPONI.xml:S3:231:1	O
.	SIMPONI.xml:S3:232:1	O

Invasive	SIMPONI.xml:S3:239:8	B-AdverseReaction
fungal	SIMPONI.xml:S3:248:6	I-AdverseReaction
infections	SIMPONI.xml:S3:255:10	I-AdverseReaction
-	SIMPONI.xml:S3:266:1	O
For	SIMPONI.xml:S3:268:3	O
patients	SIMPONI.xml:S3:272:8	O
who	SIMPONI.xml:S3:281:3	O
develop	SIMPONI.xml:S3:285:7	O
a	SIMPONI.xml:S3:293:1	O
systemic	SIMPONI.xml:S3:295:8	O
illness	SIMPONI.xml:S3:304:7	O
on	SIMPONI.xml:S3:312:2	O
SIMPONI	SIMPONI.xml:S3:315:7	O
ARIA	SIMPONI.xml:S3:323:4	O
,	SIMPONI.xml:S3:327:1	O
consider	SIMPONI.xml:S3:329:8	O
empiric	SIMPONI.xml:S3:338:7	O
antifungal	SIMPONI.xml:S3:346:10	O
therapy	SIMPONI.xml:S3:357:7	O
for	SIMPONI.xml:S3:365:3	O
those	SIMPONI.xml:S3:369:5	O
who	SIMPONI.xml:S3:375:3	O
reside	SIMPONI.xml:S3:379:6	O
in	SIMPONI.xml:S3:386:2	O
or	SIMPONI.xml:S3:389:2	O
travel	SIMPONI.xml:S3:392:6	O
to	SIMPONI.xml:S3:399:2	O
regions	SIMPONI.xml:S3:402:7	O
where	SIMPONI.xml:S3:410:5	O
mycoses	SIMPONI.xml:S3:416:7	O
are	SIMPONI.xml:S3:424:3	O
endemic	SIMPONI.xml:S3:428:7	O
(	SIMPONI.xml:S3:436:1	O
5.1	SIMPONI.xml:S3:439:3	O
)	SIMPONI.xml:S3:444:1	O
.	SIMPONI.xml:S3:445:1	O

Hepatitis	SIMPONI.xml:S3:452:9	B-AdverseReaction
B	SIMPONI.xml:S3:462:1	I-AdverseReaction
reactivation	SIMPONI.xml:S3:464:12	I-AdverseReaction
-	SIMPONI.xml:S3:477:1	O
Monitor	SIMPONI.xml:S3:479:7	O
HBV	SIMPONI.xml:S3:487:3	O
carriers	SIMPONI.xml:S3:491:8	O
during	SIMPONI.xml:S3:500:6	O
and	SIMPONI.xml:S3:507:3	O
several	SIMPONI.xml:S3:511:7	O
months	SIMPONI.xml:S3:519:6	O
after	SIMPONI.xml:S3:526:5	O
therapy	SIMPONI.xml:S3:532:7	O
.	SIMPONI.xml:S3:539:1	O

If	SIMPONI.xml:S3:541:2	O
reactivation	SIMPONI.xml:S3:544:12	O
occurs	SIMPONI.xml:S3:557:6	O
,	SIMPONI.xml:S3:563:1	O
stop	SIMPONI.xml:S3:565:4	O
SIMPONI	SIMPONI.xml:S3:570:7	O
ARIA	SIMPONI.xml:S3:578:4	O
and	SIMPONI.xml:S3:583:3	O
begin	SIMPONI.xml:S3:587:5	O
anti	SIMPONI.xml:S3:593:4	O
-	SIMPONI.xml:S3:597:1	O
viral	SIMPONI.xml:S3:598:5	O
therapy	SIMPONI.xml:S3:604:7	O
(	SIMPONI.xml:S3:612:1	O
5.1	SIMPONI.xml:S3:615:3	O
)	SIMPONI.xml:S3:620:1	O
.	SIMPONI.xml:S3:621:1	O

Malignancies	SIMPONI.xml:S3:628:12	B-AdverseReaction
-	SIMPONI.xml:S3:641:1	O
More	SIMPONI.xml:S3:643:4	O
cases	SIMPONI.xml:S3:648:5	O
of	SIMPONI.xml:S3:654:2	O
lymphoma	SIMPONI.xml:S3:657:8	B-AdverseReaction
have	SIMPONI.xml:S3:666:4	O
been	SIMPONI.xml:S3:671:4	O
observed	SIMPONI.xml:S3:676:8	O
among	SIMPONI.xml:S3:685:5	O
patients	SIMPONI.xml:S3:691:8	O
receiving	SIMPONI.xml:S3:700:9	O
TNF	SIMPONI.xml:S3:710:3	O
-	SIMPONI.xml:S3:713:1	O
blockers	SIMPONI.xml:S3:714:8	O
compared	SIMPONI.xml:S3:723:8	O
with	SIMPONI.xml:S3:732:4	O
patients	SIMPONI.xml:S3:737:8	O
in	SIMPONI.xml:S3:746:2	O
the	SIMPONI.xml:S3:749:3	O
control	SIMPONI.xml:S3:753:7	O
groups	SIMPONI.xml:S3:761:6	O
.	SIMPONI.xml:S3:767:1	O

Cases	SIMPONI.xml:S3:769:5	O
of	SIMPONI.xml:S3:775:2	O
other	SIMPONI.xml:S3:778:5	O
malignancies	SIMPONI.xml:S3:784:12	B-AdverseReaction
have	SIMPONI.xml:S3:797:4	O
been	SIMPONI.xml:S3:802:4	O
observed	SIMPONI.xml:S3:807:8	O
among	SIMPONI.xml:S3:816:5	O
patients	SIMPONI.xml:S3:822:8	O
receiving	SIMPONI.xml:S3:831:9	O
TNF	SIMPONI.xml:S3:841:3	O
-	SIMPONI.xml:S3:844:1	O
blockers	SIMPONI.xml:S3:845:8	O
(	SIMPONI.xml:S3:854:1	O
5.2	SIMPONI.xml:S3:857:3	O
)	SIMPONI.xml:S3:862:1	O
.	SIMPONI.xml:S3:863:1	O

Heart	SIMPONI.xml:S3:870:5	B-AdverseReaction
failure	SIMPONI.xml:S3:876:7	I-AdverseReaction
-	SIMPONI.xml:S3:884:1	O
Worsening	SIMPONI.xml:S3:886:9	I-AdverseReaction
,	SIMPONI.xml:S3:895:1	O
or	SIMPONI.xml:S3:897:2	O
new	SIMPONI.xml:S3:900:3	I-AdverseReaction
onset	SIMPONI.xml:S3:904:5	I-AdverseReaction
,	SIMPONI.xml:S3:909:1	O
may	SIMPONI.xml:S3:911:3	B-Factor
occur	SIMPONI.xml:S3:915:5	O
.	SIMPONI.xml:S3:920:1	O

Stop	SIMPONI.xml:S3:922:4	O
SIMPONI	SIMPONI.xml:S3:927:7	O
ARIA	SIMPONI.xml:S3:935:4	O
if	SIMPONI.xml:S3:940:2	O
new	SIMPONI.xml:S3:943:3	O
or	SIMPONI.xml:S3:947:2	O
worsening	SIMPONI.xml:S3:950:9	O
symptoms	SIMPONI.xml:S3:960:8	O
occur	SIMPONI.xml:S3:969:5	O
(	SIMPONI.xml:S3:975:1	O
5.3	SIMPONI.xml:S3:978:3	O
)	SIMPONI.xml:S3:983:1	O
.	SIMPONI.xml:S3:984:1	O

Demyelinating	SIMPONI.xml:S3:991:13	B-AdverseReaction
disease	SIMPONI.xml:S3:1005:7	I-AdverseReaction
,	SIMPONI.xml:S3:1012:1	O
exacerbation	SIMPONI.xml:S3:1014:12	I-AdverseReaction
or	SIMPONI.xml:S3:1027:2	O
new	SIMPONI.xml:S3:1030:3	I-AdverseReaction
onset	SIMPONI.xml:S3:1034:5	I-AdverseReaction
,	SIMPONI.xml:S3:1039:1	O
may	SIMPONI.xml:S3:1041:3	B-Factor
occur	SIMPONI.xml:S3:1045:5	O
(	SIMPONI.xml:S3:1051:1	O
5.4	SIMPONI.xml:S3:1054:3	O
)	SIMPONI.xml:S3:1059:1	O
.	SIMPONI.xml:S3:1060:1	O

Hypersensitivity	SIMPONI.xml:S3:1067:16	B-AdverseReaction
reactions	SIMPONI.xml:S3:1084:9	I-AdverseReaction
:	SIMPONI.xml:S3:1093:1	O
Serious	SIMPONI.xml:S3:1095:7	B-Severity
systemic	SIMPONI.xml:S3:1103:8	B-AdverseReaction
hypersensitivity	SIMPONI.xml:S3:1112:16	I-AdverseReaction
reactions	SIMPONI.xml:S3:1129:9	I-AdverseReaction
including	SIMPONI.xml:S3:1139:9	O
anaphylaxis	SIMPONI.xml:S3:1149:11	B-AdverseReaction
may	SIMPONI.xml:S3:1161:3	B-Factor
occur	SIMPONI.xml:S3:1165:5	O
(	SIMPONI.xml:S3:1171:1	O
5.10	SIMPONI.xml:S3:1174:4	O
)	SIMPONI.xml:S3:1180:1	O
.	SIMPONI.xml:S3:1181:1	O

5.1	SIMPONI.xml:S3:1195:3	O

Serious	SIMPONI.xml:S3:1199:7	O

Infections	SIMPONI.xml:S3:1207:10	O

Patients	SIMPONI.xml:S3:1223:8	O
treated	SIMPONI.xml:S3:1232:7	O
with	SIMPONI.xml:S3:1240:4	O
SIMPONI	SIMPONI.xml:S3:1245:7	O
ARIA	SIMPONI.xml:S3:1253:4	O
are	SIMPONI.xml:S3:1258:3	O
at	SIMPONI.xml:S3:1262:2	O
increased	SIMPONI.xml:S3:1265:9	O
risk	SIMPONI.xml:S3:1275:4	B-Factor
for	SIMPONI.xml:S3:1280:3	O
developing	SIMPONI.xml:S3:1284:10	O
serious	SIMPONI.xml:S3:1295:7	B-Severity
infections	SIMPONI.xml:S3:1303:10	B-AdverseReaction
involving	SIMPONI.xml:S3:1314:9	O
various	SIMPONI.xml:S3:1324:7	O
organ	SIMPONI.xml:S3:1332:5	O
systems	SIMPONI.xml:S3:1338:7	O
and	SIMPONI.xml:S3:1346:3	O
sites	SIMPONI.xml:S3:1350:5	O
that	SIMPONI.xml:S3:1356:4	O
may	SIMPONI.xml:S3:1361:3	B-Factor
lead	SIMPONI.xml:S3:1365:4	O
to	SIMPONI.xml:S3:1370:2	O
hospitalization	SIMPONI.xml:S3:1373:15	O
or	SIMPONI.xml:S3:1389:2	O
death	SIMPONI.xml:S3:1392:5	B-AdverseReaction
.	SIMPONI.xml:S3:1397:1	O

Opportunistic	SIMPONI.xml:S3:1403:13	B-AdverseReaction
infections	SIMPONI.xml:S3:1417:10	I-AdverseReaction
due	SIMPONI.xml:S3:1428:3	O
to	SIMPONI.xml:S3:1432:2	O
bacterial	SIMPONI.xml:S3:1435:9	I-AdverseReaction
,	SIMPONI.xml:S3:1444:1	O
mycobacterial	SIMPONI.xml:S3:1446:13	I-AdverseReaction
,	SIMPONI.xml:S3:1459:1	O
invasive	SIMPONI.xml:S3:1461:8	I-AdverseReaction
fungal	SIMPONI.xml:S3:1470:6	I-AdverseReaction
,	SIMPONI.xml:S3:1476:1	O
viral	SIMPONI.xml:S3:1478:5	I-AdverseReaction
,	SIMPONI.xml:S3:1483:1	O
or	SIMPONI.xml:S3:1485:2	O
parasitic	SIMPONI.xml:S3:1488:9	I-AdverseReaction
organisms	SIMPONI.xml:S3:1498:9	O
including	SIMPONI.xml:S3:1508:9	O
aspergillosis	SIMPONI.xml:S3:1518:13	B-AdverseReaction
,	SIMPONI.xml:S3:1531:1	O
blastomycosis	SIMPONI.xml:S3:1533:13	B-AdverseReaction
,	SIMPONI.xml:S3:1546:1	O
candidiasis	SIMPONI.xml:S3:1548:11	B-AdverseReaction
,	SIMPONI.xml:S3:1559:1	O
coccidioidomycosis	SIMPONI.xml:S3:1561:18	B-AdverseReaction
,	SIMPONI.xml:S3:1579:1	O
histoplasmosis	SIMPONI.xml:S3:1581:14	B-AdverseReaction
,	SIMPONI.xml:S3:1595:1	O
legionellosis	SIMPONI.xml:S3:1597:13	B-AdverseReaction
,	SIMPONI.xml:S3:1610:1	O
listeriosis	SIMPONI.xml:S3:1612:11	B-AdverseReaction
,	SIMPONI.xml:S3:1623:1	O
pneumocystosis	SIMPONI.xml:S3:1625:14	B-AdverseReaction
,	SIMPONI.xml:S3:1639:1	O
and	SIMPONI.xml:S3:1641:3	O
tuberculosis	SIMPONI.xml:S3:1645:12	B-AdverseReaction
have	SIMPONI.xml:S3:1658:4	O
been	SIMPONI.xml:S3:1663:4	O
reported	SIMPONI.xml:S3:1668:8	O
with	SIMPONI.xml:S3:1677:4	O
TNF	SIMPONI.xml:S3:1682:3	B-DrugClass
-	SIMPONI.xml:S3:1685:1	I-DrugClass
blockers	SIMPONI.xml:S3:1686:8	I-DrugClass
.	SIMPONI.xml:S3:1694:1	O

Patients	SIMPONI.xml:S3:1696:8	O
have	SIMPONI.xml:S3:1705:4	O
frequently	SIMPONI.xml:S3:1710:10	O
presented	SIMPONI.xml:S3:1721:9	O
with	SIMPONI.xml:S3:1731:4	O
disseminated	SIMPONI.xml:S3:1736:12	O
rather	SIMPONI.xml:S3:1749:6	O
than	SIMPONI.xml:S3:1756:4	O
localized	SIMPONI.xml:S3:1761:9	O
disease	SIMPONI.xml:S3:1771:7	O
.	SIMPONI.xml:S3:1778:1	O

The	SIMPONI.xml:S3:1780:3	O
concomitant	SIMPONI.xml:S3:1784:11	O
use	SIMPONI.xml:S3:1796:3	O
of	SIMPONI.xml:S3:1800:2	O
a	SIMPONI.xml:S3:1803:1	O
TNF	SIMPONI.xml:S3:1805:3	O
-	SIMPONI.xml:S3:1808:1	O
blocker	SIMPONI.xml:S3:1809:7	O
and	SIMPONI.xml:S3:1817:3	O
abatacept	SIMPONI.xml:S3:1821:9	O
or	SIMPONI.xml:S3:1831:2	O
anakinra	SIMPONI.xml:S3:1834:8	O
was	SIMPONI.xml:S3:1843:3	O
associated	SIMPONI.xml:S3:1847:10	O
with	SIMPONI.xml:S3:1858:4	O
a	SIMPONI.xml:S3:1863:1	O
higher	SIMPONI.xml:S3:1865:6	O
risk	SIMPONI.xml:S3:1872:4	O
of	SIMPONI.xml:S3:1877:2	O
serious	SIMPONI.xml:S3:1880:7	O
infections	SIMPONI.xml:S3:1888:10	O
;	SIMPONI.xml:S3:1898:1	O
therefore	SIMPONI.xml:S3:1900:9	O
,	SIMPONI.xml:S3:1909:1	O
the	SIMPONI.xml:S3:1911:3	O
concomitant	SIMPONI.xml:S3:1915:11	O
use	SIMPONI.xml:S3:1927:3	O
of	SIMPONI.xml:S3:1931:2	O
SIMPONI	SIMPONI.xml:S3:1934:7	O
ARIA	SIMPONI.xml:S3:1942:4	O
and	SIMPONI.xml:S3:1947:3	O
these	SIMPONI.xml:S3:1951:5	O
biologic	SIMPONI.xml:S3:1957:8	O
products	SIMPONI.xml:S3:1966:8	O
is	SIMPONI.xml:S3:1975:2	O
not	SIMPONI.xml:S3:1978:3	O
recommended	SIMPONI.xml:S3:1982:11	O
[	SIMPONI.xml:S3:1994:1	O
see	SIMPONI.xml:S3:1995:3	O
Warnings	SIMPONI.xml:S3:2000:8	O
and	SIMPONI.xml:S3:2009:3	O
Precautions	SIMPONI.xml:S3:2013:11	O
(	SIMPONI.xml:S3:2025:1	O
5.5	SIMPONI.xml:S3:2026:3	O
,	SIMPONI.xml:S3:2031:1	O
5.6	SIMPONI.xml:S3:2034:3	O
)	SIMPONI.xml:S3:2039:1	O
and	SIMPONI.xml:S3:2041:3	O
Drug	SIMPONI.xml:S3:2046:4	O
Interactions	SIMPONI.xml:S3:2051:12	O
(	SIMPONI.xml:S3:2064:1	O
7.2	SIMPONI.xml:S3:2065:3	O
)	SIMPONI.xml:S3:2068:1	O
]	SIMPONI.xml:S3:2071:1	O
.	SIMPONI.xml:S3:2074:1	O

Treatment	SIMPONI.xml:S3:2080:9	O
with	SIMPONI.xml:S3:2090:4	O
SIMPONI	SIMPONI.xml:S3:2095:7	O
ARIA	SIMPONI.xml:S3:2103:4	O
should	SIMPONI.xml:S3:2108:6	O
not	SIMPONI.xml:S3:2115:3	O
be	SIMPONI.xml:S3:2119:2	O
initiated	SIMPONI.xml:S3:2122:9	O
in	SIMPONI.xml:S3:2132:2	O
patients	SIMPONI.xml:S3:2135:8	O
with	SIMPONI.xml:S3:2144:4	O
an	SIMPONI.xml:S3:2149:2	O
active	SIMPONI.xml:S3:2152:6	O
infection	SIMPONI.xml:S3:2159:9	O
,	SIMPONI.xml:S3:2168:1	O
including	SIMPONI.xml:S3:2170:9	O
clinically	SIMPONI.xml:S3:2180:10	O
important	SIMPONI.xml:S3:2191:9	O
localized	SIMPONI.xml:S3:2201:9	O
infections	SIMPONI.xml:S3:2211:10	O
.	SIMPONI.xml:S3:2221:1	O

Patients	SIMPONI.xml:S3:2223:8	O
greater	SIMPONI.xml:S3:2232:7	O
than	SIMPONI.xml:S3:2240:4	O
65	SIMPONI.xml:S3:2245:2	O
years	SIMPONI.xml:S3:2248:5	O
of	SIMPONI.xml:S3:2254:2	O
age	SIMPONI.xml:S3:2257:3	O
,	SIMPONI.xml:S3:2260:1	O
patients	SIMPONI.xml:S3:2262:8	O
with	SIMPONI.xml:S3:2271:4	O
co	SIMPONI.xml:S3:2276:2	O
-	SIMPONI.xml:S3:2278:1	O
morbid	SIMPONI.xml:S3:2279:6	O
conditions	SIMPONI.xml:S3:2286:10	O
and	SIMPONI.xml:S3:2297:3	O
or	SIMPONI.xml:S3:2301:2	O
patients	SIMPONI.xml:S3:2304:8	O
taking	SIMPONI.xml:S3:2313:6	O
concomitant	SIMPONI.xml:S3:2320:11	O
immunosuppressants	SIMPONI.xml:S3:2332:18	O
such	SIMPONI.xml:S3:2351:4	O
as	SIMPONI.xml:S3:2356:2	O
corticosteroids	SIMPONI.xml:S3:2359:15	O
or	SIMPONI.xml:S3:2375:2	O
methotrexate	SIMPONI.xml:S3:2378:12	O
may	SIMPONI.xml:S3:2391:3	O
be	SIMPONI.xml:S3:2395:2	O
at	SIMPONI.xml:S3:2398:2	O
greater	SIMPONI.xml:S3:2401:7	O
risk	SIMPONI.xml:S3:2409:4	O
of	SIMPONI.xml:S3:2414:2	O
infection	SIMPONI.xml:S3:2417:9	O
.	SIMPONI.xml:S3:2426:1	O

Consider	SIMPONI.xml:S3:2428:8	O
the	SIMPONI.xml:S3:2437:3	O
risks	SIMPONI.xml:S3:2441:5	O
and	SIMPONI.xml:S3:2447:3	O
benefits	SIMPONI.xml:S3:2451:8	O
of	SIMPONI.xml:S3:2460:2	O
treatment	SIMPONI.xml:S3:2463:9	O
prior	SIMPONI.xml:S3:2473:5	O
to	SIMPONI.xml:S3:2479:2	O
initiating	SIMPONI.xml:S3:2482:10	O
SIMPONI	SIMPONI.xml:S3:2493:7	O
ARIA	SIMPONI.xml:S3:2501:4	O
in	SIMPONI.xml:S3:2506:2	O
patients	SIMPONI.xml:S3:2509:8	O
:	SIMPONI.xml:S3:2517:1	O

with	SIMPONI.xml:S3:2526:4	O
chronic	SIMPONI.xml:S3:2531:7	O
or	SIMPONI.xml:S3:2539:2	O
recurrent	SIMPONI.xml:S3:2542:9	O
infection	SIMPONI.xml:S3:2552:9	O
;	SIMPONI.xml:S3:2561:1	O

who	SIMPONI.xml:S3:2568:3	O
have	SIMPONI.xml:S3:2572:4	O
been	SIMPONI.xml:S3:2577:4	O
exposed	SIMPONI.xml:S3:2582:7	O
to	SIMPONI.xml:S3:2590:2	O
tuberculosis	SIMPONI.xml:S3:2593:12	O
;	SIMPONI.xml:S3:2605:1	O

with	SIMPONI.xml:S3:2612:4	O
a	SIMPONI.xml:S3:2617:1	O
history	SIMPONI.xml:S3:2619:7	O
of	SIMPONI.xml:S3:2627:2	O
an	SIMPONI.xml:S3:2630:2	O
opportunistic	SIMPONI.xml:S3:2633:13	O
infection	SIMPONI.xml:S3:2647:9	O
;	SIMPONI.xml:S3:2656:1	O

who	SIMPONI.xml:S3:2663:3	O
have	SIMPONI.xml:S3:2667:4	O
resided	SIMPONI.xml:S3:2672:7	O
or	SIMPONI.xml:S3:2680:2	O
traveled	SIMPONI.xml:S3:2683:8	O
in	SIMPONI.xml:S3:2692:2	O
areas	SIMPONI.xml:S3:2695:5	O
of	SIMPONI.xml:S3:2701:2	O
endemic	SIMPONI.xml:S3:2704:7	O
tuberculosis	SIMPONI.xml:S3:2712:12	O
or	SIMPONI.xml:S3:2725:2	O
endemic	SIMPONI.xml:S3:2728:7	O
mycoses	SIMPONI.xml:S3:2736:7	O
,	SIMPONI.xml:S3:2743:1	O
such	SIMPONI.xml:S3:2745:4	O
as	SIMPONI.xml:S3:2750:2	O
histoplasmosis	SIMPONI.xml:S3:2753:14	O
,	SIMPONI.xml:S3:2767:1	O
coccidioidomycosis	SIMPONI.xml:S3:2769:18	O
,	SIMPONI.xml:S3:2787:1	O
or	SIMPONI.xml:S3:2789:2	O
blastomycosis	SIMPONI.xml:S3:2792:13	O
;	SIMPONI.xml:S3:2805:1	O
or	SIMPONI.xml:S3:2807:2	O

with	SIMPONI.xml:S3:2815:4	O
underlying	SIMPONI.xml:S3:2820:10	O
conditions	SIMPONI.xml:S3:2831:10	O
that	SIMPONI.xml:S3:2842:4	O
may	SIMPONI.xml:S3:2847:3	O
predispose	SIMPONI.xml:S3:2851:10	O
them	SIMPONI.xml:S3:2862:4	O
to	SIMPONI.xml:S3:2867:2	O
infection	SIMPONI.xml:S3:2870:9	O
.	SIMPONI.xml:S3:2879:1	O

Monitoring	SIMPONI.xml:S3:2889:10	O

Closely	SIMPONI.xml:S3:2906:7	O

monitor	SIMPONI.xml:S3:2914:7	O
patients	SIMPONI.xml:S3:2922:8	O
for	SIMPONI.xml:S3:2931:3	O
the	SIMPONI.xml:S3:2935:3	O
development	SIMPONI.xml:S3:2939:11	O
of	SIMPONI.xml:S3:2951:2	O
signs	SIMPONI.xml:S3:2954:5	O
and	SIMPONI.xml:S3:2960:3	O
symptoms	SIMPONI.xml:S3:2964:8	O
of	SIMPONI.xml:S3:2973:2	O
infection	SIMPONI.xml:S3:2976:9	O
during	SIMPONI.xml:S3:2986:6	O
and	SIMPONI.xml:S3:2993:3	O
after	SIMPONI.xml:S3:2997:5	O
treatment	SIMPONI.xml:S3:3003:9	O
with	SIMPONI.xml:S3:3013:4	O
SIMPONI	SIMPONI.xml:S3:3018:7	O
ARIA	SIMPONI.xml:S3:3026:4	O
.	SIMPONI.xml:S3:3030:1	O

Discontinue	SIMPONI.xml:S3:3032:11	O
SIMPONI	SIMPONI.xml:S3:3044:7	O
ARIA	SIMPONI.xml:S3:3052:4	O
if	SIMPONI.xml:S3:3057:2	O
a	SIMPONI.xml:S3:3060:1	O
patient	SIMPONI.xml:S3:3062:7	O
develops	SIMPONI.xml:S3:3070:8	O
a	SIMPONI.xml:S3:3079:1	O
serious	SIMPONI.xml:S3:3081:7	O
infection	SIMPONI.xml:S3:3089:9	O
,	SIMPONI.xml:S3:3098:1	O
an	SIMPONI.xml:S3:3100:2	O
opportunistic	SIMPONI.xml:S3:3103:13	O
infection	SIMPONI.xml:S3:3117:9	O
,	SIMPONI.xml:S3:3126:1	O
or	SIMPONI.xml:S3:3128:2	O
sepsis	SIMPONI.xml:S3:3131:6	O
.	SIMPONI.xml:S3:3137:1	O

For	SIMPONI.xml:S3:3139:3	O
patients	SIMPONI.xml:S3:3143:8	O
who	SIMPONI.xml:S3:3152:3	O
develop	SIMPONI.xml:S3:3156:7	O
a	SIMPONI.xml:S3:3164:1	O
new	SIMPONI.xml:S3:3166:3	O
infection	SIMPONI.xml:S3:3170:9	O
during	SIMPONI.xml:S3:3180:6	O
treatment	SIMPONI.xml:S3:3187:9	O
with	SIMPONI.xml:S3:3197:4	O
SIMPONI	SIMPONI.xml:S3:3202:7	O
ARIA	SIMPONI.xml:S3:3210:4	O
,	SIMPONI.xml:S3:3214:1	O
perform	SIMPONI.xml:S3:3216:7	O
a	SIMPONI.xml:S3:3224:1	O
prompt	SIMPONI.xml:S3:3226:6	O
and	SIMPONI.xml:S3:3233:3	O
complete	SIMPONI.xml:S3:3237:8	O
diagnostic	SIMPONI.xml:S3:3246:10	O
workup	SIMPONI.xml:S3:3257:6	O
appropriate	SIMPONI.xml:S3:3264:11	O
for	SIMPONI.xml:S3:3276:3	O
an	SIMPONI.xml:S3:3280:2	O
immunocompromised	SIMPONI.xml:S3:3283:17	O
patient	SIMPONI.xml:S3:3301:7	O
and	SIMPONI.xml:S3:3309:3	O
initiate	SIMPONI.xml:S3:3313:8	O
appropriate	SIMPONI.xml:S3:3322:11	O
antimicrobial	SIMPONI.xml:S3:3334:13	O
therapy	SIMPONI.xml:S3:3348:7	O
and	SIMPONI.xml:S3:3356:3	O
closely	SIMPONI.xml:S3:3360:7	O
monitor	SIMPONI.xml:S3:3368:7	O
them	SIMPONI.xml:S3:3376:4	O
.	SIMPONI.xml:S3:3380:1	O

Tuberculosis	SIMPONI.xml:S3:3389:12	O

Cases	SIMPONI.xml:S3:3408:5	O
of	SIMPONI.xml:S3:3414:2	O
reactivation	SIMPONI.xml:S3:3417:12	B-AdverseReaction
of	SIMPONI.xml:S3:3430:2	I-AdverseReaction
tuberculosis	SIMPONI.xml:S3:3433:12	I-AdverseReaction
or	SIMPONI.xml:S3:3446:2	O
new	SIMPONI.xml:S3:3449:3	B-AdverseReaction
tuberculosis	SIMPONI.xml:S3:3453:12	I-AdverseReaction
infections	SIMPONI.xml:S3:3466:10	I-AdverseReaction
have	SIMPONI.xml:S3:3477:4	O
been	SIMPONI.xml:S3:3482:4	O
observed	SIMPONI.xml:S3:3487:8	O
in	SIMPONI.xml:S3:3496:2	O
patients	SIMPONI.xml:S3:3499:8	O
receiving	SIMPONI.xml:S3:3508:9	O
TNF	SIMPONI.xml:S3:3518:3	O
-	SIMPONI.xml:S3:3521:1	O
blockers	SIMPONI.xml:S3:3522:8	O
,	SIMPONI.xml:S3:3530:1	O
including	SIMPONI.xml:S3:3532:9	O
patients	SIMPONI.xml:S3:3542:8	O
who	SIMPONI.xml:S3:3551:3	O
have	SIMPONI.xml:S3:3555:4	O
previously	SIMPONI.xml:S3:3560:10	O
received	SIMPONI.xml:S3:3571:8	O
treatment	SIMPONI.xml:S3:3580:9	O
for	SIMPONI.xml:S3:3590:3	O
latent	SIMPONI.xml:S3:3594:6	O
or	SIMPONI.xml:S3:3601:2	O
active	SIMPONI.xml:S3:3604:6	O
tuberculosis	SIMPONI.xml:S3:3611:12	O
.	SIMPONI.xml:S3:3623:1	O

Evaluate	SIMPONI.xml:S3:3625:8	O
patients	SIMPONI.xml:S3:3634:8	O
for	SIMPONI.xml:S3:3643:3	O
tuberculosis	SIMPONI.xml:S3:3647:12	O
risk	SIMPONI.xml:S3:3660:4	O
factors	SIMPONI.xml:S3:3665:7	O
and	SIMPONI.xml:S3:3673:3	O
test	SIMPONI.xml:S3:3677:4	O
for	SIMPONI.xml:S3:3682:3	O
latent	SIMPONI.xml:S3:3686:6	O
infection	SIMPONI.xml:S3:3693:9	O
prior	SIMPONI.xml:S3:3703:5	O
to	SIMPONI.xml:S3:3709:2	O
initiating	SIMPONI.xml:S3:3712:10	O
SIMPONI	SIMPONI.xml:S3:3723:7	O
ARIA	SIMPONI.xml:S3:3731:4	O
and	SIMPONI.xml:S3:3736:3	O
periodically	SIMPONI.xml:S3:3740:12	O
during	SIMPONI.xml:S3:3753:6	O
therapy	SIMPONI.xml:S3:3760:7	O
.	SIMPONI.xml:S3:3767:1	O

Treatment	SIMPONI.xml:S3:3773:9	O
of	SIMPONI.xml:S3:3783:2	O
latent	SIMPONI.xml:S3:3786:6	O
tuberculosis	SIMPONI.xml:S3:3793:12	O
infection	SIMPONI.xml:S3:3806:9	O
prior	SIMPONI.xml:S3:3816:5	O
to	SIMPONI.xml:S3:3822:2	O
therapy	SIMPONI.xml:S3:3825:7	O
with	SIMPONI.xml:S3:3833:4	O
TNF	SIMPONI.xml:S3:3838:3	O
-	SIMPONI.xml:S3:3841:1	O
blockers	SIMPONI.xml:S3:3842:8	O
has	SIMPONI.xml:S3:3851:3	O
been	SIMPONI.xml:S3:3855:4	O
shown	SIMPONI.xml:S3:3860:5	O
to	SIMPONI.xml:S3:3866:2	O
reduce	SIMPONI.xml:S3:3869:6	O
the	SIMPONI.xml:S3:3876:3	O
risk	SIMPONI.xml:S3:3880:4	O
of	SIMPONI.xml:S3:3885:2	O
tuberculosis	SIMPONI.xml:S3:3888:12	O
reactivation	SIMPONI.xml:S3:3901:12	O
during	SIMPONI.xml:S3:3914:6	O
therapy	SIMPONI.xml:S3:3921:7	O
.	SIMPONI.xml:S3:3928:1	O

Prior	SIMPONI.xml:S3:3930:5	O
to	SIMPONI.xml:S3:3936:2	O
initiating	SIMPONI.xml:S3:3939:10	O
SIMPONI	SIMPONI.xml:S3:3950:7	O
ARIA	SIMPONI.xml:S3:3958:4	O
,	SIMPONI.xml:S3:3962:1	O
assess	SIMPONI.xml:S3:3964:6	O
if	SIMPONI.xml:S3:3971:2	O
treatment	SIMPONI.xml:S3:3974:9	O
for	SIMPONI.xml:S3:3984:3	O
latent	SIMPONI.xml:S3:3988:6	O
tuberculosis	SIMPONI.xml:S3:3995:12	O
is	SIMPONI.xml:S3:4008:2	O
needed	SIMPONI.xml:S3:4011:6	O
;	SIMPONI.xml:S3:4017:1	O
An	SIMPONI.xml:S3:4019:2	O
induration	SIMPONI.xml:S3:4022:10	O
of	SIMPONI.xml:S3:4033:2	O
5	SIMPONI.xml:S3:4036:1	O
mm	SIMPONI.xml:S3:4038:2	O
or	SIMPONI.xml:S3:4041:2	O
greater	SIMPONI.xml:S3:4044:7	O
is	SIMPONI.xml:S3:4052:2	O
a	SIMPONI.xml:S3:4055:1	O
positive	SIMPONI.xml:S3:4057:8	O
tuberculin	SIMPONI.xml:S3:4066:10	O
skin	SIMPONI.xml:S3:4077:4	O
test	SIMPONI.xml:S3:4082:4	O
,	SIMPONI.xml:S3:4086:1	O
even	SIMPONI.xml:S3:4088:4	O
for	SIMPONI.xml:S3:4093:3	O
patients	SIMPONI.xml:S3:4097:8	O
previously	SIMPONI.xml:S3:4106:10	O
vaccinated	SIMPONI.xml:S3:4117:10	O
with	SIMPONI.xml:S3:4128:4	O
Bacille	SIMPONI.xml:S3:4133:7	O
Calmette	SIMPONI.xml:S3:4141:8	O
-	SIMPONI.xml:S3:4149:1	O
Guerin	SIMPONI.xml:S3:4150:6	O
(	SIMPONI.xml:S3:4157:1	O
BCG	SIMPONI.xml:S3:4158:3	O
)	SIMPONI.xml:S3:4161:1	O
.	SIMPONI.xml:S3:4162:1	O

Consider	SIMPONI.xml:S3:4168:8	O
anti	SIMPONI.xml:S3:4177:4	O
-	SIMPONI.xml:S3:4181:1	O
tuberculosis	SIMPONI.xml:S3:4182:12	O
therapy	SIMPONI.xml:S3:4195:7	O
prior	SIMPONI.xml:S3:4203:5	O
to	SIMPONI.xml:S3:4209:2	O
initiation	SIMPONI.xml:S3:4212:10	O
of	SIMPONI.xml:S3:4223:2	O
SIMPONI	SIMPONI.xml:S3:4226:7	O
ARIA	SIMPONI.xml:S3:4234:4	O
in	SIMPONI.xml:S3:4239:2	O
patients	SIMPONI.xml:S3:4242:8	O
with	SIMPONI.xml:S3:4251:4	O
a	SIMPONI.xml:S3:4256:1	O
past	SIMPONI.xml:S3:4258:4	O
history	SIMPONI.xml:S3:4263:7	O
of	SIMPONI.xml:S3:4271:2	O
latent	SIMPONI.xml:S3:4274:6	O
or	SIMPONI.xml:S3:4281:2	O
active	SIMPONI.xml:S3:4284:6	O
tuberculosis	SIMPONI.xml:S3:4291:12	O
in	SIMPONI.xml:S3:4304:2	O
whom	SIMPONI.xml:S3:4307:4	O
an	SIMPONI.xml:S3:4312:2	O
adequate	SIMPONI.xml:S3:4315:8	O
course	SIMPONI.xml:S3:4324:6	O
of	SIMPONI.xml:S3:4331:2	O
treatment	SIMPONI.xml:S3:4334:9	O
cannot	SIMPONI.xml:S3:4344:6	O
be	SIMPONI.xml:S3:4351:2	O
confirmed	SIMPONI.xml:S3:4354:9	O
,	SIMPONI.xml:S3:4363:1	O
and	SIMPONI.xml:S3:4365:3	O
for	SIMPONI.xml:S3:4369:3	O
patients	SIMPONI.xml:S3:4373:8	O
with	SIMPONI.xml:S3:4382:4	O
a	SIMPONI.xml:S3:4387:1	O
negative	SIMPONI.xml:S3:4389:8	O
test	SIMPONI.xml:S3:4398:4	O
for	SIMPONI.xml:S3:4403:3	O
latent	SIMPONI.xml:S3:4407:6	O
tuberculosis	SIMPONI.xml:S3:4414:12	O
but	SIMPONI.xml:S3:4427:3	O
having	SIMPONI.xml:S3:4431:6	O
risk	SIMPONI.xml:S3:4438:4	O
factors	SIMPONI.xml:S3:4443:7	O
for	SIMPONI.xml:S3:4451:3	O
tuberculosis	SIMPONI.xml:S3:4455:12	O
infection	SIMPONI.xml:S3:4468:9	O
.	SIMPONI.xml:S3:4477:1	O

Consultation	SIMPONI.xml:S3:4479:12	O
with	SIMPONI.xml:S3:4492:4	O
a	SIMPONI.xml:S3:4497:1	O
physician	SIMPONI.xml:S3:4499:9	O
with	SIMPONI.xml:S3:4509:4	O
expertise	SIMPONI.xml:S3:4514:9	O
in	SIMPONI.xml:S3:4524:2	O
the	SIMPONI.xml:S3:4527:3	O
treatment	SIMPONI.xml:S3:4531:9	O
of	SIMPONI.xml:S3:4541:2	O
tuberculosis	SIMPONI.xml:S3:4544:12	O
is	SIMPONI.xml:S3:4557:2	O
recommended	SIMPONI.xml:S3:4560:11	O
to	SIMPONI.xml:S3:4572:2	O
aid	SIMPONI.xml:S3:4575:3	O
in	SIMPONI.xml:S3:4579:2	O
the	SIMPONI.xml:S3:4582:3	O
decision	SIMPONI.xml:S3:4586:8	O
whether	SIMPONI.xml:S3:4595:7	O
initiating	SIMPONI.xml:S3:4603:10	O
anti	SIMPONI.xml:S3:4614:4	O
-	SIMPONI.xml:S3:4618:1	O
tuberculosis	SIMPONI.xml:S3:4619:12	O
therapy	SIMPONI.xml:S3:4632:7	O
is	SIMPONI.xml:S3:4640:2	O
appropriate	SIMPONI.xml:S3:4643:11	O
for	SIMPONI.xml:S3:4655:3	O
an	SIMPONI.xml:S3:4659:2	O
individual	SIMPONI.xml:S3:4662:10	O
patient	SIMPONI.xml:S3:4673:7	O
.	SIMPONI.xml:S3:4680:1	O

Cases	SIMPONI.xml:S3:4687:5	O
of	SIMPONI.xml:S3:4693:2	O
active	SIMPONI.xml:S3:4696:6	O
tuberculosis	SIMPONI.xml:S3:4703:12	O
have	SIMPONI.xml:S3:4716:4	O
occurred	SIMPONI.xml:S3:4721:8	O
in	SIMPONI.xml:S3:4730:2	O
patients	SIMPONI.xml:S3:4733:8	O
treated	SIMPONI.xml:S3:4742:7	O
with	SIMPONI.xml:S3:4750:4	O
the	SIMPONI.xml:S3:4755:3	O
subcutaneous	SIMPONI.xml:S3:4759:12	O
formulation	SIMPONI.xml:S3:4772:11	O
of	SIMPONI.xml:S3:4784:2	O
golimumab	SIMPONI.xml:S3:4787:9	O
during	SIMPONI.xml:S3:4797:6	O
and	SIMPONI.xml:S3:4804:3	O
after	SIMPONI.xml:S3:4808:5	O
treatment	SIMPONI.xml:S3:4814:9	O
for	SIMPONI.xml:S3:4824:3	O
latent	SIMPONI.xml:S3:4828:6	O
tuberculosis	SIMPONI.xml:S3:4835:12	O
.	SIMPONI.xml:S3:4847:1	O

Monitor	SIMPONI.xml:S3:4849:7	O
patients	SIMPONI.xml:S3:4857:8	O
for	SIMPONI.xml:S3:4866:3	O
the	SIMPONI.xml:S3:4870:3	O
development	SIMPONI.xml:S3:4874:11	O
of	SIMPONI.xml:S3:4886:2	O
signs	SIMPONI.xml:S3:4889:5	O
and	SIMPONI.xml:S3:4895:3	O
symptoms	SIMPONI.xml:S3:4899:8	O
of	SIMPONI.xml:S3:4908:2	O
tuberculosis	SIMPONI.xml:S3:4911:12	O
including	SIMPONI.xml:S3:4924:9	O
patients	SIMPONI.xml:S3:4934:8	O
who	SIMPONI.xml:S3:4943:3	O
tested	SIMPONI.xml:S3:4947:6	O
negative	SIMPONI.xml:S3:4954:8	O
for	SIMPONI.xml:S3:4963:3	O
latent	SIMPONI.xml:S3:4967:6	O
tuberculosis	SIMPONI.xml:S3:4974:12	O
infection	SIMPONI.xml:S3:4987:9	O
prior	SIMPONI.xml:S3:4997:5	O
to	SIMPONI.xml:S3:5003:2	O
initiating	SIMPONI.xml:S3:5006:10	O
therapy	SIMPONI.xml:S3:5017:7	O
,	SIMPONI.xml:S3:5024:1	O
patients	SIMPONI.xml:S3:5026:8	O
who	SIMPONI.xml:S3:5035:3	O
are	SIMPONI.xml:S3:5039:3	O
on	SIMPONI.xml:S3:5043:2	O
treatment	SIMPONI.xml:S3:5046:9	O
for	SIMPONI.xml:S3:5056:3	O
latent	SIMPONI.xml:S3:5060:6	O
tuberculosis	SIMPONI.xml:S3:5067:12	O
,	SIMPONI.xml:S3:5079:1	O
or	SIMPONI.xml:S3:5081:2	O
patients	SIMPONI.xml:S3:5084:8	O
who	SIMPONI.xml:S3:5093:3	O
were	SIMPONI.xml:S3:5097:4	O
previously	SIMPONI.xml:S3:5102:10	O
treated	SIMPONI.xml:S3:5113:7	O
for	SIMPONI.xml:S3:5121:3	O
tuberculosis	SIMPONI.xml:S3:5125:12	O
infection	SIMPONI.xml:S3:5138:9	O
.	SIMPONI.xml:S3:5147:1	O

Consider	SIMPONI.xml:S3:5155:8	O
tuberculosis	SIMPONI.xml:S3:5164:12	O
in	SIMPONI.xml:S3:5177:2	O
the	SIMPONI.xml:S3:5180:3	O
differential	SIMPONI.xml:S3:5184:12	O
diagnosis	SIMPONI.xml:S3:5197:9	O
in	SIMPONI.xml:S3:5207:2	O
patients	SIMPONI.xml:S3:5210:8	O
who	SIMPONI.xml:S3:5219:3	O
develop	SIMPONI.xml:S3:5223:7	O
a	SIMPONI.xml:S3:5231:1	O
new	SIMPONI.xml:S3:5233:3	O
infection	SIMPONI.xml:S3:5237:9	O
during	SIMPONI.xml:S3:5247:6	O
SIMPONI	SIMPONI.xml:S3:5254:7	O
ARIA	SIMPONI.xml:S3:5262:4	O
treatment	SIMPONI.xml:S3:5267:9	O
,	SIMPONI.xml:S3:5276:1	O
especially	SIMPONI.xml:S3:5278:10	O
in	SIMPONI.xml:S3:5289:2	O
patients	SIMPONI.xml:S3:5292:8	O
who	SIMPONI.xml:S3:5301:3	O
have	SIMPONI.xml:S3:5305:4	O
previously	SIMPONI.xml:S3:5310:10	O
or	SIMPONI.xml:S3:5321:2	O
recently	SIMPONI.xml:S3:5324:8	O
traveled	SIMPONI.xml:S3:5333:8	O
to	SIMPONI.xml:S3:5342:2	O
countries	SIMPONI.xml:S3:5345:9	O
with	SIMPONI.xml:S3:5355:4	O
a	SIMPONI.xml:S3:5360:1	O
high	SIMPONI.xml:S3:5362:4	O
prevalence	SIMPONI.xml:S3:5367:10	O
of	SIMPONI.xml:S3:5378:2	O
tuberculosis	SIMPONI.xml:S3:5381:12	O
,	SIMPONI.xml:S3:5393:1	O
or	SIMPONI.xml:S3:5395:2	O
who	SIMPONI.xml:S3:5398:3	O
have	SIMPONI.xml:S3:5402:4	O
had	SIMPONI.xml:S3:5407:3	O
close	SIMPONI.xml:S3:5411:5	O
contact	SIMPONI.xml:S3:5417:7	O
with	SIMPONI.xml:S3:5425:4	O
a	SIMPONI.xml:S3:5430:1	O
person	SIMPONI.xml:S3:5432:6	O
with	SIMPONI.xml:S3:5439:4	O
active	SIMPONI.xml:S3:5444:6	O
tuberculosis	SIMPONI.xml:S3:5451:12	O
.	SIMPONI.xml:S3:5463:1	O

Invasive	SIMPONI.xml:S3:5472:8	O
Fungal	SIMPONI.xml:S3:5481:6	O
Infections	SIMPONI.xml:S3:5488:10	O

If	SIMPONI.xml:S3:5505:2	O
patients	SIMPONI.xml:S3:5508:8	O
develop	SIMPONI.xml:S3:5517:7	O
a	SIMPONI.xml:S3:5525:1	O
serious	SIMPONI.xml:S3:5527:7	O
systemic	SIMPONI.xml:S3:5535:8	O
illness	SIMPONI.xml:S3:5544:7	O
and	SIMPONI.xml:S3:5552:3	O
they	SIMPONI.xml:S3:5556:4	O
reside	SIMPONI.xml:S3:5561:6	O
or	SIMPONI.xml:S3:5568:2	O
travel	SIMPONI.xml:S3:5571:6	O
in	SIMPONI.xml:S3:5578:2	O
regions	SIMPONI.xml:S3:5581:7	O
where	SIMPONI.xml:S3:5589:5	O
mycoses	SIMPONI.xml:S3:5595:7	O
are	SIMPONI.xml:S3:5603:3	O
endemic	SIMPONI.xml:S3:5607:7	O
,	SIMPONI.xml:S3:5614:1	O
consider	SIMPONI.xml:S3:5616:8	O
invasive	SIMPONI.xml:S3:5625:8	O
fungal	SIMPONI.xml:S3:5634:6	O
infection	SIMPONI.xml:S3:5641:9	O
in	SIMPONI.xml:S3:5651:2	O
the	SIMPONI.xml:S3:5654:3	O
differential	SIMPONI.xml:S3:5658:12	O
diagnosis	SIMPONI.xml:S3:5671:9	O
.	SIMPONI.xml:S3:5680:1	O

Consider	SIMPONI.xml:S3:5682:8	O
appropriate	SIMPONI.xml:S3:5691:11	O
empiric	SIMPONI.xml:S3:5703:7	O
antifungal	SIMPONI.xml:S3:5711:10	O
therapy	SIMPONI.xml:S3:5722:7	O
and	SIMPONI.xml:S3:5730:3	O
take	SIMPONI.xml:S3:5734:4	O
into	SIMPONI.xml:S3:5739:4	O
account	SIMPONI.xml:S3:5744:7	O
both	SIMPONI.xml:S3:5752:4	O
the	SIMPONI.xml:S3:5757:3	O
risk	SIMPONI.xml:S3:5761:4	O
for	SIMPONI.xml:S3:5766:3	O
severe	SIMPONI.xml:S3:5770:6	O
fungal	SIMPONI.xml:S3:5777:6	O
infection	SIMPONI.xml:S3:5784:9	O
and	SIMPONI.xml:S3:5794:3	O
the	SIMPONI.xml:S3:5798:3	O
risks	SIMPONI.xml:S3:5802:5	O
of	SIMPONI.xml:S3:5808:2	O
antifungal	SIMPONI.xml:S3:5811:10	O
therapy	SIMPONI.xml:S3:5822:7	O
while	SIMPONI.xml:S3:5830:5	O
a	SIMPONI.xml:S3:5836:1	O
diagnostic	SIMPONI.xml:S3:5838:10	O
workup	SIMPONI.xml:S3:5849:6	O
is	SIMPONI.xml:S3:5856:2	O
being	SIMPONI.xml:S3:5859:5	O
performed	SIMPONI.xml:S3:5865:9	O
.	SIMPONI.xml:S3:5874:1	O

Antigen	SIMPONI.xml:S3:5876:7	O
and	SIMPONI.xml:S3:5884:3	O
antibody	SIMPONI.xml:S3:5888:8	O
testing	SIMPONI.xml:S3:5897:7	O
for	SIMPONI.xml:S3:5905:3	O
histoplasmosis	SIMPONI.xml:S3:5909:14	O
may	SIMPONI.xml:S3:5924:3	O
be	SIMPONI.xml:S3:5928:2	O
negative	SIMPONI.xml:S3:5931:8	O
in	SIMPONI.xml:S3:5940:2	O
some	SIMPONI.xml:S3:5943:4	O
patients	SIMPONI.xml:S3:5948:8	O
with	SIMPONI.xml:S3:5957:4	O
active	SIMPONI.xml:S3:5962:6	O
infection	SIMPONI.xml:S3:5969:9	O
.	SIMPONI.xml:S3:5978:1	O

To	SIMPONI.xml:S3:5980:2	O
aid	SIMPONI.xml:S3:5983:3	O
in	SIMPONI.xml:S3:5987:2	O
the	SIMPONI.xml:S3:5990:3	O
management	SIMPONI.xml:S3:5994:10	O
of	SIMPONI.xml:S3:6005:2	O
such	SIMPONI.xml:S3:6008:4	O
patients	SIMPONI.xml:S3:6013:8	O
,	SIMPONI.xml:S3:6021:1	O
consider	SIMPONI.xml:S3:6023:8	O
consultation	SIMPONI.xml:S3:6032:12	O
with	SIMPONI.xml:S3:6045:4	O
a	SIMPONI.xml:S3:6050:1	O
physician	SIMPONI.xml:S3:6052:9	O
with	SIMPONI.xml:S3:6062:4	O
expertise	SIMPONI.xml:S3:6067:9	O
in	SIMPONI.xml:S3:6077:2	O
the	SIMPONI.xml:S3:6080:3	O
diagnosis	SIMPONI.xml:S3:6084:9	O
and	SIMPONI.xml:S3:6094:3	O
treatment	SIMPONI.xml:S3:6098:9	O
of	SIMPONI.xml:S3:6108:2	O
invasive	SIMPONI.xml:S3:6111:8	O
fungal	SIMPONI.xml:S3:6120:6	O
infections	SIMPONI.xml:S3:6127:10	O
.	SIMPONI.xml:S3:6137:1	O

Hepatitis	SIMPONI.xml:S3:6146:9	O
B	SIMPONI.xml:S3:6156:1	O
Virus	SIMPONI.xml:S3:6158:5	O
Reactivation	SIMPONI.xml:S3:6164:12	O

The	SIMPONI.xml:S3:6183:3	O
use	SIMPONI.xml:S3:6187:3	O
of	SIMPONI.xml:S3:6191:2	O
TNF	SIMPONI.xml:S3:6194:3	O
-	SIMPONI.xml:S3:6197:1	O
blockers	SIMPONI.xml:S3:6198:8	O
,	SIMPONI.xml:S3:6206:1	O
of	SIMPONI.xml:S3:6208:2	O
which	SIMPONI.xml:S3:6211:5	O
SIMPONI	SIMPONI.xml:S3:6217:7	O
ARIA	SIMPONI.xml:S3:6225:4	O
is	SIMPONI.xml:S3:6230:2	O
a	SIMPONI.xml:S3:6233:1	O
member	SIMPONI.xml:S3:6235:6	O
,	SIMPONI.xml:S3:6241:1	O
has	SIMPONI.xml:S3:6243:3	O
been	SIMPONI.xml:S3:6247:4	O
associated	SIMPONI.xml:S3:6252:10	O
with	SIMPONI.xml:S3:6263:4	O
reactivation	SIMPONI.xml:S3:6268:12	B-AdverseReaction
of	SIMPONI.xml:S3:6281:2	I-AdverseReaction
hepatitis	SIMPONI.xml:S3:6284:9	I-AdverseReaction
B	SIMPONI.xml:S3:6294:1	I-AdverseReaction
virus	SIMPONI.xml:S3:6296:5	I-AdverseReaction
(	SIMPONI.xml:S3:6302:1	O
HBV	SIMPONI.xml:S3:6303:3	I-AdverseReaction
)	SIMPONI.xml:S3:6306:1	O
in	SIMPONI.xml:S3:6308:2	O
patients	SIMPONI.xml:S3:6311:8	O
who	SIMPONI.xml:S3:6320:3	O
are	SIMPONI.xml:S3:6324:3	O
chronic	SIMPONI.xml:S3:6328:7	O
hepatitis	SIMPONI.xml:S3:6336:9	O
B	SIMPONI.xml:S3:6346:1	O
carriers	SIMPONI.xml:S3:6348:8	O
(	SIMPONI.xml:S3:6357:1	O
i	SIMPONI.xml:S3:6358:1	O
.	SIMPONI.xml:S3:6359:1	O
e	SIMPONI.xml:S3:6360:1	O
.	SIMPONI.xml:S3:6361:1	O
,	SIMPONI.xml:S3:6362:1	O
surface	SIMPONI.xml:S3:6364:7	O
antigen	SIMPONI.xml:S3:6372:7	O
positive	SIMPONI.xml:S3:6380:8	O
)	SIMPONI.xml:S3:6388:1	O
.	SIMPONI.xml:S3:6389:1	O

In	SIMPONI.xml:S3:6391:2	O
some	SIMPONI.xml:S3:6394:4	O
instances	SIMPONI.xml:S3:6399:9	O
,	SIMPONI.xml:S3:6408:1	O
HBV	SIMPONI.xml:S3:6410:3	B-AdverseReaction
reactivation	SIMPONI.xml:S3:6414:12	I-AdverseReaction
occurring	SIMPONI.xml:S3:6427:9	O
in	SIMPONI.xml:S3:6437:2	O
conjunction	SIMPONI.xml:S3:6440:11	O
with	SIMPONI.xml:S3:6452:4	O
TNF	SIMPONI.xml:S3:6457:3	O
-	SIMPONI.xml:S3:6460:1	O
blocker	SIMPONI.xml:S3:6461:7	O
therapy	SIMPONI.xml:S3:6469:7	O
has	SIMPONI.xml:S3:6477:3	O
been	SIMPONI.xml:S3:6481:4	O
fatal	SIMPONI.xml:S3:6486:5	B-AdverseReaction
.	SIMPONI.xml:S3:6491:1	O

The	SIMPONI.xml:S3:6493:3	O
majority	SIMPONI.xml:S3:6497:8	O
of	SIMPONI.xml:S3:6506:2	O
these	SIMPONI.xml:S3:6509:5	O
reports	SIMPONI.xml:S3:6515:7	O
have	SIMPONI.xml:S3:6523:4	O
occurred	SIMPONI.xml:S3:6528:8	O
in	SIMPONI.xml:S3:6537:2	O
patients	SIMPONI.xml:S3:6540:8	O
who	SIMPONI.xml:S3:6549:3	O
received	SIMPONI.xml:S3:6553:8	O
concomitant	SIMPONI.xml:S3:6562:11	O
immunosuppressants	SIMPONI.xml:S3:6574:18	O
.	SIMPONI.xml:S3:6592:1	O

All	SIMPONI.xml:S3:6598:3	O
patients	SIMPONI.xml:S3:6602:8	O
should	SIMPONI.xml:S3:6611:6	O
be	SIMPONI.xml:S3:6618:2	O
tested	SIMPONI.xml:S3:6621:6	O
for	SIMPONI.xml:S3:6628:3	O
HBV	SIMPONI.xml:S3:6632:3	O
infection	SIMPONI.xml:S3:6636:9	O
before	SIMPONI.xml:S3:6646:6	O
initiating	SIMPONI.xml:S3:6653:10	O
TNF	SIMPONI.xml:S3:6664:3	O
-	SIMPONI.xml:S3:6667:1	O
blocker	SIMPONI.xml:S3:6668:7	O
therapy	SIMPONI.xml:S3:6676:7	O
.	SIMPONI.xml:S3:6683:1	O

For	SIMPONI.xml:S3:6685:3	O
patients	SIMPONI.xml:S3:6689:8	O
who	SIMPONI.xml:S3:6698:3	O
test	SIMPONI.xml:S3:6702:4	O
positive	SIMPONI.xml:S3:6707:8	O
for	SIMPONI.xml:S3:6716:3	O
hepatitis	SIMPONI.xml:S3:6720:9	O
B	SIMPONI.xml:S3:6730:1	O
surface	SIMPONI.xml:S3:6732:7	O
antigen	SIMPONI.xml:S3:6740:7	O
,	SIMPONI.xml:S3:6747:1	O
consultation	SIMPONI.xml:S3:6749:12	O
with	SIMPONI.xml:S3:6762:4	O
a	SIMPONI.xml:S3:6767:1	O
physician	SIMPONI.xml:S3:6769:9	O
with	SIMPONI.xml:S3:6779:4	O
expertise	SIMPONI.xml:S3:6784:9	O
in	SIMPONI.xml:S3:6794:2	O
the	SIMPONI.xml:S3:6797:3	O
treatment	SIMPONI.xml:S3:6801:9	O
of	SIMPONI.xml:S3:6811:2	O
hepatitis	SIMPONI.xml:S3:6814:9	O
B	SIMPONI.xml:S3:6824:1	O
is	SIMPONI.xml:S3:6826:2	O
recommended	SIMPONI.xml:S3:6829:11	O
before	SIMPONI.xml:S3:6841:6	O
initiating	SIMPONI.xml:S3:6848:10	O
TNF	SIMPONI.xml:S3:6859:3	O
-	SIMPONI.xml:S3:6862:1	O
blocker	SIMPONI.xml:S3:6863:7	O
therapy	SIMPONI.xml:S3:6871:7	O
.	SIMPONI.xml:S3:6878:1	O

The	SIMPONI.xml:S3:6880:3	O
risks	SIMPONI.xml:S3:6884:5	O
and	SIMPONI.xml:S3:6890:3	O
benefits	SIMPONI.xml:S3:6894:8	O
of	SIMPONI.xml:S3:6903:2	O
treatment	SIMPONI.xml:S3:6906:9	O
should	SIMPONI.xml:S3:6916:6	O
be	SIMPONI.xml:S3:6923:2	O
considered	SIMPONI.xml:S3:6926:10	O
prior	SIMPONI.xml:S3:6937:5	O
to	SIMPONI.xml:S3:6943:2	O
prescribing	SIMPONI.xml:S3:6946:11	O
TNF	SIMPONI.xml:S3:6958:3	O
-	SIMPONI.xml:S3:6961:1	O
blockers	SIMPONI.xml:S3:6962:8	O
,	SIMPONI.xml:S3:6970:1	O
including	SIMPONI.xml:S3:6972:9	O
SIMPONI	SIMPONI.xml:S3:6982:7	O
ARIA	SIMPONI.xml:S3:6990:4	O
,	SIMPONI.xml:S3:6994:1	O
to	SIMPONI.xml:S3:6996:2	O
patients	SIMPONI.xml:S3:6999:8	O
who	SIMPONI.xml:S3:7008:3	O
are	SIMPONI.xml:S3:7012:3	O
carriers	SIMPONI.xml:S3:7016:8	O
of	SIMPONI.xml:S3:7025:2	O
HBV	SIMPONI.xml:S3:7028:3	O
.	SIMPONI.xml:S3:7031:1	O

Adequate	SIMPONI.xml:S3:7033:8	O
data	SIMPONI.xml:S3:7042:4	O
are	SIMPONI.xml:S3:7047:3	O
not	SIMPONI.xml:S3:7051:3	O
available	SIMPONI.xml:S3:7055:9	O
on	SIMPONI.xml:S3:7065:2	O
whether	SIMPONI.xml:S3:7068:7	O
anti	SIMPONI.xml:S3:7076:4	O
-	SIMPONI.xml:S3:7080:1	O
viral	SIMPONI.xml:S3:7081:5	O
therapy	SIMPONI.xml:S3:7087:7	O
can	SIMPONI.xml:S3:7095:3	O
reduce	SIMPONI.xml:S3:7099:6	O
the	SIMPONI.xml:S3:7106:3	O
risk	SIMPONI.xml:S3:7110:4	O
of	SIMPONI.xml:S3:7115:2	O
HBV	SIMPONI.xml:S3:7118:3	O
reactivation	SIMPONI.xml:S3:7122:12	O
in	SIMPONI.xml:S3:7135:2	O
HBV	SIMPONI.xml:S3:7138:3	O
carriers	SIMPONI.xml:S3:7142:8	O
who	SIMPONI.xml:S3:7151:3	O
are	SIMPONI.xml:S3:7155:3	O
treated	SIMPONI.xml:S3:7159:7	O
with	SIMPONI.xml:S3:7167:4	O
TNF	SIMPONI.xml:S3:7172:3	O
-	SIMPONI.xml:S3:7175:1	O
blockers	SIMPONI.xml:S3:7176:8	O
.	SIMPONI.xml:S3:7184:1	O

Patients	SIMPONI.xml:S3:7186:8	O
who	SIMPONI.xml:S3:7195:3	O
are	SIMPONI.xml:S3:7199:3	O
carriers	SIMPONI.xml:S3:7203:8	O
of	SIMPONI.xml:S3:7212:2	O
HBV	SIMPONI.xml:S3:7215:3	O
and	SIMPONI.xml:S3:7219:3	O
require	SIMPONI.xml:S3:7223:7	O
treatment	SIMPONI.xml:S3:7231:9	O
with	SIMPONI.xml:S3:7241:4	O
TNF	SIMPONI.xml:S3:7246:3	O
-	SIMPONI.xml:S3:7249:1	O
blockers	SIMPONI.xml:S3:7250:8	O
should	SIMPONI.xml:S3:7259:6	O
be	SIMPONI.xml:S3:7266:2	O
closely	SIMPONI.xml:S3:7269:7	O
monitored	SIMPONI.xml:S3:7277:9	O
for	SIMPONI.xml:S3:7287:3	O
clinical	SIMPONI.xml:S3:7291:8	O
and	SIMPONI.xml:S3:7300:3	O
laboratory	SIMPONI.xml:S3:7304:10	O
signs	SIMPONI.xml:S3:7315:5	O
of	SIMPONI.xml:S3:7321:2	O
active	SIMPONI.xml:S3:7324:6	O
HBV	SIMPONI.xml:S3:7331:3	O
infection	SIMPONI.xml:S3:7335:9	O
throughout	SIMPONI.xml:S3:7345:10	O
therapy	SIMPONI.xml:S3:7356:7	O
and	SIMPONI.xml:S3:7364:3	O
for	SIMPONI.xml:S3:7368:3	O
several	SIMPONI.xml:S3:7372:7	O
months	SIMPONI.xml:S3:7380:6	O
following	SIMPONI.xml:S3:7387:9	O
termination	SIMPONI.xml:S3:7397:11	O
of	SIMPONI.xml:S3:7409:2	O
therapy	SIMPONI.xml:S3:7412:7	O
.	SIMPONI.xml:S3:7419:1	O

In	SIMPONI.xml:S3:7425:2	O
patients	SIMPONI.xml:S3:7428:8	O
who	SIMPONI.xml:S3:7437:3	O
develop	SIMPONI.xml:S3:7441:7	O
HBV	SIMPONI.xml:S3:7449:3	O
reactivation	SIMPONI.xml:S3:7453:12	O
,	SIMPONI.xml:S3:7465:1	O
TNF	SIMPONI.xml:S3:7467:3	O
-	SIMPONI.xml:S3:7470:1	O
blockers	SIMPONI.xml:S3:7471:8	O
should	SIMPONI.xml:S3:7480:6	O
be	SIMPONI.xml:S3:7487:2	O
stopped	SIMPONI.xml:S3:7490:7	O
and	SIMPONI.xml:S3:7498:3	O
antiviral	SIMPONI.xml:S3:7502:9	O
therapy	SIMPONI.xml:S3:7512:7	O
with	SIMPONI.xml:S3:7520:4	O
appropriate	SIMPONI.xml:S3:7525:11	O
supportive	SIMPONI.xml:S3:7537:10	O
treatment	SIMPONI.xml:S3:7548:9	O
should	SIMPONI.xml:S3:7558:6	O
be	SIMPONI.xml:S3:7565:2	O
initiated	SIMPONI.xml:S3:7568:9	O
.	SIMPONI.xml:S3:7577:1	O

The	SIMPONI.xml:S3:7579:3	O
safety	SIMPONI.xml:S3:7583:6	O
of	SIMPONI.xml:S3:7590:2	O
resuming	SIMPONI.xml:S3:7593:8	O
TNF	SIMPONI.xml:S3:7602:3	O
-	SIMPONI.xml:S3:7605:1	O
blockers	SIMPONI.xml:S3:7606:8	O
after	SIMPONI.xml:S3:7615:5	O
HBV	SIMPONI.xml:S3:7621:3	O
reactivation	SIMPONI.xml:S3:7625:12	O
has	SIMPONI.xml:S3:7638:3	O
been	SIMPONI.xml:S3:7642:4	O
controlled	SIMPONI.xml:S3:7647:10	O
is	SIMPONI.xml:S3:7658:2	O
not	SIMPONI.xml:S3:7661:3	O
known	SIMPONI.xml:S3:7665:5	O
.	SIMPONI.xml:S3:7670:1	O

Therefore	SIMPONI.xml:S3:7672:9	O
,	SIMPONI.xml:S3:7681:1	O
prescribers	SIMPONI.xml:S3:7683:11	O
should	SIMPONI.xml:S3:7695:6	O
exercise	SIMPONI.xml:S3:7702:8	O
caution	SIMPONI.xml:S3:7711:7	O
when	SIMPONI.xml:S3:7719:4	O
considering	SIMPONI.xml:S3:7724:11	O
resumption	SIMPONI.xml:S3:7736:10	O
of	SIMPONI.xml:S3:7747:2	O
TNF	SIMPONI.xml:S3:7750:3	O
-	SIMPONI.xml:S3:7753:1	O
blockers	SIMPONI.xml:S3:7754:8	O
in	SIMPONI.xml:S3:7763:2	O
this	SIMPONI.xml:S3:7766:4	O
situation	SIMPONI.xml:S3:7771:9	O
and	SIMPONI.xml:S3:7781:3	O
monitor	SIMPONI.xml:S3:7785:7	O
patients	SIMPONI.xml:S3:7793:8	O
closely	SIMPONI.xml:S3:7802:7	O
.	SIMPONI.xml:S3:7809:1	O

5.2	SIMPONI.xml:S3:7818:3	O
Malignancies	SIMPONI.xml:S3:7822:12	O

Malignancies	SIMPONI.xml:S3:7841:12	O
in	SIMPONI.xml:S3:7854:2	O
Pediatric	SIMPONI.xml:S3:7857:9	O
Patients	SIMPONI.xml:S3:7867:8	O

Malignancies	SIMPONI.xml:S3:7882:12	B-AdverseReaction
,	SIMPONI.xml:S3:7894:1	O
some	SIMPONI.xml:S3:7896:4	O
fatal	SIMPONI.xml:S3:7901:5	B-AdverseReaction
,	SIMPONI.xml:S3:7906:1	O
have	SIMPONI.xml:S3:7908:4	O
been	SIMPONI.xml:S3:7913:4	O
reported	SIMPONI.xml:S3:7918:8	O
among	SIMPONI.xml:S3:7927:5	O
children	SIMPONI.xml:S3:7933:8	O
,	SIMPONI.xml:S3:7941:1	O
adolescents	SIMPONI.xml:S3:7943:11	O
,	SIMPONI.xml:S3:7954:1	O
and	SIMPONI.xml:S3:7956:3	O
young	SIMPONI.xml:S3:7960:5	O
adults	SIMPONI.xml:S3:7966:6	O
who	SIMPONI.xml:S3:7973:3	O
received	SIMPONI.xml:S3:7977:8	O
treatment	SIMPONI.xml:S3:7986:9	O
with	SIMPONI.xml:S3:7996:4	O
TNF	SIMPONI.xml:S3:8001:3	O
-	SIMPONI.xml:S3:8004:1	O
blocking	SIMPONI.xml:S3:8005:8	O
agents	SIMPONI.xml:S3:8014:6	O
(	SIMPONI.xml:S3:8021:1	O
initiation	SIMPONI.xml:S3:8022:10	O
of	SIMPONI.xml:S3:8033:2	O
therapy	SIMPONI.xml:S3:8036:7	O
18	SIMPONI.xml:S3:8047:2	O
years	SIMPONI.xml:S3:8050:5	O
of	SIMPONI.xml:S3:8056:2	O
age	SIMPONI.xml:S3:8059:3	O
)	SIMPONI.xml:S3:8062:1	O
,	SIMPONI.xml:S3:8063:1	O
of	SIMPONI.xml:S3:8065:2	O
which	SIMPONI.xml:S3:8068:5	O
SIMPONI	SIMPONI.xml:S3:8074:7	O
ARIA	SIMPONI.xml:S3:8082:4	O
is	SIMPONI.xml:S3:8087:2	O
a	SIMPONI.xml:S3:8090:1	O
member	SIMPONI.xml:S3:8092:6	O
.	SIMPONI.xml:S3:8098:1	O

Approximately	SIMPONI.xml:S3:8100:13	O
half	SIMPONI.xml:S3:8114:4	O
the	SIMPONI.xml:S3:8119:3	O
cases	SIMPONI.xml:S3:8123:5	O
were	SIMPONI.xml:S3:8129:4	O
lymphomas	SIMPONI.xml:S3:8134:9	B-AdverseReaction
,	SIMPONI.xml:S3:8143:1	O
including	SIMPONI.xml:S3:8145:9	O
Hodgkin	SIMPONI.xml:S3:8155:7	B-AdverseReaction
's	SIMPONI.xml:S3:8162:2	I-AdverseReaction
and	SIMPONI.xml:S3:8165:3	O
non	SIMPONI.xml:S3:8169:3	B-AdverseReaction
-	SIMPONI.xml:S3:8172:1	I-AdverseReaction
Hodgkin	SIMPONI.xml:S3:8173:7	I-AdverseReaction
's	SIMPONI.xml:S3:8180:2	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:8183:8	I-AdverseReaction
.	SIMPONI.xml:S3:8191:1	O

The	SIMPONI.xml:S3:8193:3	O
other	SIMPONI.xml:S3:8197:5	O
cases	SIMPONI.xml:S3:8203:5	O
represented	SIMPONI.xml:S3:8209:11	O
a	SIMPONI.xml:S3:8221:1	O
variety	SIMPONI.xml:S3:8223:7	O
of	SIMPONI.xml:S3:8231:2	O
malignancies	SIMPONI.xml:S3:8234:12	B-AdverseReaction
,	SIMPONI.xml:S3:8246:1	O
including	SIMPONI.xml:S3:8248:9	O
rare	SIMPONI.xml:S3:8258:4	B-AdverseReaction
malignancies	SIMPONI.xml:S3:8263:12	I-AdverseReaction
that	SIMPONI.xml:S3:8276:4	O
are	SIMPONI.xml:S3:8281:3	O
usually	SIMPONI.xml:S3:8285:7	O
associated	SIMPONI.xml:S3:8293:10	O
with	SIMPONI.xml:S3:8304:4	O
immunosuppression	SIMPONI.xml:S3:8309:17	B-AdverseReaction
,	SIMPONI.xml:S3:8326:1	O
and	SIMPONI.xml:S3:8328:3	O
malignancies	SIMPONI.xml:S3:8332:12	O
that	SIMPONI.xml:S3:8345:4	O
are	SIMPONI.xml:S3:8350:3	O
not	SIMPONI.xml:S3:8354:3	O
usually	SIMPONI.xml:S3:8358:7	O
observed	SIMPONI.xml:S3:8366:8	O
in	SIMPONI.xml:S3:8375:2	O
children	SIMPONI.xml:S3:8378:8	O
and	SIMPONI.xml:S3:8387:3	O
adolescents	SIMPONI.xml:S3:8391:11	O
.	SIMPONI.xml:S3:8402:1	O

The	SIMPONI.xml:S3:8404:3	O
malignancies	SIMPONI.xml:S3:8408:12	O
occurred	SIMPONI.xml:S3:8421:8	O
after	SIMPONI.xml:S3:8430:5	O
a	SIMPONI.xml:S3:8436:1	O
median	SIMPONI.xml:S3:8438:6	O
of	SIMPONI.xml:S3:8445:2	O
30	SIMPONI.xml:S3:8448:2	O
months	SIMPONI.xml:S3:8451:6	O
(	SIMPONI.xml:S3:8458:1	O
range	SIMPONI.xml:S3:8459:5	O
1	SIMPONI.xml:S3:8465:1	O
to	SIMPONI.xml:S3:8467:2	O
84	SIMPONI.xml:S3:8470:2	O
months	SIMPONI.xml:S3:8473:6	O
)	SIMPONI.xml:S3:8479:1	O
after	SIMPONI.xml:S3:8481:5	O
the	SIMPONI.xml:S3:8487:3	O
first	SIMPONI.xml:S3:8491:5	O
dose	SIMPONI.xml:S3:8497:4	O
of	SIMPONI.xml:S3:8502:2	O
TNF	SIMPONI.xml:S3:8505:3	O
-	SIMPONI.xml:S3:8508:1	O
blocker	SIMPONI.xml:S3:8509:7	O
therapy	SIMPONI.xml:S3:8517:7	O
.	SIMPONI.xml:S3:8524:1	O

Most	SIMPONI.xml:S3:8526:4	O
of	SIMPONI.xml:S3:8531:2	O
the	SIMPONI.xml:S3:8534:3	O
patients	SIMPONI.xml:S3:8538:8	O
were	SIMPONI.xml:S3:8547:4	O
receiving	SIMPONI.xml:S3:8552:9	O
concomitant	SIMPONI.xml:S3:8562:11	O
immunosuppressants	SIMPONI.xml:S3:8574:18	O
.	SIMPONI.xml:S3:8592:1	O

These	SIMPONI.xml:S3:8594:5	O
cases	SIMPONI.xml:S3:8600:5	O
were	SIMPONI.xml:S3:8606:4	O
reported	SIMPONI.xml:S3:8611:8	O
post	SIMPONI.xml:S3:8620:4	O
-	SIMPONI.xml:S3:8624:1	O
marketing	SIMPONI.xml:S3:8625:9	O
and	SIMPONI.xml:S3:8635:3	O
are	SIMPONI.xml:S3:8639:3	O
derived	SIMPONI.xml:S3:8643:7	O
from	SIMPONI.xml:S3:8651:4	O
a	SIMPONI.xml:S3:8656:1	O
variety	SIMPONI.xml:S3:8658:7	O
of	SIMPONI.xml:S3:8666:2	O
sources	SIMPONI.xml:S3:8669:7	O
,	SIMPONI.xml:S3:8676:1	O
including	SIMPONI.xml:S3:8678:9	O
registries	SIMPONI.xml:S3:8688:10	O
and	SIMPONI.xml:S3:8699:3	O
spontaneous	SIMPONI.xml:S3:8703:11	O
post	SIMPONI.xml:S3:8715:4	O
-	SIMPONI.xml:S3:8719:1	O
marketing	SIMPONI.xml:S3:8720:9	O
reports	SIMPONI.xml:S3:8730:7	O
.	SIMPONI.xml:S3:8737:1	O

Use	SIMPONI.xml:S3:8739:3	O
of	SIMPONI.xml:S3:8743:2	O
SIMPONI	SIMPONI.xml:S3:8746:7	O
ARIA	SIMPONI.xml:S3:8754:4	O
in	SIMPONI.xml:S3:8759:2	O
patients	SIMPONI.xml:S3:8762:8	O
under	SIMPONI.xml:S3:8771:5	O
18	SIMPONI.xml:S3:8777:2	O
years	SIMPONI.xml:S3:8780:5	O
of	SIMPONI.xml:S3:8786:2	O
age	SIMPONI.xml:S3:8789:3	O
has	SIMPONI.xml:S3:8793:3	O
not	SIMPONI.xml:S3:8797:3	O
been	SIMPONI.xml:S3:8801:4	O
established	SIMPONI.xml:S3:8806:11	O
.	SIMPONI.xml:S3:8817:1	O

Malignancies	SIMPONI.xml:S3:8826:12	O
in	SIMPONI.xml:S3:8839:2	O
Adult	SIMPONI.xml:S3:8842:5	O
Patients	SIMPONI.xml:S3:8848:8	O

The	SIMPONI.xml:S3:8863:3	O
risks	SIMPONI.xml:S3:8867:5	O
and	SIMPONI.xml:S3:8873:3	O
benefits	SIMPONI.xml:S3:8877:8	O
of	SIMPONI.xml:S3:8886:2	O
TNF	SIMPONI.xml:S3:8889:3	O
-	SIMPONI.xml:S3:8892:1	O
blocker	SIMPONI.xml:S3:8893:7	O
treatment	SIMPONI.xml:S3:8901:9	O
including	SIMPONI.xml:S3:8911:9	O
SIMPONI	SIMPONI.xml:S3:8921:7	O
ARIA	SIMPONI.xml:S3:8929:4	O
should	SIMPONI.xml:S3:8934:6	O
be	SIMPONI.xml:S3:8941:2	O
considered	SIMPONI.xml:S3:8944:10	O
prior	SIMPONI.xml:S3:8955:5	O
to	SIMPONI.xml:S3:8961:2	O
initiating	SIMPONI.xml:S3:8964:10	O
therapy	SIMPONI.xml:S3:8975:7	O
in	SIMPONI.xml:S3:8983:2	O
patients	SIMPONI.xml:S3:8986:8	O
with	SIMPONI.xml:S3:8995:4	O
a	SIMPONI.xml:S3:9000:1	O
known	SIMPONI.xml:S3:9002:5	O
malignancy	SIMPONI.xml:S3:9008:10	O
other	SIMPONI.xml:S3:9019:5	O
than	SIMPONI.xml:S3:9025:4	O
a	SIMPONI.xml:S3:9030:1	O
successfully	SIMPONI.xml:S3:9032:12	O
treated	SIMPONI.xml:S3:9045:7	O
non	SIMPONI.xml:S3:9053:3	O
-	SIMPONI.xml:S3:9056:1	O
melanoma	SIMPONI.xml:S3:9057:8	O
skin	SIMPONI.xml:S3:9066:4	O
cancer	SIMPONI.xml:S3:9071:6	O
(	SIMPONI.xml:S3:9078:1	O
NMSC	SIMPONI.xml:S3:9079:4	O
)	SIMPONI.xml:S3:9083:1	O
or	SIMPONI.xml:S3:9085:2	O
when	SIMPONI.xml:S3:9088:4	O
considering	SIMPONI.xml:S3:9093:11	O
continuing	SIMPONI.xml:S3:9105:10	O
a	SIMPONI.xml:S3:9116:1	O
TNF	SIMPONI.xml:S3:9118:3	O
-	SIMPONI.xml:S3:9121:1	O
blocker	SIMPONI.xml:S3:9122:7	O
in	SIMPONI.xml:S3:9130:2	O
patients	SIMPONI.xml:S3:9133:8	O
who	SIMPONI.xml:S3:9142:3	O
develop	SIMPONI.xml:S3:9146:7	O
a	SIMPONI.xml:S3:9154:1	O
malignancy	SIMPONI.xml:S3:9156:10	O
.	SIMPONI.xml:S3:9166:1	O

In	SIMPONI.xml:S3:9172:2	O
the	SIMPONI.xml:S3:9175:3	O
controlled	SIMPONI.xml:S3:9179:10	O
portions	SIMPONI.xml:S3:9190:8	O
of	SIMPONI.xml:S3:9199:2	O
clinical	SIMPONI.xml:S3:9202:8	O
trials	SIMPONI.xml:S3:9211:6	O
of	SIMPONI.xml:S3:9218:2	O
TNF	SIMPONI.xml:S3:9221:3	O
-	SIMPONI.xml:S3:9224:1	O
blockers	SIMPONI.xml:S3:9225:8	O
including	SIMPONI.xml:S3:9234:9	O
the	SIMPONI.xml:S3:9244:3	O
subcutaneous	SIMPONI.xml:S3:9248:12	O
formulation	SIMPONI.xml:S3:9261:11	O
of	SIMPONI.xml:S3:9273:2	O
golimumab	SIMPONI.xml:S3:9276:9	O
more	SIMPONI.xml:S3:9286:4	O
cases	SIMPONI.xml:S3:9291:5	O
of	SIMPONI.xml:S3:9297:2	O
lymphoma	SIMPONI.xml:S3:9300:8	B-AdverseReaction
have	SIMPONI.xml:S3:9309:4	O
been	SIMPONI.xml:S3:9314:4	O
observed	SIMPONI.xml:S3:9319:8	O
among	SIMPONI.xml:S3:9328:5	O
patients	SIMPONI.xml:S3:9334:8	O
receiving	SIMPONI.xml:S3:9343:9	O
anti	SIMPONI.xml:S3:9353:4	O
-	SIMPONI.xml:S3:9357:1	O
TNF	SIMPONI.xml:S3:9358:3	O
treatment	SIMPONI.xml:S3:9362:9	O
compared	SIMPONI.xml:S3:9372:8	O
with	SIMPONI.xml:S3:9381:4	O
patients	SIMPONI.xml:S3:9386:8	O
in	SIMPONI.xml:S3:9395:2	O
the	SIMPONI.xml:S3:9398:3	O
control	SIMPONI.xml:S3:9402:7	O
groups	SIMPONI.xml:S3:9410:6	O
.	SIMPONI.xml:S3:9416:1	O

Patients	SIMPONI.xml:S3:9418:8	O
with	SIMPONI.xml:S3:9427:4	O
RA	SIMPONI.xml:S3:9432:2	O
and	SIMPONI.xml:S3:9435:3	O
other	SIMPONI.xml:S3:9439:5	O
chronic	SIMPONI.xml:S3:9445:7	O
inflammatory	SIMPONI.xml:S3:9453:12	O
diseases	SIMPONI.xml:S3:9466:8	O
,	SIMPONI.xml:S3:9474:1	O
particularly	SIMPONI.xml:S3:9476:12	O
patients	SIMPONI.xml:S3:9489:8	O
with	SIMPONI.xml:S3:9498:4	O
highly	SIMPONI.xml:S3:9503:6	O
active	SIMPONI.xml:S3:9510:6	O
disease	SIMPONI.xml:S3:9517:7	O
and	SIMPONI.xml:S3:9525:3	O
or	SIMPONI.xml:S3:9529:2	O
chronic	SIMPONI.xml:S3:9532:7	O
exposure	SIMPONI.xml:S3:9540:8	O
to	SIMPONI.xml:S3:9549:2	O
immunosuppressant	SIMPONI.xml:S3:9552:17	O
therapies	SIMPONI.xml:S3:9570:9	O
,	SIMPONI.xml:S3:9579:1	O
may	SIMPONI.xml:S3:9581:3	O
be	SIMPONI.xml:S3:9585:2	O
at	SIMPONI.xml:S3:9588:2	O
higher	SIMPONI.xml:S3:9591:6	O
risk	SIMPONI.xml:S3:9598:4	B-Factor
(	SIMPONI.xml:S3:9603:1	O
up	SIMPONI.xml:S3:9604:2	O
to	SIMPONI.xml:S3:9607:2	O
several	SIMPONI.xml:S3:9610:7	O
fold	SIMPONI.xml:S3:9618:4	O
)	SIMPONI.xml:S3:9622:1	O
than	SIMPONI.xml:S3:9624:4	O
the	SIMPONI.xml:S3:9629:3	O
general	SIMPONI.xml:S3:9633:7	O
population	SIMPONI.xml:S3:9641:10	O
for	SIMPONI.xml:S3:9652:3	O
the	SIMPONI.xml:S3:9656:3	O
development	SIMPONI.xml:S3:9660:11	O
of	SIMPONI.xml:S3:9672:2	O
lymphoma	SIMPONI.xml:S3:9675:8	B-AdverseReaction
,	SIMPONI.xml:S3:9683:1	O
even	SIMPONI.xml:S3:9685:4	O
in	SIMPONI.xml:S3:9690:2	O
the	SIMPONI.xml:S3:9693:3	O
absence	SIMPONI.xml:S3:9697:7	O
of	SIMPONI.xml:S3:9705:2	O
TNF	SIMPONI.xml:S3:9708:3	O
-	SIMPONI.xml:S3:9711:1	O
blocking	SIMPONI.xml:S3:9712:8	O
therapy	SIMPONI.xml:S3:9721:7	O
.	SIMPONI.xml:S3:9728:1	O

Cases	SIMPONI.xml:S3:9730:5	O
of	SIMPONI.xml:S3:9736:2	O
acute	SIMPONI.xml:S3:9739:5	B-AdverseReaction
and	SIMPONI.xml:S3:9745:3	O
chronic	SIMPONI.xml:S3:9749:7	B-AdverseReaction
leukemia	SIMPONI.xml:S3:9757:8	I-AdverseReaction
have	SIMPONI.xml:S3:9766:4	O
been	SIMPONI.xml:S3:9771:4	O
reported	SIMPONI.xml:S3:9776:8	O
with	SIMPONI.xml:S3:9785:4	O
post	SIMPONI.xml:S3:9790:4	O
-	SIMPONI.xml:S3:9794:1	O
marketing	SIMPONI.xml:S3:9795:9	O
TNF	SIMPONI.xml:S3:9805:3	O
-	SIMPONI.xml:S3:9808:1	O
blocker	SIMPONI.xml:S3:9809:7	O
use	SIMPONI.xml:S3:9817:3	O
in	SIMPONI.xml:S3:9821:2	O
rheumatoid	SIMPONI.xml:S3:9824:10	O
arthritis	SIMPONI.xml:S3:9835:9	O
and	SIMPONI.xml:S3:9845:3	O
other	SIMPONI.xml:S3:9849:5	O
indications	SIMPONI.xml:S3:9855:11	O
.	SIMPONI.xml:S3:9866:1	O

Even	SIMPONI.xml:S3:9868:4	O
in	SIMPONI.xml:S3:9873:2	O
the	SIMPONI.xml:S3:9876:3	O
absence	SIMPONI.xml:S3:9880:7	O
of	SIMPONI.xml:S3:9888:2	O
TNF	SIMPONI.xml:S3:9891:3	O
-	SIMPONI.xml:S3:9894:1	O
blocker	SIMPONI.xml:S3:9895:7	O
therapy	SIMPONI.xml:S3:9903:7	O
,	SIMPONI.xml:S3:9910:1	O
patients	SIMPONI.xml:S3:9912:8	O
with	SIMPONI.xml:S3:9921:4	O
rheumatoid	SIMPONI.xml:S3:9926:10	O
arthritis	SIMPONI.xml:S3:9937:9	O
may	SIMPONI.xml:S3:9947:3	O
be	SIMPONI.xml:S3:9951:2	O
at	SIMPONI.xml:S3:9954:2	O
a	SIMPONI.xml:S3:9957:1	O
higher	SIMPONI.xml:S3:9959:6	O
risk	SIMPONI.xml:S3:9966:4	O
(	SIMPONI.xml:S3:9971:1	O
approximately	SIMPONI.xml:S3:9972:13	O
2	SIMPONI.xml:S3:9986:1	O
-	SIMPONI.xml:S3:9987:1	O
fold	SIMPONI.xml:S3:9988:4	O
)	SIMPONI.xml:S3:9992:1	O
than	SIMPONI.xml:S3:9994:4	O
the	SIMPONI.xml:S3:9999:3	O
general	SIMPONI.xml:S3:10003:7	O
population	SIMPONI.xml:S3:10011:10	O
for	SIMPONI.xml:S3:10022:3	O
the	SIMPONI.xml:S3:10026:3	O
development	SIMPONI.xml:S3:10030:11	O
of	SIMPONI.xml:S3:10042:2	O
leukemia	SIMPONI.xml:S3:10045:8	O
.	SIMPONI.xml:S3:10053:1	O

Rare	SIMPONI.xml:S3:10060:4	O
post	SIMPONI.xml:S3:10065:4	O
-	SIMPONI.xml:S3:10069:1	O
marketing	SIMPONI.xml:S3:10070:9	O
cases	SIMPONI.xml:S3:10080:5	O
of	SIMPONI.xml:S3:10086:2	O
hepatosplenic	SIMPONI.xml:S3:10089:13	B-AdverseReaction
T	SIMPONI.xml:S3:10103:1	I-AdverseReaction
-	SIMPONI.xml:S3:10104:1	I-AdverseReaction
cell	SIMPONI.xml:S3:10105:4	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:10110:8	I-AdverseReaction
(	SIMPONI.xml:S3:10119:1	O
HSTCL	SIMPONI.xml:S3:10120:5	B-AdverseReaction
)	SIMPONI.xml:S3:10125:1	O
have	SIMPONI.xml:S3:10127:4	O
been	SIMPONI.xml:S3:10132:4	O
reported	SIMPONI.xml:S3:10137:8	O
in	SIMPONI.xml:S3:10146:2	O
patients	SIMPONI.xml:S3:10149:8	O
treated	SIMPONI.xml:S3:10158:7	O
with	SIMPONI.xml:S3:10166:4	O
TNF	SIMPONI.xml:S3:10171:3	O
-	SIMPONI.xml:S3:10174:1	O
blocking	SIMPONI.xml:S3:10175:8	O
agents	SIMPONI.xml:S3:10184:6	O
.	SIMPONI.xml:S3:10190:1	O

This	SIMPONI.xml:S3:10192:4	O
rare	SIMPONI.xml:S3:10197:4	B-AdverseReaction
type	SIMPONI.xml:S3:10202:4	I-AdverseReaction
of	SIMPONI.xml:S3:10207:2	I-AdverseReaction
T	SIMPONI.xml:S3:10210:1	I-AdverseReaction
-	SIMPONI.xml:S3:10211:1	I-AdverseReaction
cell	SIMPONI.xml:S3:10212:4	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:10217:8	I-AdverseReaction
has	SIMPONI.xml:S3:10226:3	O
a	SIMPONI.xml:S3:10230:1	O
very	SIMPONI.xml:S3:10232:4	O
aggressive	SIMPONI.xml:S3:10237:10	O
disease	SIMPONI.xml:S3:10248:7	O
course	SIMPONI.xml:S3:10256:6	O
and	SIMPONI.xml:S3:10263:3	O
is	SIMPONI.xml:S3:10267:2	O
usually	SIMPONI.xml:S3:10270:7	O
fatal	SIMPONI.xml:S3:10278:5	B-AdverseReaction
.	SIMPONI.xml:S3:10283:1	O

Nearly	SIMPONI.xml:S3:10285:6	O
all	SIMPONI.xml:S3:10292:3	O
of	SIMPONI.xml:S3:10296:2	O
the	SIMPONI.xml:S3:10299:3	O
reported	SIMPONI.xml:S3:10303:8	O
TNF	SIMPONI.xml:S3:10312:3	O
-	SIMPONI.xml:S3:10315:1	O
blocker	SIMPONI.xml:S3:10316:7	O
associated	SIMPONI.xml:S3:10324:10	O
cases	SIMPONI.xml:S3:10335:5	O
have	SIMPONI.xml:S3:10341:4	O
occurred	SIMPONI.xml:S3:10346:8	O
in	SIMPONI.xml:S3:10355:2	O
patients	SIMPONI.xml:S3:10358:8	O
with	SIMPONI.xml:S3:10367:4	O
Crohn	SIMPONI.xml:S3:10372:5	O
's	SIMPONI.xml:S3:10377:2	O
disease	SIMPONI.xml:S3:10380:7	O
or	SIMPONI.xml:S3:10388:2	O
ulcerative	SIMPONI.xml:S3:10391:10	O
colitis	SIMPONI.xml:S3:10402:7	O
.	SIMPONI.xml:S3:10409:1	O

The	SIMPONI.xml:S3:10411:3	O
majority	SIMPONI.xml:S3:10415:8	O
were	SIMPONI.xml:S3:10424:4	O
in	SIMPONI.xml:S3:10429:2	O
adolescent	SIMPONI.xml:S3:10432:10	O
and	SIMPONI.xml:S3:10443:3	O
young	SIMPONI.xml:S3:10447:5	O
adult	SIMPONI.xml:S3:10453:5	O
males	SIMPONI.xml:S3:10459:5	O
.	SIMPONI.xml:S3:10464:1	O

Almost	SIMPONI.xml:S3:10466:6	O
all	SIMPONI.xml:S3:10473:3	O
these	SIMPONI.xml:S3:10477:5	O
patients	SIMPONI.xml:S3:10483:8	O
had	SIMPONI.xml:S3:10492:3	O
received	SIMPONI.xml:S3:10496:8	O
treatment	SIMPONI.xml:S3:10505:9	O
with	SIMPONI.xml:S3:10515:4	O
azathioprine	SIMPONI.xml:S3:10520:12	O
(	SIMPONI.xml:S3:10533:1	O
AZA	SIMPONI.xml:S3:10534:3	O
)	SIMPONI.xml:S3:10537:1	O
or	SIMPONI.xml:S3:10539:2	O
6	SIMPONI.xml:S3:10542:1	O
-	SIMPONI.xml:S3:10543:1	O
mercaptopurine	SIMPONI.xml:S3:10544:14	O
(	SIMPONI.xml:S3:10559:1	O
6	SIMPONI.xml:S3:10560:1	O
-	SIMPONI.xml:S3:10561:1	O
MP	SIMPONI.xml:S3:10562:2	O
)	SIMPONI.xml:S3:10564:1	O
concomitantly	SIMPONI.xml:S3:10566:13	O
with	SIMPONI.xml:S3:10580:4	O
a	SIMPONI.xml:S3:10585:1	O
TNF	SIMPONI.xml:S3:10587:3	O
-	SIMPONI.xml:S3:10590:1	O
blocker	SIMPONI.xml:S3:10591:7	O
at	SIMPONI.xml:S3:10599:2	O
or	SIMPONI.xml:S3:10602:2	O
prior	SIMPONI.xml:S3:10605:5	O
to	SIMPONI.xml:S3:10611:2	O
diagnosis	SIMPONI.xml:S3:10614:9	O
.	SIMPONI.xml:S3:10623:1	O

A	SIMPONI.xml:S3:10625:1	O
risk	SIMPONI.xml:S3:10627:4	O
for	SIMPONI.xml:S3:10632:3	O
the	SIMPONI.xml:S3:10636:3	O
development	SIMPONI.xml:S3:10640:11	O
for	SIMPONI.xml:S3:10652:3	O
hepatosplenic	SIMPONI.xml:S3:10656:13	O
T	SIMPONI.xml:S3:10670:1	O
-	SIMPONI.xml:S3:10671:1	O
cell	SIMPONI.xml:S3:10672:4	O
lymphoma	SIMPONI.xml:S3:10677:8	O
in	SIMPONI.xml:S3:10686:2	O
patients	SIMPONI.xml:S3:10689:8	O
treated	SIMPONI.xml:S3:10698:7	O
with	SIMPONI.xml:S3:10706:4	O
TNF	SIMPONI.xml:S3:10711:3	O
-	SIMPONI.xml:S3:10714:1	O
blockers	SIMPONI.xml:S3:10715:8	O
cannot	SIMPONI.xml:S3:10724:6	O
be	SIMPONI.xml:S3:10731:2	O
excluded	SIMPONI.xml:S3:10734:8	O
.	SIMPONI.xml:S3:10742:1	O

Melanoma	SIMPONI.xml:S3:10750:8	B-AdverseReaction
has	SIMPONI.xml:S3:10759:3	O
been	SIMPONI.xml:S3:10763:4	O
reported	SIMPONI.xml:S3:10768:8	O
in	SIMPONI.xml:S3:10777:2	O
patients	SIMPONI.xml:S3:10780:8	O
treated	SIMPONI.xml:S3:10789:7	O
with	SIMPONI.xml:S3:10797:4	O
TNF	SIMPONI.xml:S3:10802:3	O
-	SIMPONI.xml:S3:10805:1	O
blocking	SIMPONI.xml:S3:10806:8	O
agents	SIMPONI.xml:S3:10815:6	O
,	SIMPONI.xml:S3:10821:1	O
including	SIMPONI.xml:S3:10823:9	O
the	SIMPONI.xml:S3:10833:3	O
subcutaneous	SIMPONI.xml:S3:10837:12	O
formulation	SIMPONI.xml:S3:10850:11	O
of	SIMPONI.xml:S3:10862:2	O
golimumab	SIMPONI.xml:S3:10865:9	O
.	SIMPONI.xml:S3:10874:1	O

Merkel	SIMPONI.xml:S3:10876:6	B-AdverseReaction
cell	SIMPONI.xml:S3:10883:4	I-AdverseReaction
carcinoma	SIMPONI.xml:S3:10888:9	I-AdverseReaction
has	SIMPONI.xml:S3:10898:3	O
been	SIMPONI.xml:S3:10902:4	O
reported	SIMPONI.xml:S3:10907:8	O
in	SIMPONI.xml:S3:10916:2	O
patients	SIMPONI.xml:S3:10919:8	O
treated	SIMPONI.xml:S3:10928:7	O
with	SIMPONI.xml:S3:10936:4	O
TNF	SIMPONI.xml:S3:10941:3	O
-	SIMPONI.xml:S3:10944:1	O
blocking	SIMPONI.xml:S3:10945:8	O
agents	SIMPONI.xml:S3:10954:6	O
.	SIMPONI.xml:S3:10960:1	O

Periodic	SIMPONI.xml:S3:10962:8	O
skin	SIMPONI.xml:S3:10971:4	O
examination	SIMPONI.xml:S3:10976:11	O
is	SIMPONI.xml:S3:10988:2	O
recommended	SIMPONI.xml:S3:10991:11	O
for	SIMPONI.xml:S3:11003:3	O
all	SIMPONI.xml:S3:11007:3	O
patients	SIMPONI.xml:S3:11011:8	O
,	SIMPONI.xml:S3:11019:1	O
particularly	SIMPONI.xml:S3:11021:12	O
those	SIMPONI.xml:S3:11034:5	O
with	SIMPONI.xml:S3:11040:4	O
risk	SIMPONI.xml:S3:11045:4	O
factors	SIMPONI.xml:S3:11050:7	O
for	SIMPONI.xml:S3:11058:3	O
skin	SIMPONI.xml:S3:11062:4	O
cancer	SIMPONI.xml:S3:11067:6	O
.	SIMPONI.xml:S3:11073:1	O

In	SIMPONI.xml:S3:11079:2	O
controlled	SIMPONI.xml:S3:11082:10	O
trials	SIMPONI.xml:S3:11093:6	O
of	SIMPONI.xml:S3:11100:2	O
other	SIMPONI.xml:S3:11103:5	O
TNF	SIMPONI.xml:S3:11109:3	O
-	SIMPONI.xml:S3:11112:1	O
blockers	SIMPONI.xml:S3:11113:8	O
in	SIMPONI.xml:S3:11122:2	O
patients	SIMPONI.xml:S3:11125:8	O
at	SIMPONI.xml:S3:11134:2	O
higher	SIMPONI.xml:S3:11137:6	O
risk	SIMPONI.xml:S3:11144:4	O
for	SIMPONI.xml:S3:11149:3	O
malignancies	SIMPONI.xml:S3:11153:12	O
(	SIMPONI.xml:S3:11166:1	O
e	SIMPONI.xml:S3:11167:1	O
.	SIMPONI.xml:S3:11168:1	O
g	SIMPONI.xml:S3:11169:1	O
.	SIMPONI.xml:S3:11170:1	O
,	SIMPONI.xml:S3:11171:1	O
patients	SIMPONI.xml:S3:11173:8	O
with	SIMPONI.xml:S3:11182:4	O
COPD	SIMPONI.xml:S3:11187:4	O
,	SIMPONI.xml:S3:11191:1	O
patients	SIMPONI.xml:S3:11193:8	O
with	SIMPONI.xml:S3:11202:4	O
Wegener	SIMPONI.xml:S3:11207:7	O
's	SIMPONI.xml:S3:11214:2	O
granulomatosis	SIMPONI.xml:S3:11217:14	O
treated	SIMPONI.xml:S3:11232:7	O
with	SIMPONI.xml:S3:11240:4	O
concomitant	SIMPONI.xml:S3:11245:11	O
cyclophosphamide	SIMPONI.xml:S3:11257:16	O
)	SIMPONI.xml:S3:11273:1	O
a	SIMPONI.xml:S3:11275:1	O
greater	SIMPONI.xml:S3:11277:7	O
portion	SIMPONI.xml:S3:11285:7	O
of	SIMPONI.xml:S3:11293:2	O
malignancies	SIMPONI.xml:S3:11296:12	B-AdverseReaction
occurred	SIMPONI.xml:S3:11309:8	O
in	SIMPONI.xml:S3:11318:2	O
the	SIMPONI.xml:S3:11321:3	O
TNF	SIMPONI.xml:S3:11325:3	O
-	SIMPONI.xml:S3:11328:1	O
blocker	SIMPONI.xml:S3:11329:7	O
group	SIMPONI.xml:S3:11337:5	O
compared	SIMPONI.xml:S3:11343:8	O
to	SIMPONI.xml:S3:11352:2	O
the	SIMPONI.xml:S3:11355:3	O
controlled	SIMPONI.xml:S3:11359:10	O
group	SIMPONI.xml:S3:11370:5	O
.	SIMPONI.xml:S3:11375:1	O

In	SIMPONI.xml:S3:11377:2	O
an	SIMPONI.xml:S3:11380:2	O
exploratory	SIMPONI.xml:S3:11383:11	O
clinical	SIMPONI.xml:S3:11395:8	O
trial	SIMPONI.xml:S3:11404:5	O
evaluating	SIMPONI.xml:S3:11410:10	O
the	SIMPONI.xml:S3:11421:3	O
use	SIMPONI.xml:S3:11425:3	O
of	SIMPONI.xml:S3:11429:2	O
the	SIMPONI.xml:S3:11432:3	O
subcutaneous	SIMPONI.xml:S3:11436:12	O
formulation	SIMPONI.xml:S3:11449:11	O
of	SIMPONI.xml:S3:11461:2	O
golimumab	SIMPONI.xml:S3:11464:9	O
in	SIMPONI.xml:S3:11474:2	O
patients	SIMPONI.xml:S3:11477:8	O
with	SIMPONI.xml:S3:11486:4	O
severe	SIMPONI.xml:S3:11491:6	O
persistent	SIMPONI.xml:S3:11498:10	O
asthma	SIMPONI.xml:S3:11509:6	O
,	SIMPONI.xml:S3:11515:1	O
more	SIMPONI.xml:S3:11517:4	O
patients	SIMPONI.xml:S3:11522:8	O
treated	SIMPONI.xml:S3:11531:7	O
with	SIMPONI.xml:S3:11539:4	O
golimumab	SIMPONI.xml:S3:11544:9	O
reported	SIMPONI.xml:S3:11554:8	O
malignancies	SIMPONI.xml:S3:11563:12	B-AdverseReaction
compared	SIMPONI.xml:S3:11576:8	O
with	SIMPONI.xml:S3:11585:4	O
control	SIMPONI.xml:S3:11590:7	O
patients	SIMPONI.xml:S3:11598:8	O
.	SIMPONI.xml:S3:11606:1	O

The	SIMPONI.xml:S3:11608:3	O
significance	SIMPONI.xml:S3:11612:12	O
of	SIMPONI.xml:S3:11625:2	O
this	SIMPONI.xml:S3:11628:4	O
finding	SIMPONI.xml:S3:11633:7	O
is	SIMPONI.xml:S3:11641:2	O
unknown	SIMPONI.xml:S3:11644:7	O
.	SIMPONI.xml:S3:11651:1	O

During	SIMPONI.xml:S3:11657:6	O
the	SIMPONI.xml:S3:11664:3	O
controlled	SIMPONI.xml:S3:11668:10	O
portion	SIMPONI.xml:S3:11679:7	O
of	SIMPONI.xml:S3:11687:2	O
the	SIMPONI.xml:S3:11690:3	O
Phase	SIMPONI.xml:S3:11694:5	O
3	SIMPONI.xml:S3:11700:1	O
trial	SIMPONI.xml:S3:11702:5	O
in	SIMPONI.xml:S3:11708:2	O
RA	SIMPONI.xml:S3:11711:2	O
for	SIMPONI.xml:S3:11714:3	O
SIMPONI	SIMPONI.xml:S3:11718:7	O
ARIA	SIMPONI.xml:S3:11726:4	O
,	SIMPONI.xml:S3:11730:1	O
the	SIMPONI.xml:S3:11732:3	O
incidence	SIMPONI.xml:S3:11736:9	O
of	SIMPONI.xml:S3:11746:2	O
malignancies	SIMPONI.xml:S3:11749:12	B-AdverseReaction
other	SIMPONI.xml:S3:11762:5	O
than	SIMPONI.xml:S3:11768:4	O
lymphoma	SIMPONI.xml:S3:11773:8	O
and	SIMPONI.xml:S3:11782:3	O
NMSC	SIMPONI.xml:S3:11786:4	O
per	SIMPONI.xml:S3:11791:3	O
100	SIMPONI.xml:S3:11795:3	O
-	SIMPONI.xml:S3:11798:1	O
patient	SIMPONI.xml:S3:11799:7	O
-	SIMPONI.xml:S3:11806:1	O
years	SIMPONI.xml:S3:11807:5	O
of	SIMPONI.xml:S3:11813:2	O
follow	SIMPONI.xml:S3:11816:6	O
-	SIMPONI.xml:S3:11822:1	O
up	SIMPONI.xml:S3:11823:2	O
was	SIMPONI.xml:S3:11826:3	O
0.56	SIMPONI.xml:S3:11830:4	O
(	SIMPONI.xml:S3:11835:1	O
95%	SIMPONI.xml:S3:11836:3	O
CI	SIMPONI.xml:S3:11840:2	O
:	SIMPONI.xml:S3:11842:1	O
0.01	SIMPONI.xml:S3:11844:4	O
,	SIMPONI.xml:S3:11848:1	O
3.11	SIMPONI.xml:S3:11850:4	O
)	SIMPONI.xml:S3:11854:1	O
in	SIMPONI.xml:S3:11856:2	O
the	SIMPONI.xml:S3:11859:3	O
SIMPONI	SIMPONI.xml:S3:11863:7	O
ARIA	SIMPONI.xml:S3:11871:4	O
group	SIMPONI.xml:S3:11876:5	O
compared	SIMPONI.xml:S3:11882:8	O
with	SIMPONI.xml:S3:11891:4	O
an	SIMPONI.xml:S3:11896:2	O
incidence	SIMPONI.xml:S3:11899:9	O
of	SIMPONI.xml:S3:11909:2	O
0	SIMPONI.xml:S3:11912:1	O
(	SIMPONI.xml:S3:11914:1	O
95%	SIMPONI.xml:S3:11915:3	O
CI	SIMPONI.xml:S3:11919:2	O
:	SIMPONI.xml:S3:11921:1	O
0.00	SIMPONI.xml:S3:11923:4	O
,	SIMPONI.xml:S3:11927:1	O
3.79	SIMPONI.xml:S3:11929:4	O
)	SIMPONI.xml:S3:11933:1	O
in	SIMPONI.xml:S3:11935:2	O
the	SIMPONI.xml:S3:11938:3	O
placebo	SIMPONI.xml:S3:11942:7	O
group	SIMPONI.xml:S3:11950:5	O
.	SIMPONI.xml:S3:11955:1	O

5.3	SIMPONI.xml:S3:11964:3	O
Congestive	SIMPONI.xml:S3:11968:10	O
Heart	SIMPONI.xml:S3:11979:5	O
Failure	SIMPONI.xml:S3:11985:7	O

Cases	SIMPONI.xml:S3:11998:5	O
of	SIMPONI.xml:S3:12004:2	O
worsening	SIMPONI.xml:S3:12007:9	B-AdverseReaction
congestive	SIMPONI.xml:S3:12017:10	I-AdverseReaction
heart	SIMPONI.xml:S3:12028:5	I-AdverseReaction
failure	SIMPONI.xml:S3:12034:7	I-AdverseReaction
(	SIMPONI.xml:S3:12042:1	O
CHF	SIMPONI.xml:S3:12043:3	I-AdverseReaction
)	SIMPONI.xml:S3:12046:1	O
and	SIMPONI.xml:S3:12048:3	O
new	SIMPONI.xml:S3:12052:3	B-AdverseReaction
onset	SIMPONI.xml:S3:12056:5	I-AdverseReaction
CHF	SIMPONI.xml:S3:12062:3	I-AdverseReaction
have	SIMPONI.xml:S3:12066:4	O
been	SIMPONI.xml:S3:12071:4	O
reported	SIMPONI.xml:S3:12076:8	O
with	SIMPONI.xml:S3:12085:4	O
TNF	SIMPONI.xml:S3:12090:3	O
-	SIMPONI.xml:S3:12093:1	O
blockers	SIMPONI.xml:S3:12094:8	O
,	SIMPONI.xml:S3:12102:1	O
including	SIMPONI.xml:S3:12104:9	O
SIMPONI	SIMPONI.xml:S3:12114:7	O
ARIA	SIMPONI.xml:S3:12122:4	O
.	SIMPONI.xml:S3:12126:1	O

In	SIMPONI.xml:S3:12128:2	O
several	SIMPONI.xml:S3:12131:7	O
exploratory	SIMPONI.xml:S3:12139:11	O
trials	SIMPONI.xml:S3:12151:6	O
of	SIMPONI.xml:S3:12158:2	O
other	SIMPONI.xml:S3:12161:5	O
TNF	SIMPONI.xml:S3:12167:3	O
-	SIMPONI.xml:S3:12170:1	O
blockers	SIMPONI.xml:S3:12171:8	O
in	SIMPONI.xml:S3:12180:2	O
the	SIMPONI.xml:S3:12183:3	O
treatment	SIMPONI.xml:S3:12187:9	O
of	SIMPONI.xml:S3:12197:2	O
CHF	SIMPONI.xml:S3:12200:3	O
,	SIMPONI.xml:S3:12203:1	O
there	SIMPONI.xml:S3:12205:5	O
were	SIMPONI.xml:S3:12211:4	O
greater	SIMPONI.xml:S3:12216:7	O
proportions	SIMPONI.xml:S3:12224:11	O
of	SIMPONI.xml:S3:12236:2	O
TNF	SIMPONI.xml:S3:12239:3	O
-	SIMPONI.xml:S3:12242:1	O
blocker	SIMPONI.xml:S3:12243:7	O
treated	SIMPONI.xml:S3:12251:7	O
patients	SIMPONI.xml:S3:12259:8	O
who	SIMPONI.xml:S3:12268:3	O
had	SIMPONI.xml:S3:12272:3	O
CHF	SIMPONI.xml:S3:12276:3	B-AdverseReaction
exacerbations	SIMPONI.xml:S3:12280:13	I-AdverseReaction
requiring	SIMPONI.xml:S3:12294:9	O
hospitalization	SIMPONI.xml:S3:12304:15	O
or	SIMPONI.xml:S3:12320:2	O
increased	SIMPONI.xml:S3:12323:9	B-AdverseReaction
mortality	SIMPONI.xml:S3:12333:9	I-AdverseReaction
.	SIMPONI.xml:S3:12342:1	O

SIMPONI	SIMPONI.xml:S3:12344:7	O
ARIA	SIMPONI.xml:S3:12352:4	O
has	SIMPONI.xml:S3:12357:3	O
not	SIMPONI.xml:S3:12361:3	O
been	SIMPONI.xml:S3:12365:4	O
studied	SIMPONI.xml:S3:12370:7	O
in	SIMPONI.xml:S3:12378:2	O
patients	SIMPONI.xml:S3:12381:8	O
with	SIMPONI.xml:S3:12390:4	O
a	SIMPONI.xml:S3:12395:1	O
history	SIMPONI.xml:S3:12397:7	O
of	SIMPONI.xml:S3:12405:2	O
CHF	SIMPONI.xml:S3:12408:3	O
and	SIMPONI.xml:S3:12412:3	O
SIMPONI	SIMPONI.xml:S3:12416:7	O
ARIA	SIMPONI.xml:S3:12424:4	O
should	SIMPONI.xml:S3:12429:6	O
be	SIMPONI.xml:S3:12436:2	O
used	SIMPONI.xml:S3:12439:4	O
with	SIMPONI.xml:S3:12444:4	O
caution	SIMPONI.xml:S3:12449:7	O
in	SIMPONI.xml:S3:12457:2	O
patients	SIMPONI.xml:S3:12460:8	O
with	SIMPONI.xml:S3:12469:4	O
CHF	SIMPONI.xml:S3:12474:3	O
.	SIMPONI.xml:S3:12477:1	O

If	SIMPONI.xml:S3:12479:2	O
a	SIMPONI.xml:S3:12482:1	O
decision	SIMPONI.xml:S3:12484:8	O
is	SIMPONI.xml:S3:12493:2	O
made	SIMPONI.xml:S3:12496:4	O
to	SIMPONI.xml:S3:12501:2	O
administer	SIMPONI.xml:S3:12504:10	O
SIMPONI	SIMPONI.xml:S3:12515:7	O
ARIA	SIMPONI.xml:S3:12523:4	O
to	SIMPONI.xml:S3:12528:2	O
RA	SIMPONI.xml:S3:12531:2	O
patients	SIMPONI.xml:S3:12534:8	O
with	SIMPONI.xml:S3:12543:4	O
CHF	SIMPONI.xml:S3:12548:3	O
,	SIMPONI.xml:S3:12551:1	O
these	SIMPONI.xml:S3:12553:5	O
patients	SIMPONI.xml:S3:12559:8	O
should	SIMPONI.xml:S3:12568:6	O
be	SIMPONI.xml:S3:12575:2	O
closely	SIMPONI.xml:S3:12578:7	O
monitored	SIMPONI.xml:S3:12586:9	O
during	SIMPONI.xml:S3:12596:6	O
therapy	SIMPONI.xml:S3:12603:7	O
,	SIMPONI.xml:S3:12610:1	O
and	SIMPONI.xml:S3:12612:3	O
SIMPONI	SIMPONI.xml:S3:12616:7	O
ARIA	SIMPONI.xml:S3:12624:4	O
should	SIMPONI.xml:S3:12629:6	O
be	SIMPONI.xml:S3:12636:2	O
discontinued	SIMPONI.xml:S3:12639:12	O
if	SIMPONI.xml:S3:12652:2	O
new	SIMPONI.xml:S3:12655:3	O
or	SIMPONI.xml:S3:12659:2	O
worsening	SIMPONI.xml:S3:12662:9	O
symptoms	SIMPONI.xml:S3:12672:8	O
of	SIMPONI.xml:S3:12681:2	O
CHF	SIMPONI.xml:S3:12684:3	O
appear	SIMPONI.xml:S3:12688:6	O
.	SIMPONI.xml:S3:12694:1	O

5.4	SIMPONI.xml:S3:12703:3	O
Demyelinating	SIMPONI.xml:S3:12707:13	O
Disorders	SIMPONI.xml:S3:12721:9	O

Use	SIMPONI.xml:S3:12736:3	O
of	SIMPONI.xml:S3:12740:2	O
TNF	SIMPONI.xml:S3:12743:3	O
-	SIMPONI.xml:S3:12746:1	O
blockers	SIMPONI.xml:S3:12747:8	O
,	SIMPONI.xml:S3:12755:1	O
of	SIMPONI.xml:S3:12757:2	O
which	SIMPONI.xml:S3:12760:5	O
SIMPONI	SIMPONI.xml:S3:12766:7	O
ARIA	SIMPONI.xml:S3:12774:4	O
is	SIMPONI.xml:S3:12779:2	O
a	SIMPONI.xml:S3:12782:1	O
member	SIMPONI.xml:S3:12784:6	O
,	SIMPONI.xml:S3:12790:1	O
has	SIMPONI.xml:S3:12792:3	O
been	SIMPONI.xml:S3:12796:4	O
associated	SIMPONI.xml:S3:12801:10	O
with	SIMPONI.xml:S3:12812:4	O
rare	SIMPONI.xml:S3:12817:4	O
cases	SIMPONI.xml:S3:12822:5	O
of	SIMPONI.xml:S3:12828:2	O
new	SIMPONI.xml:S3:12831:3	B-AdverseReaction
onset	SIMPONI.xml:S3:12835:5	I-AdverseReaction
or	SIMPONI.xml:S3:12841:2	O
exacerbation	SIMPONI.xml:S3:12844:12	B-AdverseReaction
of	SIMPONI.xml:S3:12857:2	I-AdverseReaction
central	SIMPONI.xml:S3:12860:7	I-AdverseReaction
nervous	SIMPONI.xml:S3:12868:7	I-AdverseReaction
system	SIMPONI.xml:S3:12876:6	I-AdverseReaction
(	SIMPONI.xml:S3:12883:1	O
CNS	SIMPONI.xml:S3:12884:3	I-AdverseReaction
)	SIMPONI.xml:S3:12887:1	O
demyelinating	SIMPONI.xml:S3:12889:13	I-AdverseReaction
disorders	SIMPONI.xml:S3:12903:9	I-AdverseReaction
,	SIMPONI.xml:S3:12912:1	O
including	SIMPONI.xml:S3:12914:9	O
multiple	SIMPONI.xml:S3:12924:8	B-AdverseReaction
sclerosis	SIMPONI.xml:S3:12933:9	I-AdverseReaction
(	SIMPONI.xml:S3:12943:1	O
MS	SIMPONI.xml:S3:12944:2	B-AdverseReaction
)	SIMPONI.xml:S3:12946:1	O
and	SIMPONI.xml:S3:12948:3	O
peripheral	SIMPONI.xml:S3:12952:10	B-AdverseReaction
demyelinating	SIMPONI.xml:S3:12963:13	I-AdverseReaction
disorders	SIMPONI.xml:S3:12977:9	I-AdverseReaction
,	SIMPONI.xml:S3:12986:1	O
including	SIMPONI.xml:S3:12988:9	O
Guillain	SIMPONI.xml:S3:12998:8	B-AdverseReaction
-	SIMPONI.xml:S3:13006:1	I-AdverseReaction
Barre	SIMPONI.xml:S3:13007:5	I-AdverseReaction
syndrome	SIMPONI.xml:S3:13013:8	I-AdverseReaction
.	SIMPONI.xml:S3:13021:1	O

Cases	SIMPONI.xml:S3:13023:5	O
of	SIMPONI.xml:S3:13029:2	O
central	SIMPONI.xml:S3:13032:7	B-AdverseReaction
demyelination	SIMPONI.xml:S3:13040:13	I-AdverseReaction
,	SIMPONI.xml:S3:13053:1	O
MS	SIMPONI.xml:S3:13055:2	B-AdverseReaction
,	SIMPONI.xml:S3:13057:1	O
optic	SIMPONI.xml:S3:13059:5	B-AdverseReaction
neuritis	SIMPONI.xml:S3:13065:8	I-AdverseReaction
,	SIMPONI.xml:S3:13073:1	O
and	SIMPONI.xml:S3:13075:3	O
peripheral	SIMPONI.xml:S3:13079:10	B-AdverseReaction
demyelinating	SIMPONI.xml:S3:13090:13	I-AdverseReaction
polyneuropathy	SIMPONI.xml:S3:13104:14	I-AdverseReaction
have	SIMPONI.xml:S3:13119:4	O
rarely	SIMPONI.xml:S3:13124:6	O
been	SIMPONI.xml:S3:13131:4	O
reported	SIMPONI.xml:S3:13136:8	O
in	SIMPONI.xml:S3:13145:2	O
patients	SIMPONI.xml:S3:13148:8	O
treated	SIMPONI.xml:S3:13157:7	O
with	SIMPONI.xml:S3:13165:4	O
the	SIMPONI.xml:S3:13170:3	O
subcutaneous	SIMPONI.xml:S3:13174:12	O
formulation	SIMPONI.xml:S3:13187:11	O
of	SIMPONI.xml:S3:13199:2	O
golimumab	SIMPONI.xml:S3:13202:9	O
.	SIMPONI.xml:S3:13211:1	O

Prescribers	SIMPONI.xml:S3:13213:11	O
should	SIMPONI.xml:S3:13225:6	O
exercise	SIMPONI.xml:S3:13232:8	O
caution	SIMPONI.xml:S3:13241:7	O
in	SIMPONI.xml:S3:13249:2	O
considering	SIMPONI.xml:S3:13252:11	O
the	SIMPONI.xml:S3:13264:3	O
use	SIMPONI.xml:S3:13268:3	O
of	SIMPONI.xml:S3:13272:2	O
TNF	SIMPONI.xml:S3:13275:3	O
-	SIMPONI.xml:S3:13278:1	O
blockers	SIMPONI.xml:S3:13279:8	O
,	SIMPONI.xml:S3:13287:1	O
including	SIMPONI.xml:S3:13289:9	O
SIMPONI	SIMPONI.xml:S3:13299:7	O
ARIA	SIMPONI.xml:S3:13307:4	O
,	SIMPONI.xml:S3:13311:1	O
in	SIMPONI.xml:S3:13313:2	O
patients	SIMPONI.xml:S3:13316:8	O
with	SIMPONI.xml:S3:13325:4	O
central	SIMPONI.xml:S3:13330:7	O
or	SIMPONI.xml:S3:13338:2	O
peripheral	SIMPONI.xml:S3:13341:10	O
nervous	SIMPONI.xml:S3:13352:7	O
system	SIMPONI.xml:S3:13360:6	O
demyelinating	SIMPONI.xml:S3:13367:13	O
disorders	SIMPONI.xml:S3:13381:9	O
.	SIMPONI.xml:S3:13390:1	O

Discontinuation	SIMPONI.xml:S3:13392:15	O
of	SIMPONI.xml:S3:13408:2	O
SIMPONI	SIMPONI.xml:S3:13411:7	O
ARIA	SIMPONI.xml:S3:13419:4	O
should	SIMPONI.xml:S3:13424:6	O
be	SIMPONI.xml:S3:13431:2	O
considered	SIMPONI.xml:S3:13434:10	O
if	SIMPONI.xml:S3:13445:2	O
these	SIMPONI.xml:S3:13448:5	O
disorders	SIMPONI.xml:S3:13454:9	O
develop	SIMPONI.xml:S3:13464:7	O
.	SIMPONI.xml:S3:13471:1	O

5.5	SIMPONI.xml:S3:13480:3	O
Use	SIMPONI.xml:S3:13484:3	O
with	SIMPONI.xml:S3:13488:4	O
Abatacept	SIMPONI.xml:S3:13493:9	O

In	SIMPONI.xml:S3:13508:2	O
controlled	SIMPONI.xml:S3:13511:10	O
trials	SIMPONI.xml:S3:13522:6	O
,	SIMPONI.xml:S3:13528:1	O
the	SIMPONI.xml:S3:13530:3	O
concurrent	SIMPONI.xml:S3:13534:10	O
administration	SIMPONI.xml:S3:13545:14	O
of	SIMPONI.xml:S3:13560:2	O
another	SIMPONI.xml:S3:13563:7	O
TNF	SIMPONI.xml:S3:13571:3	O
-	SIMPONI.xml:S3:13574:1	O
blocker	SIMPONI.xml:S3:13575:7	O
and	SIMPONI.xml:S3:13583:3	O
abatacept	SIMPONI.xml:S3:13587:9	O
was	SIMPONI.xml:S3:13597:3	O
associated	SIMPONI.xml:S3:13601:10	O
with	SIMPONI.xml:S3:13612:4	O
a	SIMPONI.xml:S3:13617:1	O
greater	SIMPONI.xml:S3:13619:7	O
proportion	SIMPONI.xml:S3:13627:10	O
of	SIMPONI.xml:S3:13638:2	O
serious	SIMPONI.xml:S3:13641:7	O
infections	SIMPONI.xml:S3:13649:10	O
than	SIMPONI.xml:S3:13660:4	O
the	SIMPONI.xml:S3:13665:3	O
use	SIMPONI.xml:S3:13669:3	O
of	SIMPONI.xml:S3:13673:2	O
a	SIMPONI.xml:S3:13676:1	O
TNF	SIMPONI.xml:S3:13678:3	O
-	SIMPONI.xml:S3:13681:1	O
blocker	SIMPONI.xml:S3:13682:7	O
alone	SIMPONI.xml:S3:13690:5	O
;	SIMPONI.xml:S3:13695:1	O
and	SIMPONI.xml:S3:13697:3	O
the	SIMPONI.xml:S3:13701:3	O
combination	SIMPONI.xml:S3:13705:11	O
therapy	SIMPONI.xml:S3:13717:7	O
,	SIMPONI.xml:S3:13724:1	O
compared	SIMPONI.xml:S3:13726:8	O
to	SIMPONI.xml:S3:13735:2	O
the	SIMPONI.xml:S3:13738:3	O
use	SIMPONI.xml:S3:13742:3	O
of	SIMPONI.xml:S3:13746:2	O
a	SIMPONI.xml:S3:13749:1	O
TNF	SIMPONI.xml:S3:13751:3	O
-	SIMPONI.xml:S3:13754:1	O
blocker	SIMPONI.xml:S3:13755:7	O
alone	SIMPONI.xml:S3:13763:5	O
,	SIMPONI.xml:S3:13768:1	O
has	SIMPONI.xml:S3:13770:3	O
not	SIMPONI.xml:S3:13774:3	O
demonstrated	SIMPONI.xml:S3:13778:12	O
improved	SIMPONI.xml:S3:13791:8	O
clinical	SIMPONI.xml:S3:13800:8	O
benefit	SIMPONI.xml:S3:13809:7	O
in	SIMPONI.xml:S3:13817:2	O
the	SIMPONI.xml:S3:13820:3	O
treatment	SIMPONI.xml:S3:13824:9	O
of	SIMPONI.xml:S3:13834:2	O
RA	SIMPONI.xml:S3:13837:2	O
.	SIMPONI.xml:S3:13839:1	O

Therefore	SIMPONI.xml:S3:13841:9	O
,	SIMPONI.xml:S3:13850:1	O
the	SIMPONI.xml:S3:13852:3	O
combination	SIMPONI.xml:S3:13856:11	O
of	SIMPONI.xml:S3:13868:2	O
TNF	SIMPONI.xml:S3:13871:3	O
-	SIMPONI.xml:S3:13874:1	O
blockers	SIMPONI.xml:S3:13875:8	O
including	SIMPONI.xml:S3:13884:9	O
SIMPONI	SIMPONI.xml:S3:13894:7	O
ARIA	SIMPONI.xml:S3:13902:4	O
and	SIMPONI.xml:S3:13907:3	O
abatacept	SIMPONI.xml:S3:13911:9	O
is	SIMPONI.xml:S3:13921:2	O
not	SIMPONI.xml:S3:13924:3	O
recommended	SIMPONI.xml:S3:13928:11	O
[	SIMPONI.xml:S3:13940:1	O
see	SIMPONI.xml:S3:13941:3	O
Drug	SIMPONI.xml:S3:13946:4	O
Interactions	SIMPONI.xml:S3:13951:12	O
(	SIMPONI.xml:S3:13964:1	O
7.2	SIMPONI.xml:S3:13965:3	O
)	SIMPONI.xml:S3:13968:1	O
]	SIMPONI.xml:S3:13971:1	O
.	SIMPONI.xml:S3:13974:1	O

5.6	SIMPONI.xml:S3:13983:3	O
Use	SIMPONI.xml:S3:13987:3	O
with	SIMPONI.xml:S3:13991:4	O
Anakinra	SIMPONI.xml:S3:13996:8	O

Concurrent	SIMPONI.xml:S3:14010:10	O
administration	SIMPONI.xml:S3:14021:14	O
of	SIMPONI.xml:S3:14036:2	O
anakinra	SIMPONI.xml:S3:14039:8	O
(	SIMPONI.xml:S3:14048:1	O
an	SIMPONI.xml:S3:14049:2	O
interleukin	SIMPONI.xml:S3:14052:11	O
-	SIMPONI.xml:S3:14063:1	O
1	SIMPONI.xml:S3:14064:1	O
antagonist	SIMPONI.xml:S3:14066:10	O
)	SIMPONI.xml:S3:14076:1	O
and	SIMPONI.xml:S3:14078:3	O
another	SIMPONI.xml:S3:14082:7	O
TNF	SIMPONI.xml:S3:14090:3	O
-	SIMPONI.xml:S3:14093:1	O
blocker	SIMPONI.xml:S3:14094:7	O
,	SIMPONI.xml:S3:14101:1	O
was	SIMPONI.xml:S3:14103:3	O
associated	SIMPONI.xml:S3:14107:10	O
with	SIMPONI.xml:S3:14118:4	O
a	SIMPONI.xml:S3:14123:1	O
greater	SIMPONI.xml:S3:14125:7	O
portion	SIMPONI.xml:S3:14133:7	O
of	SIMPONI.xml:S3:14141:2	O
serious	SIMPONI.xml:S3:14144:7	O
infections	SIMPONI.xml:S3:14152:10	O
and	SIMPONI.xml:S3:14163:3	O
neutropenia	SIMPONI.xml:S3:14167:11	O
and	SIMPONI.xml:S3:14179:3	O
no	SIMPONI.xml:S3:14183:2	O
additional	SIMPONI.xml:S3:14186:10	O
benefits	SIMPONI.xml:S3:14197:8	O
compared	SIMPONI.xml:S3:14206:8	O
with	SIMPONI.xml:S3:14215:4	O
the	SIMPONI.xml:S3:14220:3	O
TNF	SIMPONI.xml:S3:14224:3	O
-	SIMPONI.xml:S3:14227:1	O
blocker	SIMPONI.xml:S3:14228:7	O
alone	SIMPONI.xml:S3:14236:5	O
.	SIMPONI.xml:S3:14241:1	O

Therefore	SIMPONI.xml:S3:14243:9	O
,	SIMPONI.xml:S3:14252:1	O
the	SIMPONI.xml:S3:14254:3	O
combination	SIMPONI.xml:S3:14258:11	O
of	SIMPONI.xml:S3:14270:2	O
anakinra	SIMPONI.xml:S3:14273:8	O
with	SIMPONI.xml:S3:14282:4	O
TNF	SIMPONI.xml:S3:14287:3	O
-	SIMPONI.xml:S3:14290:1	O
blockers	SIMPONI.xml:S3:14291:8	O
,	SIMPONI.xml:S3:14299:1	O
including	SIMPONI.xml:S3:14301:9	O
SIMPONI	SIMPONI.xml:S3:14311:7	O
ARIA	SIMPONI.xml:S3:14319:4	O
,	SIMPONI.xml:S3:14323:1	O
is	SIMPONI.xml:S3:14325:2	O
not	SIMPONI.xml:S3:14328:3	O
recommended	SIMPONI.xml:S3:14332:11	O
[	SIMPONI.xml:S3:14344:1	O
see	SIMPONI.xml:S3:14345:3	O
Drug	SIMPONI.xml:S3:14350:4	O
Interactions	SIMPONI.xml:S3:14355:12	O
(	SIMPONI.xml:S3:14368:1	O
7.2	SIMPONI.xml:S3:14369:3	O
)	SIMPONI.xml:S3:14372:1	O
]	SIMPONI.xml:S3:14375:1	O
.	SIMPONI.xml:S3:14378:1	O

5.7	SIMPONI.xml:S3:14387:3	O
Switching	SIMPONI.xml:S3:14391:9	O
Between	SIMPONI.xml:S3:14401:7	O
Biological	SIMPONI.xml:S3:14409:10	O
Disease	SIMPONI.xml:S3:14420:7	O
Modifying	SIMPONI.xml:S3:14428:9	O
Antirheumatic	SIMPONI.xml:S3:14438:13	O
Drugs	SIMPONI.xml:S3:14452:5	O
(	SIMPONI.xml:S3:14458:1	O
DMARDs	SIMPONI.xml:S3:14459:6	O
)	SIMPONI.xml:S3:14465:1	O

Care	SIMPONI.xml:S3:14472:4	O
should	SIMPONI.xml:S3:14477:6	O
be	SIMPONI.xml:S3:14484:2	O
taken	SIMPONI.xml:S3:14487:5	O
when	SIMPONI.xml:S3:14493:4	O
switching	SIMPONI.xml:S3:14498:9	O
from	SIMPONI.xml:S3:14508:4	O
one	SIMPONI.xml:S3:14513:3	O
biologic	SIMPONI.xml:S3:14517:8	O
product	SIMPONI.xml:S3:14526:7	O
to	SIMPONI.xml:S3:14534:2	O
another	SIMPONI.xml:S3:14537:7	O
biologic	SIMPONI.xml:S3:14545:8	O
product	SIMPONI.xml:S3:14554:7	O
since	SIMPONI.xml:S3:14562:5	O
overlapping	SIMPONI.xml:S3:14568:11	O
biological	SIMPONI.xml:S3:14580:10	O
activity	SIMPONI.xml:S3:14591:8	O
may	SIMPONI.xml:S3:14600:3	O
further	SIMPONI.xml:S3:14604:7	O
increase	SIMPONI.xml:S3:14612:8	O
the	SIMPONI.xml:S3:14621:3	O
risk	SIMPONI.xml:S3:14625:4	O
of	SIMPONI.xml:S3:14630:2	O
infection	SIMPONI.xml:S3:14633:9	O
.	SIMPONI.xml:S3:14642:1	O

5.8	SIMPONI.xml:S3:14651:3	O
Hematologic	SIMPONI.xml:S3:14655:11	O
Cytopenias	SIMPONI.xml:S3:14667:10	O

There	SIMPONI.xml:S3:14683:5	O
have	SIMPONI.xml:S3:14689:4	O
been	SIMPONI.xml:S3:14694:4	O
post	SIMPONI.xml:S3:14699:4	O
-	SIMPONI.xml:S3:14703:1	O
marketing	SIMPONI.xml:S3:14704:9	O
reports	SIMPONI.xml:S3:14714:7	O
of	SIMPONI.xml:S3:14722:2	O
pancytopenia	SIMPONI.xml:S3:14725:12	B-AdverseReaction
,	SIMPONI.xml:S3:14737:1	O
leukopenia	SIMPONI.xml:S3:14739:10	B-AdverseReaction
,	SIMPONI.xml:S3:14749:1	O
neutropenia	SIMPONI.xml:S3:14751:11	B-AdverseReaction
,	SIMPONI.xml:S3:14762:1	O
aplastic	SIMPONI.xml:S3:14764:8	B-AdverseReaction
anemia	SIMPONI.xml:S3:14773:6	I-AdverseReaction
,	SIMPONI.xml:S3:14779:1	O
and	SIMPONI.xml:S3:14781:3	O
thrombocytopenia	SIMPONI.xml:S3:14785:16	B-AdverseReaction
in	SIMPONI.xml:S3:14802:2	O
patients	SIMPONI.xml:S3:14805:8	O
receiving	SIMPONI.xml:S3:14814:9	O
TNF	SIMPONI.xml:S3:14824:3	O
-	SIMPONI.xml:S3:14827:1	O
blockers	SIMPONI.xml:S3:14828:8	O
.	SIMPONI.xml:S3:14836:1	O

In	SIMPONI.xml:S3:14838:2	O
clinical	SIMPONI.xml:S3:14841:8	O
studies	SIMPONI.xml:S3:14850:7	O
,	SIMPONI.xml:S3:14857:1	O
cases	SIMPONI.xml:S3:14859:5	O
of	SIMPONI.xml:S3:14865:2	O
pancytopenia	SIMPONI.xml:S3:14868:12	B-AdverseReaction
,	SIMPONI.xml:S3:14880:1	O
leukopenia	SIMPONI.xml:S3:14882:10	B-AdverseReaction
,	SIMPONI.xml:S3:14892:1	O
neutropenia	SIMPONI.xml:S3:14894:11	B-AdverseReaction
,	SIMPONI.xml:S3:14905:1	O
and	SIMPONI.xml:S3:14907:3	O
thrombocytopenia	SIMPONI.xml:S3:14911:16	B-AdverseReaction
have	SIMPONI.xml:S3:14928:4	O
also	SIMPONI.xml:S3:14933:4	O
occurred	SIMPONI.xml:S3:14938:8	O
in	SIMPONI.xml:S3:14947:2	O
SIMPONI	SIMPONI.xml:S3:14950:7	O
ARIA	SIMPONI.xml:S3:14958:4	O
-	SIMPONI.xml:S3:14962:1	O
treated	SIMPONI.xml:S3:14963:7	O
patients	SIMPONI.xml:S3:14971:8	O
.	SIMPONI.xml:S3:14979:1	O

Caution	SIMPONI.xml:S3:14981:7	O
should	SIMPONI.xml:S3:14989:6	O
be	SIMPONI.xml:S3:14996:2	O
exercised	SIMPONI.xml:S3:14999:9	O
when	SIMPONI.xml:S3:15009:4	O
using	SIMPONI.xml:S3:15014:5	O
TNF	SIMPONI.xml:S3:15020:3	O
-	SIMPONI.xml:S3:15023:1	O
blockers	SIMPONI.xml:S3:15024:8	O
,	SIMPONI.xml:S3:15032:1	O
including	SIMPONI.xml:S3:15034:9	O
SIMPONI	SIMPONI.xml:S3:15044:7	O
ARIA	SIMPONI.xml:S3:15052:4	O
,	SIMPONI.xml:S3:15056:1	O
in	SIMPONI.xml:S3:15058:2	O
patients	SIMPONI.xml:S3:15061:8	O
who	SIMPONI.xml:S3:15070:3	O
have	SIMPONI.xml:S3:15074:4	O
or	SIMPONI.xml:S3:15079:2	O
have	SIMPONI.xml:S3:15082:4	O
had	SIMPONI.xml:S3:15087:3	O
significant	SIMPONI.xml:S3:15091:11	O
cytopenias	SIMPONI.xml:S3:15103:10	O
.	SIMPONI.xml:S3:15113:1	O

5.9	SIMPONI.xml:S3:15122:3	O
Vaccinations	SIMPONI.xml:S3:15126:12	O
Therapeutic	SIMPONI.xml:S3:15139:11	O
Infectious	SIMPONI.xml:S3:15151:10	O
Agents	SIMPONI.xml:S3:15162:6	O

Live	SIMPONI.xml:S3:15176:4	O
Vaccines	SIMPONI.xml:S3:15181:8	O

Patients	SIMPONI.xml:S3:15199:8	O
treated	SIMPONI.xml:S3:15208:7	O
with	SIMPONI.xml:S3:15216:4	O
SIMPONI	SIMPONI.xml:S3:15221:7	O
ARIA	SIMPONI.xml:S3:15229:4	O
may	SIMPONI.xml:S3:15234:3	O
receive	SIMPONI.xml:S3:15238:7	O
vaccinations	SIMPONI.xml:S3:15246:12	O
,	SIMPONI.xml:S3:15258:1	O
except	SIMPONI.xml:S3:15260:6	O
for	SIMPONI.xml:S3:15267:3	O
live	SIMPONI.xml:S3:15271:4	O
vaccines	SIMPONI.xml:S3:15276:8	O
.	SIMPONI.xml:S3:15284:1	O

In	SIMPONI.xml:S3:15286:2	O
patients	SIMPONI.xml:S3:15289:8	O
receiving	SIMPONI.xml:S3:15298:9	O
anti	SIMPONI.xml:S3:15308:4	O
-	SIMPONI.xml:S3:15312:1	O
TNF	SIMPONI.xml:S3:15313:3	O
therapy	SIMPONI.xml:S3:15317:7	O
,	SIMPONI.xml:S3:15324:1	O
limited	SIMPONI.xml:S3:15326:7	O
data	SIMPONI.xml:S3:15334:4	O
are	SIMPONI.xml:S3:15339:3	O
available	SIMPONI.xml:S3:15343:9	O
on	SIMPONI.xml:S3:15353:2	O
the	SIMPONI.xml:S3:15356:3	O
response	SIMPONI.xml:S3:15360:8	O
to	SIMPONI.xml:S3:15369:2	O
live	SIMPONI.xml:S3:15372:4	O
vaccination	SIMPONI.xml:S3:15377:11	O
,	SIMPONI.xml:S3:15388:1	O
or	SIMPONI.xml:S3:15390:2	O
on	SIMPONI.xml:S3:15393:2	O
the	SIMPONI.xml:S3:15396:3	O
secondary	SIMPONI.xml:S3:15400:9	O
transmission	SIMPONI.xml:S3:15410:12	O
of	SIMPONI.xml:S3:15423:2	O
infection	SIMPONI.xml:S3:15426:9	O
by	SIMPONI.xml:S3:15436:2	O
live	SIMPONI.xml:S3:15439:4	O
vaccines	SIMPONI.xml:S3:15444:8	O
.	SIMPONI.xml:S3:15452:1	O

Use	SIMPONI.xml:S3:15454:3	O
of	SIMPONI.xml:S3:15458:2	O
live	SIMPONI.xml:S3:15461:4	O
vaccines	SIMPONI.xml:S3:15466:8	O
could	SIMPONI.xml:S3:15475:5	O
result	SIMPONI.xml:S3:15481:6	O
in	SIMPONI.xml:S3:15488:2	O
clinical	SIMPONI.xml:S3:15491:8	O
infections	SIMPONI.xml:S3:15500:10	O
,	SIMPONI.xml:S3:15510:1	O
including	SIMPONI.xml:S3:15512:9	O
disseminated	SIMPONI.xml:S3:15522:12	O
infections	SIMPONI.xml:S3:15535:10	O
.	SIMPONI.xml:S3:15545:1	O

Therapeutic	SIMPONI.xml:S3:15557:11	O
Infectious	SIMPONI.xml:S3:15569:10	O
Agents	SIMPONI.xml:S3:15580:6	O

Other	SIMPONI.xml:S3:15596:5	O
uses	SIMPONI.xml:S3:15602:4	O
of	SIMPONI.xml:S3:15607:2	O
therapeutic	SIMPONI.xml:S3:15610:11	O
infectious	SIMPONI.xml:S3:15622:10	O
agents	SIMPONI.xml:S3:15633:6	O
such	SIMPONI.xml:S3:15640:4	O
as	SIMPONI.xml:S3:15645:2	O
live	SIMPONI.xml:S3:15648:4	O
attenuated	SIMPONI.xml:S3:15653:10	O
bacteria	SIMPONI.xml:S3:15664:8	O
(	SIMPONI.xml:S3:15673:1	O
e	SIMPONI.xml:S3:15674:1	O
.	SIMPONI.xml:S3:15675:1	O
g	SIMPONI.xml:S3:15676:1	O
.	SIMPONI.xml:S3:15677:1	O
,	SIMPONI.xml:S3:15678:1	O
BCG	SIMPONI.xml:S3:15680:3	O
bladder	SIMPONI.xml:S3:15684:7	O
instillation	SIMPONI.xml:S3:15692:12	O
for	SIMPONI.xml:S3:15705:3	O
the	SIMPONI.xml:S3:15709:3	O
treatment	SIMPONI.xml:S3:15713:9	O
of	SIMPONI.xml:S3:15723:2	O
cancer	SIMPONI.xml:S3:15726:6	O
)	SIMPONI.xml:S3:15732:1	O
could	SIMPONI.xml:S3:15734:5	O
result	SIMPONI.xml:S3:15740:6	O
in	SIMPONI.xml:S3:15747:2	O
clinical	SIMPONI.xml:S3:15750:8	O
infections	SIMPONI.xml:S3:15759:10	O
,	SIMPONI.xml:S3:15769:1	O
including	SIMPONI.xml:S3:15771:9	O
disseminated	SIMPONI.xml:S3:15781:12	O
infections	SIMPONI.xml:S3:15794:10	O
.	SIMPONI.xml:S3:15804:1	O

It	SIMPONI.xml:S3:15806:2	O
is	SIMPONI.xml:S3:15809:2	O
recommended	SIMPONI.xml:S3:15812:11	O
that	SIMPONI.xml:S3:15824:4	O
therapeutic	SIMPONI.xml:S3:15829:11	O
infectious	SIMPONI.xml:S3:15841:10	O
agents	SIMPONI.xml:S3:15852:6	O
not	SIMPONI.xml:S3:15859:3	O
be	SIMPONI.xml:S3:15863:2	O
given	SIMPONI.xml:S3:15866:5	O
concurrently	SIMPONI.xml:S3:15872:12	O
with	SIMPONI.xml:S3:15885:4	O
SIMPONI	SIMPONI.xml:S3:15890:7	O
ARIA	SIMPONI.xml:S3:15898:4	O
.	SIMPONI.xml:S3:15902:1	O

5.10	SIMPONI.xml:S3:15913:4	O
Hypersensitivity	SIMPONI.xml:S3:15918:16	O
Reactions	SIMPONI.xml:S3:15935:9	O

In	SIMPONI.xml:S3:15950:2	O
post	SIMPONI.xml:S3:15953:4	O
-	SIMPONI.xml:S3:15957:1	O
marketing	SIMPONI.xml:S3:15958:9	O
experience	SIMPONI.xml:S3:15968:10	O
,	SIMPONI.xml:S3:15978:1	O
serious	SIMPONI.xml:S3:15980:7	B-Severity
systemic	SIMPONI.xml:S3:15988:8	O
hypersensitivity	SIMPONI.xml:S3:15997:16	B-AdverseReaction
reactions	SIMPONI.xml:S3:16014:9	I-AdverseReaction
(	SIMPONI.xml:S3:16024:1	O
including	SIMPONI.xml:S3:16025:9	O
anaphylactic	SIMPONI.xml:S3:16035:12	B-AdverseReaction
reaction	SIMPONI.xml:S3:16048:8	I-AdverseReaction
)	SIMPONI.xml:S3:16056:1	O
have	SIMPONI.xml:S3:16058:4	O
been	SIMPONI.xml:S3:16063:4	O
reported	SIMPONI.xml:S3:16068:8	O
following	SIMPONI.xml:S3:16077:9	O
administration	SIMPONI.xml:S3:16087:14	O
of	SIMPONI.xml:S3:16102:2	O
the	SIMPONI.xml:S3:16105:3	O
subcutaneous	SIMPONI.xml:S3:16109:12	O
formulation	SIMPONI.xml:S3:16122:11	O
of	SIMPONI.xml:S3:16134:2	O
golimumab	SIMPONI.xml:S3:16137:9	O
.	SIMPONI.xml:S3:16146:1	O

Some	SIMPONI.xml:S3:16148:4	O
of	SIMPONI.xml:S3:16153:2	O
these	SIMPONI.xml:S3:16156:5	O
reactions	SIMPONI.xml:S3:16162:9	O
occurred	SIMPONI.xml:S3:16172:8	O
after	SIMPONI.xml:S3:16181:5	O
the	SIMPONI.xml:S3:16187:3	O
first	SIMPONI.xml:S3:16191:5	O
administration	SIMPONI.xml:S3:16197:14	O
of	SIMPONI.xml:S3:16212:2	O
golimumab	SIMPONI.xml:S3:16215:9	O
.	SIMPONI.xml:S3:16224:1	O

If	SIMPONI.xml:S3:16226:2	O
an	SIMPONI.xml:S3:16229:2	O
anaphylactic	SIMPONI.xml:S3:16232:12	O
or	SIMPONI.xml:S3:16245:2	O
other	SIMPONI.xml:S3:16248:5	O
serious	SIMPONI.xml:S3:16254:7	O
allergic	SIMPONI.xml:S3:16262:8	O
reaction	SIMPONI.xml:S3:16271:8	O
occurs	SIMPONI.xml:S3:16280:6	O
,	SIMPONI.xml:S3:16286:1	O
administration	SIMPONI.xml:S3:16288:14	O
of	SIMPONI.xml:S3:16303:2	O
SIMPONI	SIMPONI.xml:S3:16306:7	O
ARIA	SIMPONI.xml:S3:16314:4	O
should	SIMPONI.xml:S3:16319:6	O
be	SIMPONI.xml:S3:16326:2	O
discontinued	SIMPONI.xml:S3:16329:12	O
immediately	SIMPONI.xml:S3:16342:11	O
and	SIMPONI.xml:S3:16354:3	O
appropriate	SIMPONI.xml:S3:16358:11	O
therapy	SIMPONI.xml:S3:16370:7	O
instituted	SIMPONI.xml:S3:16378:10	O
.	SIMPONI.xml:S3:16388:1	O
